Improved method for reducing malodor

Abstract

This invention relates to a method for reducing malodor by bacterial metabolization of valeric acid, which is a source of malodor. The method comprises contacting valeric acid (VA) with at least two components S1 and S2, and incubating, so that S1 and S2 metabolize valeric acid VA. The invention further relates to a mixture M comprising valeric acid VA, at least one component S1 and at least one component S2. S1 is selected from Bacillus velezensis DSM 34978 and preparations thereof, mutants of Bacillus velezensis DSM 34978 and preparations thereof, Bacillus velezensis DSM 34674 and preparations thereof, mutants of Bacillus velezensis DSM 34674 and preparations thereof. S2 is selected from Bacillus licheniformis DSM 34977 and preparations thereof, mutants of Bacillus licheniformis DSM 34977 and preparations thereof, Priestia megaterium DSM 34980 and preparations thereof, mutants of Priestia megaterium DSM 34980 and preparations thereof, Bacillus subtilis DSM 34981 and preparations thereof, mutants of Bacillus subtilis DSM 34981 and preparations thereof.

Description

202400145 Foreign Filings 1malodorThis invention relates to a method for reducing malodor by bacterial metabolization of valeric acid, which is a source of malodor. The method comprises contacting valeric acid VA with at least two components Si and S2, and incubating, so that Si and S2 metabolize valeric acid VA. The invention further relates to a mixture M comprising valeric acid VA, at least one component Si and at least one component S2. Si is selected from Bacillus velezensis DSM 34978 and preparations thereof, mutants of Bacillus velezensis DSM 34978 and preparations thereof, Bacillus velezensis DSM 34674 and preparations thereof, mutants of Bacillus velezensis DSM 34674 and preparations thereof. S2 is selected from Bacillus licheniformis DSM 34977 and preparations thereof, mutants of Bacillus licheniformis DSM 34977 and preparations thereof, P estia megaterium DSM 34980 and preparations thereof, mutants of P estia megaterium DSM 34980 and preparations thereof, Bacillus subtilis DSM 34981 and preparations thereof, mutants of Bacillus subtilis DSM 34981 and preparations thereof. of the InventionThe quest for sustainability has become a paramount concern in various industries, and the cleaning as well as the personal care sector are no exceptions. As we delve deeper into the microscopic world, the potential of utilizing microorganisms for eco-friendly solutions has become known. Among these microscopic allies, Bacillus species and others, such as Priestia species, stand out for their versatility and efficiency. These robust bacteria have proven to be a treasure trove for the development of cleaning agents and the production of enzymes that pave the way for a long-lasting and sustainable approach to cleanliness.These naturally occurring bacteria produce a range of enzymes that can break down organic matter, making them ideal candidates for the formulation of biodegradable and non-toxic cleaning solutions. By tapping into the inherent properties of these microorganisms, we can create products that not only clean effectively but also contribute to the well-being of our planet and its human and animal inhabitants.Products comprising microorganisms for cleaning and disinfection are described in the art.E. Caselli et al., PLoS ONE 2018, 13(7) e0199616 describe probiotic-based cleaning systems for application in hospitals. Similarly, W. Stone et al., Microorganisms 2020, 8, 1726 compare the cleaning effect of a cleaning product comprising Bacillus spores on the microbiome of surfaces found in hospitals.A. Spok, G. Arvanitakis, G. McClung, Food Chem Toxicol. 2018, 116(PtA), 10-19 disclose microorganisms as active ingredients in household, professional and industrial cleaning applications.202400145 Foreign Filings 2US 2013 / 184196 A1 discloses an aqueous cleaning composition comprising spores of certain species of Bacillus such as Bacillus subtilis, Bacillus licheniformis, and Bacillus megaterium (= Priestia megaterium).US 2023 / 220307 A1 discloses an aqueous microbial cleaning composition comprising Bacillus spores.While the prior art thus provides for cleaning products comprising bacteria, there is still a need for further improved cleaning agents based on Bacillus and Priestia with improved spectrum of activity.One area of interest is, in this regard, the removal of malodor of objects or the human or animal body. Such malodor is caused by different substances such as ammonia, sulfide compounds [H2S, (CH3)2S, (CH3)SS(CH3), CH3SH], acetaldehyde. One further cause of malodor is valeric acid.The prior art discloses approaches to remove malodor.WO 2008 / 146958 A1 discloses the use of Bacillus megaterium and other Bacillus species for malodor removal.US 9,404,208 B2 discloses the use of malodor controlling bacteria for the control and prevention of malodor. It discloses certain bacteria strains that degrade one or more odoriferous compounds selected from guaiacol, ethyl butyrate, cis-4-heptenal, 4-methyloctanoic acid, p-anisaldehyde and isovaleric acid.WO 2011 / 163500 A2 discloses Bacillus licheniformis among other Bacillus species to prevent body malodor caused by bacteria.WO 2021 / 243324 A1 discloses microbial cleaning compositions comprising spores of Bacillus strains and use thereof to prevent the production of malodor.There still remains a need for a method to reduce valeric acid efficiently, i.e. with an agent that kicks in quickly (i.e. has a short-term effect), but also has a long-term effect in bringing down the levels of valeric acid.The problem underlying the present invention was the provision of a method and an agent to remove valeric acid-caused malodor with these properties.Detailed description of the InventionSurprisingly, it was found that certain strains of certain bacterial species, namely Bacillus velezensis on the one hand and Priestia megaterium, Bacillus licheniformis, Bacillus subtilis on the other hand, exhibit specific characteristics in the metabolism of valeric acid. These characteristics complement each other202400145 Foreign Filings 3 and are used in a surprisingly advantageous method for the reduction of malodor which is due to the presence of valeric acid.The present invention hence relates to a method for reducing malodor comprising a. contacting valeric acid VA with at least one component Si and at least one component S2 to obtain a mixture M comprising valeric acid VA, at least one component Si, and at least one component S2, wherein Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978, and wherein Si is preferably selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, and wherein Si is more preferably selected from the group consisting of Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674, and wherein Si is most preferably Bacillus velezensis DSM 34978; and wherein S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 , wherein S2 is preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , and wherein S2 is more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 ,202400145 Foreign Filings 4 and wherein S2 is even more preferably selected from the group consisting ofBacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, and wherein S2 is most preferably Bacillus licheniformis DSM 34977; b. incubating M so that the at least one component Si and the at least one component S2 metabolize at least a part of the valeric acid VA.The present invention further relates to mixture M comprising a. valeric acid VA, b. at least one component Si, and c. at least one component S2, wherein Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978, and wherein Si is preferably selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, and wherein Si is more preferably selected from the group consisting of Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674, and wherein Si is most preferably Bacillus velezensis DSM 34978; and wherein S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 , wherein S2 is preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 ,202400145 Foreign Filings 5 and wherein S2 is more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , and wherein S2 is even more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, and wherein S2 is most preferably Bacillus licheniformis DSM 34977.In the course of the studies of the present invention, the following deposited strains were identified by screening of naturally occurring isolates and were deposited at the DSMZ (“Deutsche Sammlung von Mikroorganismen und Zellkulturen”; Leibniz-lnstitute DSMZ-German Collection of Microorganisms and Cell Cultures, InhoffenstraBe 7B, 38124 Braunschweig, Germany) under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure.I. Bacillus velezensis DSM 34978 has been identified by targeted screening of naturally occurring isolates. It was isolated from the soil and has been deposited with the DSMZ on March 20, 2024 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Operations GmbH.II. Bacillus velezensis DSM 34674 has been identified by targeted screening of naturally occurring isolates. It was isolated from the soil and has been deposited with the DSMZ on July 5, 2023 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Operations GmbH.III. Bacillus licheniformis DSM 34977 has been identified by targeted screening of naturally occurring isolates. It was isolated from a bunny feces sample and has been deposited with the DSMZ on March 20, 2024 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Operations GmbH.IV. Priestia megaterium DSM 34980 has been identified by targeted screening of naturally occurring isolates. It was isolated from soil rifled by wild boar and has been deposited with the DSMZ on March 20, 2024 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Operations GmbH.202400145 Foreign Filings 6V. Bacillus subtilis DSM 34981 has been identified by targeted screening of naturally occurring isolates. It was isolated from an environmental soil sample and has been deposited with the DSMZ on March 20, 2024 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure under the Accession Number as mentioned before in the name of Evonik Operations GmbH.I. Method for reducing malodorIn a first aspect, the present invention relates to a method for reducing malodor, preferably of a human or animal body B or an object O, more preferably of an object O, comprising a. contacting valeric acid VA with at least one component Si and at least one component S2 to obtain a mixture M comprising valeric acid VA, at least one component Si, and at least one component S2, wherein Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978, and wherein Si is preferably selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, and wherein Si is more preferably selected from the group consisting of Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674, and wherein Si is most preferably Bacillus velezensis DSM 34978; wherein S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 ,202400145 Foreign Filings 7 wherein S2 is preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , and wherein S2 is more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , and wherein S2 is even more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, and wherein S2 is most preferably Bacillus licheniformis DSM 34977; b. incubating M so that the at least one component Si and the at least one component S2 metabolize at least a part of the valeric acid VA.The method according to the first aspect of the invention is preferably applied as a method for cleaning an object O or the human or animal body B, more preferably applied as a method for cleaning an object O.In those preferred embodiments where the method according to the first aspect of the invention is applied as a method for cleaning the human or animal body B, it is preferred that at least a part of the human or animal body is selected from skin, hair, most preferred hair.An “object O” is a lifeless object and preferably comprises at least one material selected from natural fibre, ceramic, metal, plastic, glass, stone, and may also be a liquid such as an aqueous solution.An “aqueous solution” is, in particular, selected from sewage water, manure and slurry.“Natural fibre” in the context of the invention preferably is one selected from the group consisting of vegetable fibres, animal fibres. Typical vegetable fibres are based on cellulose and in particular selected from wood, cotton, hemp, jute, flax, abaca, pina (pineapple fibre), ramie, sisal, bagasse, banana.Preferably, vegetable fibres are selected from the group consisting of wood, cotton. Vegetable fibres may for example be found in paper, cardboard.Typical animal fibres are in particular selected from the group consisting of wool, silk.The object O in a preferred embodiment is selected from the group consisting of a woven, a non-woven, a vehicle, crockery, cutlery, food storage containers, furniture, flooring, panelling, paving, domestic machine, garden tool, construction equipment, building for livestock or domestic animal, music instrument, toy, window. The object O, in particular, is selected from the group consisting of a woven, a202400145 Foreign Filings 8 non-woven, furniture, flooring, panelling, even more preferably selected from the group consisting of a woven, a non-woven.The woven is in particular selected from an article of clothing, curtains, napkins, bed linen, tablecloth, blanket, bedspread, duvet cover.The non-woven is in particular selected from an article of clothing, curtains, napkins, bed linen, tablecloth, blanket, bedspread, duvet cover.The article of clothing is in particular selected from the group consisting of sweaters, shirts, pants, shoes, socks, hosiery, coats, haberdashery, suits, hats, caps, bonnets, scarfs, gloves.The vehicle is in particular selected from the group consisting of car, train (which may be selected from the group consisting of railroad cars, tram cars, underground railway cars), plane, bicycle, motor-bike, rocket, water vehicles (which may be selected from ships, boats, hovercraft).Crockery is in particular selected from the group consisting of dishes, glassware (such as drinking glasses), cups, platters, mugs, pitchers, pots, cannikins.Cutlery is in particular selected from the group consisting of knives, forks, spoons, chopsticks.Food storage containers are in particular selected from the group consisting of barrels, lunchboxes, bottles, jars.Furniture is in particular selected from the group consisting of shelves, boards, wardrobes, cupboards, desks, tables, chairs, chest of drawers.Flooring is in particular selected from the group consisting of laminate floor, parquet floor, tiled floor, carpeted floor, ceramic floor.Panelling is in particular selected from the group consisting of wallpaper, wall tiles, tapestry.Paving may be any kind of road surface, and is in particular selected from cobblestone, asphalt, gravel.A domestic machine may be any electric machine used in the household, and is in particular selected from washing machine, dishwasher, vacuum cleaner, sound system, lamp, TV, computer, printer, heater, electrical kitchen appliances such as fridge, oven, stove, boiler, egg boiler, toaster, sandwich maker, waffle iron, mixer, bread machine, yogurt maker, coffee maker, electric kettle.A garden tool is preferably selected from the group consisting of rake, grate, lawnmower, scythe, spade, shovel.202400145 Foreign Filings 9Construction equipment is in particular any equipment, electrical or non-electrical, which may be used in handcraft or in construction of buildings, roads. Construction equipment is preferably selected from drilling machines, tools such as hammer, rasp, screwdriver.Building for livestock or domestic animal is in particular any container or building in which pets or farm animals may be kept. In particular, the building for livestock or domestic animal is selected from the group consisting of terrarium, aquarium, cage, pen, kennel, cowshed, hennery, pigsty, coop.Music instrument may be any keyboard instrument, string instrument, wind instrument, percussion instrument and is preferably selected from piano, guitar, drums.Toy is preferably selected from video game console, doll.Window may be any transparent light opening, and is particular selected from outside window of a building, inside window of a building, bull’s eyes of washing machines, bull’s eyes of ships, preferably selected from outside window of a building, inside window of a building.In those embodiments where the method according to the first aspect of the invention is applied as a method for cleaning the human or animal body B, this means that the method according to the invention is applied to a living human being or animal. In the embodiment wherein B selected from skin, hair, is cleaned, this means that the respective part of B of the living human being or animal is cleaned.The method according to the first aspect of the invention may be applied as a method of cleaning. In those embodiments where the human or animal body B is cleaned in the method according to the first aspect of the invention, the method is hence a cosmetic method, and non-therapeutic. It goes without saying that in those preferred embodiments where the object O is cleaned, the method is also non- therapeutic, since the object O is lifeless.1.1 Step a.In step a. of the method of the invention, valeric acid VA is contacted with at least one component Si and at least one component S2 to obtain a mixture M comprising valeric acid VA, at least one component Si, and at least one component S2.Component Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978.202400145 Foreign Filings 10Component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 .Valeric acid (abbreviated as “VA”) is pentanoic acid, i.e. CH3(CH2)3COOH (CAS-No.: 109-52-4).The gist of the invention lies in the combination of Si and S2 for the metabolization of valeric acid.Namely, it was surprisingly observed that the strains pertaining to the two components Si and S2 have different, but complementary metabolization / growth rates when it comes to the metabolization of valeric acid. This allows for their combination in a method to reduce malodor by metabolization of valeric acid.In particular, it was found that Bacillus velezensis DSM 34674 and Bacillus velezensis DSM 34978, i.e. the strains pertaining to component Si, have a high rate of metabolization of valeric acid, but a negative growth rate on valeric acid. This makes these strains destined for quick, short term metabolization of valeric acid.It was further found that, on the other hand, that Priestia megaterium DSM 34980, Bacillus licheniformis DSM 34977, Bacillus subtilis DSM 34981 , i.e. the strains pertaining to component S2, have a lower rate of metabolization of valeric acid, compared to Bacillus velezensis DSM 34674 and Bacillus velezensis DSM 34978, but a positive growth rate. This makes these strains destined for long term metabolization of valeric acid.This is shown in the example section.The combination of Si and S2 thus provides for a method of reducing valeric acid that provides a quick, short term as well as a long term effect in the reduction of valeric acid and thus the elimination of malodor.1. 1.1 Component SiComponent Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978. Preferably, component Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978. More preferably, component Si is selected from the group consisting of Bacillus202400145 Foreign Filings 11 velezensis DSM 34674, Bacillus velezensis DSM 34978. Most preferably, component Si is Bacillus velezensis DSM 34978.It was surprisingly found, that Bacillus velezensis DSM 34674 and Bacillus velezensis DSM 34978 exhibit high VA metabolization rates and thus efficient VA reduction. Although Bacillus velezensis DSM 34674 and Bacillus velezensis DSM 34978 showed smaller tolerances for this organic acid or its degradation products, it was able to metabolize VA over the course of a long incubation period (48 hours) efficiently, as shown and discussed under point IV. of the example section. Between Bacillus velezensis DSM 34674 and Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34978 showed even higher efficiency. Therefore, Bacillus velezensis DSM 34978 and mutants thereof, in some embodiments, are even more preferred as component Si over Bacillus velezensis DSM 34674 and mutants thereof.It is preferred that the Bacillus velezensis strains DSM 34674 and DSM 34978 and their mutants that may be selected as component Si in the method according to the first aspect of the invention are in a living state.Component Si is preferably selected from the group consisting of Bacillus velezensis DSM 34978 and mutants of Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674 and mutants of Bacillus velezensis DSM 34674.It is preferred that the Bacillus velezensis DSM 34978 that may preferably be selected as component Si in the method according to the first aspect of the invention is in a living state.It is preferred that the mutant of Bacillus velezensis DSM 34978 that may preferably be selected as component Si in the method according to the first aspect of the invention is in a living state.It is preferred that the Bacillus velezensis DSM 34674 that may preferably be selected as component Si in the method according to the first aspect of the invention is in a living state.It is preferred that the mutant of Bacillus velezensis DSM 34674 that may preferably be selected as component Si in the method according to the first aspect of the invention is in a living state.It is preferred that the preparation of Bacillus velezensis DSM 34978 that may be selected as component Si in the method according to the first aspect of the invention comprises Bacillus velezensis DSM 34978, even more preferred comprises Bacillus velezensis DSM 34978 in a living state.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34978 that may be selected as component Si in the method according to the first aspect of the invention comprises the mutant of Bacillus velezensis DSM 34978, even more preferred comprises the mutant of Bacillus velezensis DSM 34978 in a living state.202400145 Foreign Filings 12It is preferred that the preparation of Bacillus velezensis DSM 34674 that may be selected as component Si in the method according to the first aspect of the invention comprises Bacillus velezensis DSM 34674, even more preferred comprises Bacillus velezensis DSM 34674 in a living state.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34674 that may be selected as component Si in the method according to the first aspect of the invention comprises the mutant of Bacillus velezensis DSM 34674, even more preferred comprises the mutant of Bacillus velezensis DSM 34674 in a living state.It is preferred that the preparation of Bacillus velezensis DSM 34978 that may be selected as component Si in the method according to the first aspect of the invention comprises the genomic DNA of Bacillus velezensis DSM 34978.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34978 that may be selected as component Si in the method according to the first aspect of the invention comprises the genomic DNA of the mutant of Bacillus velezensis DSM 34978.It is preferred that the preparation of Bacillus velezensis DSM 34674 that may be selected as component Si in the method according to the first aspect of the invention comprises the genomic DNA of Bacillus velezensis DSM 34674.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34674 that may be selected as component in the method according to the first aspect of the invention comprises the genomic DNA of the mutant of Bacillus velezensis DSM 34674.1. 1.2 Component S2Component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 . Preferably, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981. More preferably, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981. Even more preferably, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980. Most preferably, component S2 is Bacillus licheniformis DSM 34977.202400145 Foreign Filings 13It was surprisingly found, that Priestia megaterium DSM 34980, Bacillus licheniformis DSM 34977, Bacillus subtilis DSM 34981 exhibit a positive, high growth rate on VA and simultaneously metabolize and thus reduce VA. Thus, these species are able to metabolize VA over the course of a long incubation period (48 hours) efficiently. Moreover, as they are able to grow on valeric acid medium, the reduction of VA increases over time. This is shown and discussed under point IV. of the example section.Of these three strains Priestia megaterium DSM 34980, Bacillus licheniformis DSM 34977, and Bacillus subtilis DSM 34981 , Bacillus licheniformis DSM 34977 showed the highest efficiency in terms of Exj; 1000 ppm. Therefore, in some embodiments, Bacillus licheniformis DSM 34977 and mutants thereof are even more preferred as component S2 over Priestia megaterium DSM 34980 and mutants thereof and Bacillus subtilis DSM 34981 and mutants thereof.It is preferred that the Priestia megaterium DSM 34980 that may be selected as component S2 in the method according to the first aspect of the invention is in a living state.It is preferred that the mutant of Priestia megaterium DSM 34980 that may be selected as component S2 in the method according to the first aspect of the invention is in a living state.It is preferred that the preparation of Priestia megaterium DSM 34980 that may be selected as component S2 in the method according to the first aspect of the invention comprises Priestia megaterium DSM 34980, more preferably comprises Priestia megaterium DSM 34980 in a living state.It is preferred that the preparation of the mutant of Priestia megaterium DSM 34980 that may be selected as component S2 in the method according to the first aspect of the invention comprises the mutant of Priestia megaterium DSM 34980, more preferably comprises the mutant of Priestia megaterium DSM 34980 in a living state.It is preferred that the Bacillus licheniformis DSM 34977 that may preferably be selected as component S2 in the method according to the first aspect of the invention is in a living state.It is preferred that the mutant of Bacillus licheniformis DSM 34977 that may preferably be selected as component S2 in the method according to the first aspect of the invention is in a living state.It is preferred that the preparation of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the method according to the first aspect of the invention comprises Bacillus licheniformis DSM 34977, more preferably comprises Bacillus licheniformis DSM 34977 in a living state.It is preferred that the preparation of the mutant of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the method according to the first aspect of the invention comprises the mutant of Bacillus licheniformis DSM 34977, more preferably comprises the mutant of Bacillus licheniformis DSM 34977 in a living state.202400145 Foreign Filings 14It is preferred that the Bacillus subtilis DSM 34981 that may preferably be selected as component S2 in the method according to the first aspect of the invention is in a living state.It is preferred that the mutant of Bacillus subtilis DSM 34981 that may preferably be selected as component S2 in the method according to the first aspect of the invention is in a living state.It is preferred that the preparation of Bacillus subtilis DSM 34981 that may be selected as component S2 in the method according to the first aspect of the invention comprises Bacillus subtilis DSM 34981 , more preferably comprises Bacillus subtilis DSM 34981 in a living state.It is preferred that the preparation of the mutant of Bacillus subtilis DSM 34981 that may be selected as component S2 in the method according to the first aspect of the invention comprises the mutant of Bacillus subtilis DSM 34981 , more preferably comprises the mutant of Bacillus subtilis DSM 34981 in a living state.It is preferred that the preparation of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the method according to the first aspect of the invention comprises the genomic DNA of Bacillus licheniformis DSM 34977.It is preferred that the preparation of a mutant of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the method according to the first aspect of the invention comprises the genomic DNA of the mutant of Bacillus licheniformis DSM 34977.It is preferred that the preparation of Priestia megaterium DSM 34980 that may be selected as component S2 in the method according to the first aspect of the invention comprises the genomic DNA of Priestia megaterium DSM 34980.It is preferred that the preparation of a mutant of Priestia megaterium DSM 34980 that may be selected as component S2 in the method according to the first aspect of the invention comprises the genomic DNA of the mutant of Priestia megaterium DSM 34980.It is preferred that the preparation of Bacillus subtilis DSM 34981 that may be selected as component S2 in the method according to the first aspect of the invention comprises the genomic DNA of Bacillus subtilis DSM 34981.It is preferred that the preparation of a mutant of Bacillus subtilis DSM 34981 that may be selected as component S2 in the method according to the first aspect of the invention comprises the genomic DNA of the mutant of Bacillus subtilis DSM 34981 .In a specific embodiment of the method according to the first aspect of the invention,202400145 Foreign Filings 15Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preferably Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34978, more preferably Bacillus velezensis DSM 34978, and S2 is selected from the group consisting Bacillus licheniformis DSM 34977, mutants of Bacillus licheniformis DSM 34977, preferably Bacillus licheniformis DSM 34977.1. 1.3 PreparationIn certain, less preferred, embodiments of the method according to the first aspect of the invention and in certain, less preferred, embodiments of the mixture M according to the second aspect of the invention, component Si is selected from preparations of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674.It is preferred that preparations of Bacillus velezensis DSM 34978 comprise Bacillus velezensis DSM 34978, wherein preferably Bacillus velezensis DSM 34978 is in a living state.It is preferred that preparations of mutants of Bacillus velezensis DSM 34978 comprise mutants of Bacillus velezensis DSM 34978, wherein preferably the mutants of Bacillus velezensis DSM 34978 are in a living state.It is preferred that preparations of Bacillus velezensis DSM 34674 comprise Bacillus velezensis DSM 34674, wherein preferably Bacillus velezensis DSM 34674 is in a living state.It is preferred that preparations of mutants of Bacillus velezensis DSM 34674 comprise mutants of Bacillus velezensis DSM 34674, wherein preferably the mutants of Bacillus velezensis DSM 34674 are in a living state.In certain, less preferred, embodiments of the method according to the first aspect of the invention and in certain, less preferred, embodiments of the mixture M according to the second aspect of the invention, component S2 is selected from preparations of Bacillus licheniformis DSM 34977, preparations of mutants of Bacillus licheniformis DSM 34977; preparations of Priestia megaterium DSM 34980, preparations of mutants of Priestia megaterium DSM 34980; preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus subtilis DSM 34981.202400145 Foreign Filings 16It is preferred that preparations of Bacillus licheniformis DSM 34977 comprise Bacillus licheniformis DSM 34977, wherein preferably Bacillus licheniformis DSM 34977 is in a living state.It is preferred that preparations of mutants of Bacillus licheniformis DSM 34977 comprise mutants of Bacillus licheniformis DSM 34977, wherein preferably the mutants of Bacillus licheniformis DSM 34977 are in a living state.It is preferred that preparations of Priestia megaterium DSM 34980 comprise Priestia megaterium DSM 34980, wherein preferably Priestia megaterium DSM 34980 is in a living state.It is preferred that preparations of mutants of Priestia megaterium DSM 34980 comprise mutants of Priestia megaterium DSM 34980, wherein preferably the mutants of Priestia megaterium DSM 34980 are in a living state.It is preferred that preparations of Bacillus subtilis DSM 34981 comprise Bacillus subtilis DSM 34981 , wherein preferably Bacillus subtilis DSM 34981 is in a living state.It is preferred that preparations of mutants of Bacillus subtilis DSM 34981 comprise mutants of Bacillus subtilis DSM 34981 , wherein preferably the mutants of Bacillus subtilis DSM 34981 are in a living state.The strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof according to the invention may, in particular when in a living state, be present, in particular in the preparation according to the invention, as spores (which are dormant), as vegetative cells (which are growing), as transition state cells (which are transitioning from growth to sporulation phase) or as a combination of at least two, in particular all of these types of cells. In a preferred embodiment, the respective preparation of the invention comprises strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof, respectively, mainly or only as spores.“Mainly as spores” in particular means that at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants202400145 Foreign Filings 17 thereof, Bacillus subtilis DSM 34981 and mutants thereof according to the invention comprised by the respective preparation are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of Bacillus velezensis DSM 34978 that are comprised by the preparation of Bacillus velezensis DSM 34978 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of a mutant of Bacillus velezensis DSM 34978 that are comprised by the preparation of the mutant of Bacillus velezensis DSM 34978 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of Bacillus velezensis DSM 34674 that are comprised by the preparation of Bacillus velezensis DSM 34674 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of a mutant of Bacillus velezensis DSM 34674 that are comprised by the preparation of the mutant of Bacillus velezensis DSM 34674 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %,202400145 Foreign Filings 18 preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of Bacillus licheniformis DSM 34977 that are comprised by the preparation of Bacillus licheniformis DSM 34977 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of a mutant of Bacillus licheniformis DSM 34977 that are comprised by the preparation of the mutant of Bacillus licheniformis DSM 34977 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of Priestia megaterium DSM 34980 that are comprised by the preparation of Priestia megaterium DSM 34980 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of a mutant of Priestia megaterium DSM 34980 that are comprised by the preparation of the mutant of Priestia megaterium DSM 34980 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of Bacillus subtilis DSM 34981 that are comprised by the preparation of Bacillus subtilis DSM 34981 are present as spores.Hence, in a particular embodiment, at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %,202400145 Foreign Filings 19 preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of a mutant of Bacillus subtilis DSM 34981 that are comprised by the preparation of the mutant of Bacillus subtilis DSM 34981 are present as spores.Further, and although it is preferred that the cells of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof comprised by the respective preparation according to the invention are in a living state, in some embodiments of the present invention at least a part, preferably a part, of the cells of the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof comprised by the respective preparation may also be present in non-living, inactivated form, or as a combination of living and inactivated cells, as also the non-living cells are expected to still retain the capability to metabolize valeric acid VA.Accordingly, preparations of the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof according to the invention, may be preparations in which at least a part, preferably a part, of the cells are intact cells, preferably living cells, wherein the respective preparation may also contain inactivated cells and / or cell debris.Further, although less preferred, the preparations according to the invention may also be cell-free preparations, wherein the cell-free preparations may contain cell debris or may be free of cell debris. Particularly preferred examples according to the invention for preparations of the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof are the fermentation broth, as obtained after finishing the fermentation of the cells, the supernatant of the fermentation broth, which is obtained by separating all or the major part of the cells from the fermentation broth, as well as cell lysates and cell extracts, i.e. cytosol preparations, which can be obtained by breaking the microbial cells. Such preparations may also be used in concentrated or dried form, wherein the dried form has preferably a total dry matter content of at least 90 wt.-%, more preferably of at least 95 wt.-%.The term “fermentation broth” according to the invention refers to the product of a cultivation of the respective bacteria, in particular the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants202400145 Foreign Filings 20 thereof according to the invention, in a suitable fermentation medium. Methods for producing such fermentation broths are well known to those skilled in the art. The fermentation broths according to the present invention can for example be obtained by culturing the strains by using the media, conditions and methods as described in US 6,060,051 A, EP 0 287 699 A2, US 2014 / 0010792 A1 . Conventional large- scale microbial culture processes include submerged fermentation, solid state fermentation, or liquid surface culture. Typically, fermentation is carried out, until a certain cell density is reached like an optical density (OD at A = 600 nm) of about 1 to 5, more preferably 3 to 5, even more preferably 4 to 5. The fermentation broths preferably contain cells in an amount of 103to 1011CFU, more preferably in an amount of 105to 1010CFU, above all in an amount of 107to 109CFU per ml of fermentation broth. The term “fermentation broth” according to the invention refers to the direct product of the cultivation, i.e. a suspension preferably containing cells in the amount as mentioned in the previous paragraph, as well as to concentrated and dried forms of such a fermentation broth, wherein the dried form (“dried fermentation broth”) preferably has a total dry matter content of at least 95 wt.-%.Drying of the preparations of the invention can be carried out by applying methods as generally known to those skilled in the art, in particular by evaporation of water, freeze-drying, lyophilization, spray drying, spray granulation, fluidized bed drying, vacuum drying and combinations thereof. After drying, the dried preparations as obtained can be further worked up, in particular by grinding and / or granulation.Cell-free preparations of the respective microorganism, namely the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof according to the invention, can be obtained by centrifugation, filtration and / or decantation of the fermentation broth and / or by centrifugation, filtration and / or decantation of the suspension as obtained after breaking the microbial cells. Depending on the technique used, these cell-free preparations may not be completely devoid of cells, but may still comprise a smaller amount of cells, in particular up to 20 wt.-% or up to 10 wt.-% of cells. As the cells produce and secret compounds like metabolites, enzymes and / or peptides into the surrounding medium, the supernatants, extracts and lysates of the cells comprises a mixture of such compounds, in particular metabolites, enzymes and / or peptides, as secreted and / or produced by the cells. In particular, the supernatants, extracts and lysates of the cells of the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof metabolize VA, preferably as determined by the test according to Assay J.In particular, the supernatants, extracts and lysates of the cells of the strains of Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof grow on 1000 ppm valeric acid, even more preferably on 5000 ppm valeric acid, preferably as determined by the test according to Assay J.202400145 Foreign Filings 21Cell lysates can be prepared either directly by breaking the cells of an optionally dried fermentation broth or by breaking the cells after first separating the cells from the fermentation broth mechanically, in particular by filtration, centrifugation and / or decantation.Breaking of the cells can be carried out by applying techniques as known to those of skill in the art, for example by mechanical means or by applying high pressure. Depending on the degree of force applied, a composition comprising only ruptured cells or a composition comprising a mixture of cell debris and intact cells is obtained. Homogenization of the cells may be realized for example by utilizing means selected from French cell press, sonicator, homogenizer, microfluidizer, ball mill, rod mill, pebble mill, bead mill, high pressure grinding roll, vertical shaft impactor, industrial blender, high shear mixer, paddle mixer, and / or polytron homogenizer. Suitable alternatives are enzymatic and / or chemical treatment of the cells. After breaking of the cells, the cell debris and remaining cells, if any, can optionally be separated from the cytosol preparation thus obtained to obtain a cell extract, i.e. a cytosol preparation, which is free of cells and cell debris.The fermentation broths of the invention, from which the cells have been removed, i.e. the cell-free supernatant and metabolites containing fractions of the fermentation broth, are also denoted as “postbiotics”, “metabiotics” or “biogenics”.A further specific preparation of the invention is a preparation containing at least in part, preferably in part, inactivated cells, i.e. cells which are not able to grow anymore. Preparations containing inactivated cells are also known as “paraprobiotics”. Such preparations can be obtained for example by heat and / or pH inactivation of the cells, preferably by heat and / or pH inactivation of a fermentation broth containing the cells.Inactivation of the cells can be carried out, e.g., by heat treatment and / or by adjusting an acid or an alkaline pH. Heat inactivation of the cells is preferably carried out by increasing the temperature to between 60 °C and 80 °C and incubation for at least 30 minutes. pH inactivation at acidic pH is preferably carried out by lowering the pH to at least 3 by addition of an acid like 5 M H2SO4 and incubation for at least 30 minutes, preferably at least one hour. pH inactivation at alkaline pH is preferably carried out by increasing the pH to at least 10 and incubation for at least 30 minutes, preferably at least one hour. Alternatively, inactivation of the cells may also be carried out by applying y- or UV-irradiation. In one specific embodiment of the invention a fermentation broth is used, in which at least 90 %, more preferably at least 95 % or 99 %, in particular all bacterial cells are inactivated. Correspondingly, in this embodiment of the invention a fermentation broth is used which preferably contains no viable cells at all.The microbial preparations of the invention contain metabolites, enzymes and / or peptides as produced and / or secreted by the microorganisms of the invention, namely the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof.202400145 Foreign Filings 22The preparations of the invention preferably comprise an effective mixture of at least three, more preferably of at least 5, 8, 12 or 15, in particular of all metabolites of at least one microorganism of the invention. The metabolites preferably possess a molecular weight of between 400 and 100000 Dalton, more preferably of between 500 and 50000 Dalton.A preparation containing an effective mixture of metabolites as contained in the microorganisms of the invention and / or as contained in the microbial preparations as mentioned before, can be obtained for example according to the methods set forth in US 6,060,051 A. The preparation may, in particular, be obtained by precipitating the metabolites as contained in the preparations mentioned before by using organic solvents like ethyl acetate and subsequent redissolving of the precipitated metabolites in an appropriate solvent. The metabolites may subsequently be purified by size exclusion filtration that groups metabolites into different fractions based on molecular weight cut-off.The preparations of the invention can also be provided in combination with a suitable carrier, wherein the carrier is preferably an inert formulation ingredient added to improve recovery, efficacy, or physical properties and / or to aid in packaging or administration of the microorganisms or microbial preparations. Such carriers may be used individually or in combination and can be added either as part of the fermentation medium, in the course of the fermentation or after the fermentation of the microorganisms has been ended.The carrier is preferably selected from anti-caking agents, antioxidants, bulking agents, binders, structurants, coatings and / or protectants. Examples of useful carriers include polysaccharides (in particular starches, maltodextrins, celluloses, methylcelluloses, gums like guar gum, xanthan gum and gum arabic, wheat middlings, corn cob meal, chitosan and / or inulins), protein sources (in particular skim milk powder, sweet-whey powder, gelatine and / or soy flour), protein hydrolysates (in particular gelatine, yeast extract and / or peptones like soy peptone), peptides, sugars (in particular lactose, trehalose, sucrose, dextrose and / or maltose), lipids (in particular lecithin, vegetable oils and / or mineral oils), salts (in particular sodium chloride, sodium carbonate, calcium carbonate, chalk, limestone, magnesium carbonate, sodium phosphate, calcium phosphate, magnesium phosphate and / or sodium citrate), silicates (in particular clays, zeolites, Fuller’s earth, clinoptilolite, montmorillonite, perlite, vermiculite, diatomaceous earth, talc, bentonites, kaolin clay, silica, in particular precipitated silica, hydrophobic silica and / or hydrophilic silica, and / or silicate salts like aluminium, magnesium and / or calcium silicate), silica gel, silica dioxide, activated carbon, lignite, magnesium and calcium oxide.202400145 Foreign Filings 231. 1.4 ContactingThe contacting of valeric acid (= “VA”) with the at least one component Si and the at least one component S2 to obtain a mixture M comprising VA, at least one component Si, and at least one component S2, is not particularly limited.In a typical embodiment, the at least one component Si and the at least one component S2 are provided as parts of at least one cleaning formulation F, and VA is present on or in an object O or on the human or animal body B, wherein VA is preferably present as an aqueous solution LVA.In particular, in case of the human or animal body B, such aqueous solution LVA may be selected from sweat, blood, sperm, urine, faeces.In the particular case of an object O, such aqueous solution LVA may also form from rain or condensed water from the air humidity that condensates on the object O and mixes with valeric acid VA which was absorbed on object O.For example, in those embodiments where an object O is cleaned, and O is selected from woven, non-woven, crockery, cutlery, and the method is for example carried out in a washing machine or dishwasher, respectively, the water for dilution may simply be provided through the water tap to which the respective machine is connected.Likewise, in those embodiments where the human or animal body B is cleaned, and in particular a part of the body selected from skin and hair is cleaned, the water for dilution may simply be provided through the water tap to which the respective tap (e.g. shower head) is connected.For example, in case the method according to the invention is carried out in a device which is selected from a dishwasher, in those embodiments where the object O is crockery or cutlery, or a washing machine, in those embodiments where the object O is woven or non-woven, the cleaning formulation F is provided in the detergent compartment, while water is provided during the wash. The cleaning formulation F and water are then mixed, for example in the wash drum of the washing machine.In step a. of the method according to the invention, upon contacting valeric acid VA with at least one component Si and at least one component S2, a mixture M comprising VA, Si, and S2 is obtained.It is preferred that the ratio of the weight of all components Si comprised by mixture M obtained in step a. to all components S2 comprised by mixture M obtained in step a. is in the range of from 99 : 1 to 1 : 99, preferably in the range of from 90 : 10 to 10 : 90, more preferably in the range of from 80 : 20 to 20 : 80, even more preferably in the range of from 70 : 30 to 30 : 70, even more preferably in the range of from 60 : 40 to 40 : 60, most preferably at 50 : 50.Mixture M is preferably an aqueous solution LVA of VA.202400145 Foreign Filings 24Even more preferably, the concentration (weight-%) of valeric acid VA in LVA is preferably < 5000 ppm, in particular in the range of from 1 ppt to 5000 ppm, more preferably in the range of from 1 ppb to 3000 ppm, even more preferably in the range of from 10 ppb to 2000 ppm, even more preferably in the range of from 20 ppb to 1000 ppm, even more preferably in the range of from 30 ppb to 1000 ppm, even more preferably in the range of from 50 ppb to 1000 ppm, even more preferably in the range of from 100 ppb to 1000 ppm, even more preferably in the range of from 1 ppm to 1000 ppm, even more preferably in the range of from 10 ppm to 1000 ppm, even more preferably in the range of from 100 ppm to 1000 ppm, relative to the total weight of LVA.The aqueous solution LVA comprising valeric acid VA may be any liquid film containing valeric acid VA that usually forms as soon as water and the at least one component Si and the at least one component S2 (for example as part of an, optionally diluted, cleaning formulation F, wherein aqueous dilution is preferred) contacts the respective surface for example during the performance of step a. of the method according to the first aspect of the invention.In a preferred step a. of the method according to the first aspect of the invention,VA on the human or animal body B, or VA in or on an object O is contacted with the at least one component Si and the at least one component S2 (for example as part of an, optionally diluted, cleaning formulation F, wherein aqueous dilution is preferred).“Contacting VA” is a further essential feature of the method according to the invention. This is to be understood as meaning that the contacting has to be so that the at least one component Si and the at least one component S2 are both able to metabolize VA. This is typically the case in the mixture M, preferably aqueous solution LVA, comprising VA, at least one component Si, and at least one component S2, which mixture M results in step a.In those embodiments of the method according to the first aspect of the invention where VA is present on or in an object O or on the human or animal body B, contacting may be carried out by bringing both the at least one component Si and the at least one component S2 and at least a part of the surface of the object O / the human or animal body B in direct contact.In the context of the present invention “in direct contact” is to be understood as meaning “wetting” of the object O / the human or animal body B, for example with a cleaning formulation F comprising the at least one component Si and the at least one component S2.It will be appreciated that the object O / the human or animal body B and the at least one component Si and the at least one component S2 are thus in direct contact at a contact surface of object O / the human or animal body B.1.2 Step b.202400145 Foreign Filings 25In step b. of the method according to the first aspect of the invention, M is incubated so that the at least one component Si and the at least one component S2 metabolize at least a part of the valeric acid VA.The gist of the method according to the present invention lies in the fact that the at least one component Si and the at least one component S2 contact valeric acid VA and are incubated to metabolize valeric acid VA.This means that during step b., the at least one component Si and the at least one component S2 metabolize at least a part of the valeric acid VA. Preferably, the incubation according to step b. is carried out until the amount of VA in the mixture M, relative to the amount of VA in the mixture M at the start of the incubation according to step b., has decreased by at least 10 wt.-%, more preferably by at least 20 wt.-%, even more preferably by at least 30 wt.-%, even more preferably by at least 40 wt.-%, even more preferably by at least 50 wt.-%, even more preferably by at least 60 wt.-%, even more preferably by at least 70 wt.-%, even more preferably by at least 80 wt.-%, even more preferably by at least 90 wt.-%, even more preferably by at least 95 wt.-%, even more preferably by at least 99 wt.-%, even more preferably by at least 99.9 wt.-%. Most preferably, during the incubation according to step b., VA in the mixture M, obtained upon the contacting of VA with the at least one component Si and the at least one component S2 in step a, is completely metabolized by the at least one component Si and the at least one component S2.“The amount of VA in the mixture M at the start of the incubation according to step b.” is typically the amount of VA in the mixture M that was obtained in step a. by contacting VA with the at least one component Si and the at least one component S2.The method for reducing malodor according to the first aspect of the present invention is preferably a method for cleaning an object O or the human or animal body B.In this embodiment, preferably, in addition to the metabolization of valeric acid VA, at least one impurity I which is absorbed or adsorbed on the object O or the human or animal body B is at least partially desorbed and thus removed from the object O or the human or animal body B and dispersed or dissolved, in particular dispersed, in the mixture M during step b. In other words: in step a., the at least one component Si and the at least one component S2 are brought in direct contact with at least a part of the surface of object O or the human or animal body B, onto which at least valeric acid VA and preferably at least one further impurity I are absorbed or adsorbed, and in step b., the valeric acid VA is metabolized and thus degraded by the at least one component Si and the at least one component S2 so that, preferably, at least one impurity I is at least partially desorbed or degraded and thus removed from the object O or the human or animal body B. The degradation products from the degradation of valeric acid VA (a particular VA degradation product being CO2) and optionally the degraded or dispersed impurity I is then dispersed or dissolved, in particular dispersed, in the mixture M.The metabolization of the at least a part of the VA in step b. may be sequential, i.e. that first, the at least one component Si metabolizes VA and then the at least one component S2 metabolizes a part of the VA, wherein the metabolization of another part of the VA by S2 only commences after at least 10 weight-% of the VA in the mixture M obtained upon the contacting of VA with the at least one component Si and the at least one component S2 in step a., is metabolized.202400145 Foreign Filings 26However, it is preferred that in step b., there preferably is a simultaneous metabolization of the at least a part of the VA in the mixture M by the at least one component Si and the at least one component S2.Therefore, in particular, after step b., an, optionally diluted, mixture M is obtained, this mixture M preferably comprising at least valeric acid VA and optionally at least one degradation product from the degradation of valeric acid VA, and preferably at least one impurity I in dissolved or dispersed, preferably dispersed, form. In this context, the product from the degradation of valeric acid VA is preferably CO2. The impurity I may either be in the form of a liquid (e.g. droplet) or a particle, and preferably is a particle.In a preferred embodiment, the impurity I is at least one impurity which may be inorganic or organic, and is preferably organic.Organic impurities are preferably selected from oils and fats, which may be of vegetable, animal or synthetic origin, food based particles, soil, pollen, sebum, body fluids, for example, blood, sperm, sweat, urine, faeces, liquor.Inorganic impurities are preferably selected from the group consisting of carbon black, fine dust, plastic particles (e.g. microplastic particles), metal oxides (preferably iron oxide), silica (such as sand), clay, dyes (such as pigments), more preferably clay, in particular kaolin.It is preferred that at least a part of the impurities I cleaned during the method of the invention are the typical substrates of Priestia megaterium DSM 34980 (i.e. proteins), Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674 (i.e. proteins, polysaccharides, cellulose), Bacillus subtilis DSM 34981 (i.e. grease and / or oils).Hence, it is preferred that the impurity I which is cleaned from the object O or the human or animal body B during the method according to the first aspect of the invention, which is used as a cleaning method, is selected from the group consisting of proteins (in particular proteins selected from casein and whey protein), polysaccharides (in particular starch), cellulose, grease, oils.The skilled person may adjust the conditions at which the at least one component Si and the at least one component S2 metabolize valeric acid VA according to the skilled person’s knowledge. Typically, the activity is triggered when during step a. the respective microorganism, namely the strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof are contacted with valeric acid VA and preferably at least one impurity I selected from the group consisting of proteins (which triggers the protease activity), polysaccharides (which triggers the amylase activity), cellulose (which triggers the cellulase activity), grease / oil (which triggers lipase activity).In addition, mixture M in step b. may also comprise at least one of nutrients, salts. These may be added to mixture M during step a. and / or step b.Preferred nutrients are selected from carbohydrates, amino acids, peptides.Peptides are preferably selected from peptone.202400145 Foreign Filings 27As amino acid, any of the natural amino acids may be selected by the skilled person. Preferably, the amino acid is selected from the group consisting of glutamine, alanine, valine, aspartate, glutamate, methionine, asparagine, preferably alanine, valine, asparagine.Carbohydrates are preferably sugars, polysaccharides.Preferred sugars are glucose, saccharose, fructose, galactose.Preferred polysaccharides are starch, inulin.Preferred salts are salts selected from sodium chloride, potassium phosphate, di-potassium hydrogen phosphate.Further additives known to the skilled person may also be applied to the mixture M, such as tris(hydroxymethyl)aminomethane (“Tris”).It is hence preferred, that, if the object O is cleaned in the method according to the first aspect of the invention, the temperature in step b. is in a range of from 10 °C to 70 °C, in particular of from 15 °C to 65 °C, preferably of from 20 °C to 50 °C, more preferably of from 25 °C to 45 °C, more preferably 30 °C to 40 °C, even more preferably 30 °C to 35 °C.If the human or animal body B is cleaned in the method according to the first aspect of the invention, and preferably in those embodiments where skin or hair, is cleaned, it is preferred that the temperature in step b. is in a range of from 15 °C to 45 °C, in particular of from 20 °C to 40 °C, preferably of from 25 °C to 35 °C, even more preferably 30 °C to 35 °C.In a further preferred embodiment, the incubation in step b. is carried out for at least 1 second (“second” = “s”), preferably at least 10 s, preferably for at least 1 minute (“minute” = “min”), more preferably for at least 5 min, preferably for at least 15 min, preferably for at least 60 min, more preferably from 15 min to 3 days (“days” = “d”), more preferably from 30 min to 2 d, more preferably from 45 min to 1 d.It is further preferred that the incubation in step b. is carried out until the amount of valeric acid VA in mixture M has decreased by at least 10 wt.-%, preferably at least 20 wt.-%, more preferably at least 30 wt.-%, more preferably at least 40 wt.-%, more preferably at least 50 wt.-%, more preferably at least60 wt.-%, more preferably at least 70 wt.-%, more preferably at least 80 wt.-%, more preferably at least90 wt.-%, more preferably at least 91 wt.-%, more preferably at least 92 wt.-%, more preferably at least93 wt.-%, more preferably at least 94 wt.-%, more preferably at least 95 wt.-%, more preferably at least96 wt.-%, more preferably at least 97 wt.-%, more preferably at least 98 wt.-%, more preferably at least99 wt.-%, more preferably at least 99.9 wt.-%, more preferably at least 99.99 wt.-%, more preferably at least 99.999 wt.-%, more preferably at least 99.9999 wt.-%, more preferably at least 99.99999 wt.-%, more preferably at least 99.999999 wt.-%, more preferably at least 99.9999999 wt.-%, more preferably at least 99.99999999 wt.-%, more preferably at least 99.999999999 wt.-%, of the valeric acid, wherein the decrease is to be understood relative to the amount of valeric acid VA in mixture M that was obtained in step a. by contacting valeric acid VA with the at least one component Si and the at least one component S2.202400145 Foreign Filings 28Preferably, in those cases where M comprises water, it is preferred that the pH of the water in M in step b. at 25 °C is from 3.5 to 9, preferably from 5 to 9, preferably from 6 to 9, and particularly preferably from 7 to 8.1.3 Step c. (optional)Where the method for reducing malodor according to the first aspect of the invention is applied on a human or animal body B or an object O, and valeric acid VA on a human or animal body B or on an object O is contacted with at least one component Si and at least one component S2, it is further preferred that, after step b., at least a part of M is separated from object O or the animal or body part B, respectively. The separation is, in a preferred embodiment, carried out so that M is essentially completely separated from object O or the animal or body part B.The skilled person is aware of how to carry out this separation in each specific context. Generally, this separation is carried out by withdrawing the object O or the animal or body part B from at least a part of M.An object O subjected to optional step c., is optionally subjected to centrifugation (for example in a washing machine).1.4 Step d.In those optional embodiments of the method according to the first aspect of the invention where step c. is carried out, it is even more preferred to carry out another optional step d. after step c.In an optional step d. of the method according to the invention, the object O or the animal or body part B is rinsed with further water.1.5 Cleaning Formulation FIn step a. of the method according to the first aspect of the invention, the at least one component Si and the at least one component S2 are preferably provided as parts of at least one cleaning formulation F, more preferably as one cleaning formulation F comprising at least one strain pertaining to component Si and at least one strain pertaining to component S2. The cleaning formulation is not further limited and may be a laundry detergent composition, a personal care product (such as an deodorant).The cleaning formulation F comprises at least one component Si and at least one component S2.It is further preferred that the cleaning formulation F comprises the respective Bacillus / Priestia strains according to the invention in a living state.202400145 Foreign Filings 29The cells of the respective Bacillus / Priestia strains according to the invention may be present, in particular in the cleaning formulation F according to the invention, as spores (which are dormant), as vegetative cells (which are growing), as transition state cells (which are transitioning from growth to sporulation phase) or as a combination of at least two, in particular all of these types of cells. In a preferred embodiment, the cleaning formulation F of the invention comprises the Bacillus / Priestia strains, i.e. the respective strains and / or mutants thereof mainly or only as spores. “Mainly as spores” in particular means that at least 50 %, preferably at least 51 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 80 %, preferably at least 85 %, preferably at least 90 %, preferably at least 91 %, preferably at least 92 %, preferably at least 93 %, preferably at least 94 %, preferably at least 95 %, preferably at least 96 %, preferably at least 97 %, preferably at least 98 %, preferably at least 99 %, preferably at least 99.9 %, preferably at least 99.99 % of all cells of the respective strains of Bacillus velezensis DSM 34978 and mutants thereof, Bacillus velezensis DSM 34674 and mutants thereof, Bacillus licheniformis DSM 34977 and mutants thereof, Priestia megaterium DSM 34980 and mutants thereof, Bacillus subtilis DSM 34981 and mutants thereof comprised by the cleaning formulation F are present as spores.1.5. 1 Optional Ingredients of the Cleaning Formulation FThe cleaning formulation F according to the present invention preferably comprises at least one of the following further ingredients. The skilled person may choose from the optional ingredients as described in the following according to his knowledge and according to the intended use of the cleaning formulation F.Hence, in a preferred embodiment, cleaning formulation F further comprises at least one of surfactants, enzymes, builders, solvents, preservatives, benefit agents, polymers, bleaching systems, antiredeposition aids, fibre protection agents, soil release agents, dye transfer inhibitors, fabric hueing agents, blueing dyes, enzyme stabilizing agents like boric acid, pH-regulators, emollients, emulsifiers, thickeners / viscosity regulators / stabilizers, UV photoprotective filters, antioxidants, hydrotropes (or polyols), solids and fillers, film formers, pearlescent additives, deodorant and antiperspirant active ingredients, insect repellents, self-tanning agents, preservatives, conditioners, perfumes, dyes, odour absorbers, cosmetic active ingredients, care additives, superfatting agents, solvents, malodor removers.1.5.1.1 SurfactantsIn a preferred embodiment, composition F comprises at least one surfactant, wherein the surfactant may be a biosurfactant SBIO (rhamnolipid, sophorolipid, glucolipid) or a non-biosurfactant, preferably is a biosurfactant SBIO-The at least one further surfactant may be selected from anionic surfactants, non-ionic surfactants, cationic surfactants, amphoteric surfactants, and in particular is selected from anionic surfactants, nonionic surfactants.202400145 Foreign Filings 301.5.1.1.1 Non-ionic surfactantsIn case the cleaning formulation F comprises at least one non-ionic surfactant, the non-ionic surfactants preferably are alkoxylated, advantageously ethoxylated, in particular primary alcohols having preferably 8 to 18 carbon atoms and on average 1 to 12 mol of ethylene oxide (“EO”) per mol of alcohol, in which the alcohol radical can be linear or branched, preferably 2-position methyl-branched, or can contain linear and methyl-branched radicals in a mixture, as are customarily present in oxo alcohol radicals. In particular, however, alcohol ethoxylates with linear radicals from alcohols of native origin having 12 to 18 carbon atoms, for example from coconut, palm, tallow fat or oleyl alcohol, and on average 2 to 8 EO per mol of alcohol are preferred. The preferred ethoxylated alcohols include, for example, Ci2-Ci4-alcohols with 3 EO, 4 EO or 7 EO, Cg-Cn-alcohol with 7 EO, Ci3-Ci5-alcohols with 3 EO, 5 EO, 7 EO or 8 EO, Ci2-Cia-alcohols with 3 EO, 5 EO or 7 EO and mixtures of these, such as mixtures of Ci2-Ci4-alcohol with 3 EO and Ci2-Cis-alcohol with 7 EO. The stated degrees of ethoxylation are statistical average values which can be an integer or a fraction for a specific product. Preferred alcohol ethoxylates have a narrow homologue distribution.In addition to these examples of non-ionic surfactants, it is also possible to use fatty alcohols with more than 12 EO. Examples thereof are tallow fatty alcohol with 14 EO, 25 EO, 30 EO or 40 EO. Non-ionic surfactants which contain EO and propylene oxide (“PO”) groups together in the molecule can also be used. In this connection, it is possible to use block copolymers with EO-PO block units or PO-EO block units, but also EO-PO-EO copolymers or PO-EO-PO copolymers.It is of course also possible to use mixed alkoxylated non-ionic surfactants in which EO and PO units are not distributed blockwise, but randomly. Such products are obtainable as a result of the simultaneous action of ethylene oxide and propylene oxide on fatty alcohols.Furthermore, alkyl glycosides can also be used as further non-ionic surfactants.A further class of preferably used non-ionic surfactants, which are used either as the sole non-ionic surfactant or in combination with other non-ionic surfactants, are alkoxylated, preferably ethoxylated or ethoxylated and propoxylated fatty acid alkyl esters, preferably having 1 to 4 carbon atoms in the alkyl chain, in particular fatty acid methyl esters, as are described for example in JP S58-217598 A or which are preferably prepared by the process described in WO 90 / 13533 A1 .Non-ionic surfactants of the amine oxide type, for example A / -cocoalkyl-A / ,A / -dimethylamine oxide and A / -tallowalkyl-A / ,A / -dihydroxyethylamine oxide, and of the fatty acid alkanolamide type may also be suitable. The amount of these non-ionic surfactants is preferably not more than that of the ethoxylated fatty alcohols, in particular not more than half thereof.Further suitable non-ionic surfactants are polyhydroxy fatty acid amides; the polyhydroxy fatty acid amides are substances which can usually be obtained by reductive amination of a reducing sugar with ammonia, an alkylamine or an alkanolamine and subsequent acylation with a fatty acid, a fatty acid alkyl ester or a fatty acid chloride.Further non-limiting examples of non-ionic surfactants include alcohol ethoxylates (“AE” or “AEO”), alcohol propoxylates, propoxylated fatty alcohols (“PFA”), alkoxylated fatty acid alkyl esters, such as ethoxylated and / or propoxylated fatty acid alkyl esters, alkylphenol ethoxylates (“APE”), nonylphenol202400145 Foreign Filings 31 ethoxylates (“NPE”), alkylpolyglycosides (“APG”), alkoxylated amines, fatty acid monoethanolamides (“FAM”), fatty acid diethanolamides (“FADA”), ethoxylated fatty acid monoethanolamides (“EFAM”), polyglycerol esters, glycerol esters, propoxylated fatty acid monoethanolamides (“PFAM”), polyhydroxy alkyl fatty acid amides, or A / -acyl A / -alkyl derivatives of glucosamine (glucamides, “GA”, or fatty acid glucamide, “FAGA”), as well as products available under the trade names “SPAN” and “TWEEN”, and combinations thereof.1.5.1 .1 .2 Anionic surfactantsIn case the cleaning formulation F comprises at least one anionic surfactant, it is preferred that these anionic surfactants are of the sulphonate and sulphate type.Suitable surfactants of the sulphonate type here are preferably Cg-Cn-alkylbenzenesulphonates, olefine sulphonates, i.e. mixtures of alkene- and hydroxyalkanesulphonates, and also disulphonates, as are obtained, for example, from Ci2-Ci8-monoolefines with a terminal or internal double bond by sulphonation with gaseous sulphur trioxide and subsequent alkaline or acidic hydrolysis of the sulphonation products. Also of suitability are alkanesulphonates which are obtained from Ci2-Cis-alkanes, for example by sulphochlorination or sulphoxidation with subsequent hydrolysis or neutralization. Similarly, the esters of a-sulpho fatty acids (ester sulphonates), for example the a-sulphonated methyl esters of hydrogenated coconut, palm kernel or tallow fatty acids, are also suitable.Further suitable anionic surfactants are sulphated fatty acid glycerol esters. Fatty acid glycerol esters are to be understood as meaning the mono-, di- and triesters, and also mixtures thereof, as are obtained in the preparation by esterification of a monoglycerol with 1 to 3 mol of fatty acid or in the transesterification of triglycerides with 0.3 to 2 mol of glycerol. Preferred sulphated fatty acid glycerol esters here are the sulphation products of saturated fatty acids having 6 to 22 carbon atoms, for example of caproic acid, caprylic acid, capric acid, myristic acid, lauric acid, palmitic acid, stearic acid or behenic acid.Preferred alkyl sulphates and alkenyl sulphates are the alkali metal and in particular the sodium salts of the sulphuric acid half-esters of the Ci2-Cis-fatty alcohols, for example from coconut fatty alcohol, tallow fatty alcohol, lauryl, myristyl, cetyl or stearyl alcohol or the C10-C20-OXO alcohols and those half-esters of secondary alcohols of these chain lengths. Furthermore, preference is given to alkyl sulphates and alkenyl sulphates of the specified chain length which contain a synthetic straight-chain alkyl radical prepared on a petrochemical basis, and which have an analogous degradation behaviour to the suitable compounds based on fatty chemical raw materials. From the point of view of washing, the Ci2-Ci6-alkyl sulphates and Ci2-Cis-alkyl sulphates and also Ci4-Cis-alkyl sulphates are preferred. 2 ,3-Alky I sulphates, which are prepared for example in accordance with the US 3,234,258 A or US 5,075,041 A and can be obtained as commercial products of the Shell Oil Company under the name DAN®, are also suitable anionic surfactants.The sulphuric acid monoesters of the straight-chain or branched C7-C2o-alcohols ethoxylated with 1 to 6 mol of ethylene oxide (“EO”), such as 2-methyl-branched Cg-Cn-alcohols having on average 3.5 mol of (“EO”) or Ci2-Cis-fatty alcohols with 1 to 4 EO, are also suitable. On account of their high foaming202400145 Foreign Filings 32 behaviour, they are used in cleaning compositions only in relatively small amounts, for example in amounts of from 1 to 5 % by weight.Further suitable anionic surfactants are also the salts of alkylsulphosuccinic acid, which are also referred to as sulphosuccinates or as sulphosuccinic acid esters and constitute the monoesters and / or diesters of sulphosuccinic acid with alcohols, preferably fatty alcohols and in particular ethoxylated fatty alcohols. Preferred sulphosuccinates contain Ca-Cia-fatty alcohol radicals or mixtures of these. Particularly preferred sulphosuccinates contain a fatty alcohol radical which is derived from ethoxylated fatty alcohols. In this connection, sulphosuccinates whose fatty alcohol radicals are derived from ethoxylated fatty alcohols with a narrow homolog distribution are particularly preferred in turn. It is likewise also possible to use alkylsuccinic acid and alkenylsuccinic acid having preferably 8 to 18 carbon atoms in the alkyl chain / alkenyl chain or salts thereof.Particularly preferred anionic surfactants are soaps. Also of suitability are saturated and unsaturated fatty acid soaps, such as the salts of lauric acid, myristic acid, palmitic acid, stearic acid, (hydrogenated) erucic acid and behenic acid, and also soap mixtures derived in particular from natural fatty acids, for example coconut, palm kernel, olive oil or tallow fatty acid.The anionic surfactants including the soaps can be in the form of their sodium, potassium or ammonium salts, as well as soluble salts of organic bases, such as mono-, di- or triethanolamine. Preferably, the anionic surfactants are in the form of their sodium or potassium salts, in particular in the form of the sodium salts.Non-limiting examples of anionic surfactants include sulphates and sulphonates, in particular, linear alkylbenzenesulphonates (“LAS”), isomers of LAS, branched alkylbenzenesulphonates (“BABS”), phenylalkanesulphonates, a-olefine sulphonates (“AOS”), olefine sulphonates, alkene sulphonates, alkane-2,3-diylbis(sulphates), hydroxyalkanesulphonates and disulphonates, alkyl sulphates (“AS”) such as sodium dodecyl sulphate (“SDS”), fatty alcohol sulphates (“FAS”), primary alcohol sulphates (“PAS”), alcohol ethersulphates (“AES” or “AEOS” or “FES”, also known as alcohol ethoxysulphates or fatty alcohol ether sulphates) such as sodium dodecylpoly(oxyethylene) sulphate (“SLES”), secondary alkanesulphonates (“SAS”), paraffin sulphonates (“PS”), ester sulphonates, sulphonated fatty acid glycerol esters, a-sulpho fatty acid methyl esters (“a-SFMe” or “SES”) including methyl ester sulphonate (“MES”), alkyl- or alkenylsuccinic acid, dodecenyl / tetradecenyl succinic acid (“DTSA”), fatty acid derivatives of amino acids, diesters and monoesters of sulfo-succinic acid or soap, and combinations thereof.1.5.1.1.3 Amphotheric surfactantsIn case the cleaning formulation F comprises at least one amphotheric surfactant, it is preferred that these amphotheric surfactants are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO - or -SOs- group in the molecule. Particularly preferred amphoteric surfactants in this connection are betaine surfactants such as alkyl- or alkylamidopropylbetaines. In particular, betaines such as the A / -alkyl-A / ,A / -dimethylammonium glycinates,202400145 Foreign Filings 33 e.g. the cocoalkyldimethylammonium glycinate, A / -acylaminopropyl-A / ,A / -dimethylammonium glycinates, e.g. the cocoacylaminopropyldimethylammonium glycinate, the Ci2-Ci8-alkyldimethylacetobetaine, the cocoamidopropyldimethylacetobetaine, 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazolines and sulphobetaines having in each case 8 to 18 carbon atoms in the alkyl or acyl group, and also the cocoacylaminoethylhydroxyethylcarboxymethyl glycinate are preferred here. A particularly preferred zwitterionic surfactant is the A / ,A / -dimethyl-A / -(lauroylamidopropyl)ammoniumacetobetaine known under the INCI name Cocamidopropyl Betaine.Further suitable amphoteric surfactants are formed by the group of amphoacetates and amphodiacetates, in particular, for example, coco- or laurylamphoacetates or -diacetates, the group of amphopropionates and amphodipropionates, and the group of amino acid-based surfactants such as acyl glutamates, in particular disodium cocoyl glutamate and sodium cocoyl glutamate, acyl glycinates, in particular cocoyl glycinates, and acyl sarcosinates, in particular ammonium lauroyl sarcosinate and sodium cocoyl sarcosinate. Non-limiting examples of amphoteric surfactants include betaine, alkyldimethylbetaine, sulfobetaine.1.5.1.1.4 Cationic surfactantsIn case the cleaning formulation F comprises at least one cationic surfactant. Non-limiting examples of cationic surfactants include alkyldimethylethanolamine quat (“ADMEAQ”), cetyltrimethylammonium bromide (“CTAB”), dimethyldistearylammonium chloride (“DSDMAC”), and alkylbenzyldimethylammonium, alkyl quaternary ammonium compounds, alkoxylated quaternary ammonium (“AQA”) compounds, and combinations thereof.1.5.1.1.5 BiosurfactantsIt is preferred that the cleaning formulation F comprises at least one biosurfactant SBIO- In the context of this invention, “biosurfactant SBIO” is preferably selected from the group consisting of glucolipids, rhamnolipids, sophorolipids, even more preferably from the group of rhamnolipids.Typical biosurfactants are glycolipids such as glucolipids, rhamnolipids, and sophorolipids. Such glycolipids are described in the art together with their syntheses, for example in EP 0 499 434 A1 (glucolipids are referred to as “glucose lipids” in this document), DE 196 48 439 A1 , DE 196 00 743 A1 . WO 03 / 006146 A1 , US 2008 / 0213194 A1 , JP H01 -304034 A1 , CN 1337439 A describe further methods for the synthesis of rhamnolipids. WO 03 / 002700 A1 , US 4,305,961 A, US 7,556,654 B1 describe further methods for the synthesis of sophorolipids.1.5.1.1.5.1 GlucolipidIn the context of the present invention, the term “glucolipid” is in particular to be understood as referring to a structure according to formula (I), even more preferred a structure according to formula (II):202400145 Foreign Filings 34In formulae (I) and (II), mGL = 3, 2, 1 or 0, preferably 1 or 0.Residues R1GLand R2GLare, independently of one another, an organic radical having 2 to 24 carbon atoms, preferably 5 to 20, more preferably 7 to 15, even more preferably 7, carbon atoms, wherein preferably R1GLand R2GLare independently of one another selected from the group consisting of optionally substituted alkyl radicals with 2 to 24 preferably 5 to 20, more preferably 7 to 15, even more preferably 7, carbon atoms, wherein hydroxy substituted alkyl radicals are preferred substituted alkyl radicals, optionally substituted alkenyl radicals with 2 to 24 carbon atoms, preferably 5 to 20, more preferably 7 to 15, even more preferably 7, carbon atoms, wherein hydroxy substituted alkenyl radicals are preferred substituted alkenyl radicals, wherein more preferably R1GLand R2GLare independently of one another selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl, tridecenyl and -(CH2)oCH3 where o = 1 to 23, preferably 4 to 12. Most preferably, R1GLand R2GLare each n-heptyl.Distinct glucolipids for mGL = 0 are abbreviated according to the following nomenclature:“GL-CX” is understood as meaning glucolipids of the general formulae (I) or (II) in which mGL = 0 and in which the radical R1GL= (CH2)o-CH3 where o = X-4.Distinct glucolipids for mGL = 1 are abbreviated according to the following nomenclature:“GL-CXCY” is understood as meaning glucolipids of the general formulae (I) or (II) in which mGL = 1 and in which one of the radicals R1GLand R2GL= (CH2)o-CH3 where o = X-4 and the remaining radical R1GLor R2GL= (CH2)O-CH3where o = Y-4.The nomenclature used thus does not differentiate between “CXCY” and “CYCX”.If one of the aforementioned indices X and / or Y is provided with “:Z”, then this means that the respective radical R1GLand / or R2GL= an unbranched, unsubstituted hydrocarbon radical with X-3 or Y-3 carbon atoms having Z double bonds.The curvy bond in structure (I) [and also structures (III), (V), (VII), (IX), (XI) described hereinafter] implies that the respective substituent may be axial or equatorial, preferably is equatorial.Alkyl radicals may be branched or linear.202400145 Foreign Filings 35Alkenyl radicals may be branched or linear and contain at least one, preferably one to three, double bonds.In those cases where structures according to formulae (I) and (II) comprise more than one residue R2GL, these residues R2GLmay be identical or different from one another.In those embodiments in which cleaning formulation F comprises glucolipids, it is preferred that 1 % by weight to 30 % by weight, preferably 5 % by weight to 25 % by weight, particularly preferably 10 % by weight to 20 % by weight, of all glucolipids comprised by cleaning formulation F are GL-C8C10, where the percentages by weight refer to the sum of all of the glucolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises glucolipids, it is alternatively preferred that 0.5 % by weight to 20 % by weight, preferably 3 % by weight to 17 % by weight, particularly preferably 5 % by weight to 15 % by weight, of all glucolipids comprised by cleaning formulation F are GL-C10C12:1 , where the percentages by weight refer to the sum of all of the glucolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises glucolipids, it is alternatively preferred that 0.5 % by weight to 20 % by weight, preferably 2 % by weight to 15 % by weight, particularly preferably 3 % by weight to 12 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C10C12, where the percentages by weight refer to the sum of all of the glucolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises glucolipids, it is alternatively preferred that1 % by weight to 30 % by weight, preferably 5 % by weight to 25 % by weight, particularly preferably 10 % by weight to 20 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C8C10, 0.5 % by weight to 20 % by weight, preferably 3 % by weight to 17 % by weight, particularly preferably 5 % by weight to 15 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C10C12:1 ,0.5 % by weight to 20 % by weight, preferably 2 % by weight to 15 % by weight, particularly preferably 3 % by weight to 12 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C10C12, where the percentages by weight refer to the sum of all of the glucolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises glucolipids, it is alternatively preferred that 10 % by weight to 20 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C8C10,202400145 Foreign Filings 365 % by weight to 15 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C10C12:1 ,3 % by weight to 12 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C10C12, where the percentages by weight refer to the sum of all of the glucolipids comprised by cleaning formulation F.Over and above this, in those embodiments in which cleaning formulation F comprises glucolipids, it is alternatively preferred that 0 % by weight to 5 % by weight, preferably 0.01 % by weight to 4 % by weight, particularly preferably 0.1 % by weight to 3 % by weight, of all the glucolipids comprised by cleaning formulation F are GL-C10, where the percentages by weight refer to the sum of all of the glucolipids comprised by cleaning formulation F.1.5.1.1.5.2 RhamnolipidsIn the context of the present invention, the term “rhamnolipid” is in particular to be understood as referring to compounds of the general formula (III) and salts thereof, preferably compounds according to the general formula (IV) and salts thereof,In formulae (III) and (IV), mRL = 2, 1 or 0, preferably 1 or 0. nRL = 1 or 0.Residues R1RLand R2RLare independently of one another, an organic radical having 2 to 24 carbon atoms, preferably 5 to 13, more preferably 7 to 10, even more preferably 7, carbon atoms, wherein preferably R1RLand R2RLare independently of one another selected from the group consisting of optionally substituted alkyl radicals with 2 to 24, preferably 5 to 13, more preferably 7 to 10, even more preferably 7, carbon atoms, wherein hydroxy substituted alkyl radicals are preferred substituted alkyl radicals,202400145 Foreign Filings 37 optionally substituted alkenyl radicals with 2 to 24, preferably 5 to 13, more preferably 7 to 10, even more preferably 7, carbon atoms, wherein hydroxy substituted alkenyl radicals are preferred substituted alkenyl radicals, wherein more preferably R1 RLand R2RLare independently of one another selected from the group consisting of pentenyl, heptenyl, nonenyl, undecenyl, tridecenyl and -(CH2)o-CH3 where o = 1 to 23, preferably 4 to 12. Most preferably, R1RLand R2RLare each n-heptyl.If nRL = 1 , the glycosidic bond between the two rhamnose units is preferably in the a-configuration. The optically active carbon atoms of the fatty acids are preferably present as R-enantiomers (e.g. (R)-3-{(R)-3- [2-O-(a-L-rhamnopyranosyl)-a-L-rhamnopyranosyl]oxydecanoyl}oxydecanoate).The term “di-rhamnolipid” in the context of the present invention is understood to mean compounds of the general formulae (III) and (IV) or salts thereof, where nRL = 1 .The term “mono-rhamnolipid” in the context of the present invention is understood to mean compounds of the general formulae (III) and (IV) or salts thereof, where nRL = 0.Distinct rhamnolipids are abbreviated according to the following nomenclature:“diRL-CXCY” are understood to mean di-rhamnolipids of the general formulae (III) and (IV), in which one of the residues R1RLand R2RL= -(CH2)o-CH3 where o = X-4 and the remaining residue R1or R2= -(CH2)O-CH3where o = Y-4.“monoRL-CXCY” are understood to mean mono-rhamnolipids of the general formulae (III) and (IV), in which one of the residues R1RLand R2RL= -(CH2)o-CH3 where o = X-4 and the remaining residue R1RLor R2RL = -(CH2)O-CH3where o = Y-4.The nomenclature used therefore does not distinguish between "CXCY" and "CYCX".For rhamnolipids where mRL=0, the terms “monoRL-CX” or “diRL-CX” are used accordingly.If one of the abovementioned indices X and / or Y is provided with “:Z”, this signifies that the respective residue R1RLand / or R2RLis equal to an unbranched, unsubstituted hydrocarbon residue having X-3 or Y-3 carbon atoms having Z double bonds.Methods for preparing the relevant rhamnolipids are disclosed, for example, in EP 2 786 743 A1 and EP 2 787 065 A1 . Rhamnolipids applicable in the context of the instant invention can also be produced by fermentation of Pseudomonas, especially Pseudomonas aeruginosa, which are preferably non genetically modified cells, a technology already disclosed in the eighties, as documented e.g. in EP 0 282 942 A1 and DE 41 27 908 A1 . Rhamnolipids produced in Pseudomonas aeruginosa cells which have been improved for higher rhamnolipid titres by genetical modification can also be used in the context of the instant invention; such cells have for example been disclosed by L. Lei, F. Zhao, S. Han, Y. Zhang, Biotechnol Lett. 2020, 42, 997-1002.Rhamnolipids produced by Pseudomonas aeruginosa are commercially available from Jeneil Biotech Inc., e.g. under the tradename Zonix, from Logos Technologies (technology acquired by Stepan), e.g. under the tradename NatSurFact, from Biotensidion GmbH, e.g. under the tradename Rhapynal, from AGAE202400145 Foreign Filings 38 technologies, e.g. under the name R90, R95, R95Md, R95Dd, from Locus Bio-Energy Solutions and from Shanghai Yusheng Industry Co. Ltd., e.g. under the tradename Bio-201 Glycolipids.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is preferred that these rhamnolipids comprised by cleaning formulation F are mixtures of mono-rhamnolipids and dirhamnolipids, wherein even more preferably the ratio of the weight of all mono-rhamnolipids comprised by cleaning formulation F to the weight of all di-rhamnolipids comprised by cleaning formulation F is in the range of from 9 : 1 to 1 : 9, preferably of from 8 : 2 to 2 : 8, more preferably of from 7 : 3 to 3 : 7, more preferred of from 6 : 4 to 4 : 6, most preferred is 1 : 1 .Mono-rhamnolipids are compounds according to formula (III), preferably (IV), wherein nRL = 0. Di-rhamnolipids are compounds according to formula (III), preferably (IV), wherein nRL = 1.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is preferred that 56 % by weight to 95 % by weight, preferably 60 % by weight to 80 % by weight, particularly preferably 66 % by weight to 70 % by weight, of all rhamnolipids comprised by cleaning formulation F are diRL-C10C10, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 0.5 % by weight to 15 % by weight, preferably 3 % by weight to 12 % by weight, particularly preferably 5 % by weight to 10 % by weight, of all rhamnolipids comprised by cleaning formulation F are diRL-C10C12:1 , where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 0.5 to 25 % by weight, preferably 3 % by weight to 15 % by weight, particularly preferably 5 % by weight to 12 % by weight, of all rhamnolipids comprised by cleaning formulation F are diRL-C10C12, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 0.1 % by weight to 25 % by weight, preferably 2 % by weight to 10 % by weight, particularly preferably 4 % by weight to 8 % by weight, of all rhamnolipids comprised by cleaning formulation F are diRL-C8C10, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is even further preferred that202400145 Foreign Filings 390.1 % by weight to 5 % by weight, preferably 0.5 % by weight to 3 % by weight, particularly preferably0.5 % by weight to 2 % by weight, of all rhamnolipids comprised by cleaning formulation F are monoRL-C8C10 and / or, preferably and,0.1 % by weight to 5 % by weight, preferably 0.5 % by weight to 3 % by weight, particularly preferably0.5 % by weight to 2 % by weight, of all rhamnolipids comprised by cleaning formulation F are monoRL-C10C10, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 10 % by weight to 30 % by weight, preferably 20 % by weight to 30 % by weight, particularly preferably 25 % by weight to 30 % by weight, of all rhamnolipids comprised by cleaning formulation F are monoRL-C10C10, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 10 % by weight to 30 % by weight, preferably 12 % by weight to 25 % by weight, particularly preferably 15 % by weight to 20 % by weight, of all rhamnolipids comprised by cleaning formulation F are diRL-C10C10, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 10 % by weight to 30 % by weight, preferably 12 % by weight to 25 % by weight, particularly preferably 15 % by weight to 20 % by weight, of all rhamnolipids comprised by cleaning formulation F are monoRL-C8C10, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 3 % by weight to 25 % by weight, preferably 5 % by weight to 20 % by weight, particularly preferably 10 % by weight to 15 % by weight, of all rhamnolipids comprised by cleaning formulation F are monoRL-C10C12:1 , where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.In those embodiments in which cleaning formulation F comprises rhamnolipids, it is alternatively preferred that 1 % by weight to 15 % by weight, preferably 2 % by weight to 10 % by weight, particularly preferably 3 % by weight to 8 % by weight, of all rhamnolipids comprised by cleaning formulation F are diRL-C10C12, where the percentages by weight refer to the sum of all of the rhamnolipids comprised by cleaning formulation F.1.5.1 .1 .5.3 Sophorolipids202400145 Foreign Filings 40In the context of the present invention, the term “sophorolipids” is in particular to be understood as referring to compounds of the general formulae (V), (VII) and salts thereof, preferably compounds of the general formulae (VI), (VIII) and salts thereof:Formulae (V), (VI) represent the acid form, Formulae (VII), (VIII) represent the lactone form.In formulae (V), (VI), nSL = 4, 3, 2, 1 or 0, preferably nSL = 1 or 0.In formulae (V), (VI), (VII), and (VIII), R1SL= H or -CO-CH3, R2SL=H or -CO-CH3, R3SL= a divalent organic moiety which comprises 6 to 32 carbon atoms, preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms.202400145 Foreign Filings 41In those cases where a compound according to one of formulae (V), (VI), comprises more than one residue R2SL, these residues R2SLmay be the same or different.R3SI_ preferably is an optionally substituted, divalent hydrocarbon moiety comprising 6 to 32 carbon atoms, wherein hydroxy substituted hydrocarbon moieties are preferred as substituted hydrocarbon moieties.R3SI_more preferably is selected from the group consisting of• optionally substituted alkylene radicals with 6 to 32, preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms, wherein hydroxy-substituted alkylene radicals are preferred substituted alkylene radicals, and wherein it is preferred that the optionally substituted alkylene radicals are unbranched,• optionally substituted alkenylene radicals with 6 to 32, preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms, wherein hydroxy-substituted alkenylene radicals are preferred substituted alkenylene radicals, and wherein it is preferred that the optionally substituted alkenylene radicals are unbranched, and wherein it is preferred that the optionally substituted alkenylene radicals comprise one to three double or triple bonds.R3SLeven more preferably is selected from the group consisting of• unbranched or branched, preferably unbranched, alkylene radicals with 6 to 32, preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms,• unbranched or branched, preferably unbranched, alkylene radicals with 6 to 32 preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms carrying at least one hydroxy group, preferably one hydroxy group,• unbranched or branched, preferably unbranched, alkenylene radicals with 6 to 32, preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms, wherein the alkenylene radicals preferably comprise one to three double or triple bonds, wherein the alkenylene radicals more preferably comprise one to three double bonds, even more preferably one double bond,• unbranched or branched, preferably unbranched, alkenylene radicals with 6 to 32, preferably 12 to 20, more preferably 14 to 16, most preferably 15, carbon atoms carrying at least one hydroxy group, preferably one hydroxy group, wherein the alkenylene radicals preferably comprise one to three double or triple bonds, wherein the alkenylene radicals more preferably comprise one to three double bonds, even more preferably one double bond.R4SL= H, CH3 or a monovalent organic radical which comprises 2 to 10 carbon atoms.R4SLis preferably selected from the group consisting of• H,• CH3,202400145 Foreign Filings 42• optionally substituted alkyl radicals with 2 to 10 carbon atoms, wherein hydroxy-substituted alkyl radicals are preferred substituted alkyl radicals, and wherein it is preferred that the optionally substituted alkyl radicals are unbranched,• optionally substituted alkenyl radicals with 2 to 10 carbon atoms, wherein hydroxy-substituted alkenyl radicals are preferred substituted alkenyl radicals, and wherein it is preferred that the optionally substituted alkenyl radicals are unbranched, and wherein it is preferred that the optionally substituted alkenyl radicals comprise one to three double or triple bonds.R4SLis more preferably selected from the group consisting of• H,• CH3,• unbranched or branched, preferably unbranched, alkyl radicals with 2 to 10 carbon atoms,• unbranched or branched, preferably unbranched, alkyl radicals with 2 to 10 carbon atoms carrying at least one hydroxy group, preferably one hydroxy group,• unbranched or branched, preferably unbranched, alkenyl radicals with 2 to 10 carbon atoms, wherein the alkenyl radicals preferably comprise one to three double or triple bonds, wherein the alkenyl radicals more preferably comprise one to three double bonds, even more preferably one double bond,• unbranched or branched, preferably unbranched, alkenyl radicals with 2 to 10 carbon atoms carrying at least one hydroxy group, preferably one hydroxy group, wherein the alkenyl radicals preferably comprise one to three double or triple bonds, wherein the alkenyl radicals more preferably comprise one to three double bonds, even more preferably one double bond.R4SLis most preferably selected from the group consisting of H, Methyl, Ethyl, even more preferably is Methyl.In an even more preferred embodiment, the term “sophorolipids” is to be understood as referring to compounds of the general formulae (IX), (XI) and salts thereof, preferably compounds of the general formulae (X), (XII) and salts thereof:202400145 Foreign Filings 43Formulae (IX), (X) represent the acid form. Formulae (XI), (XII) represent the lactone form. nSL, R1SL, R2SL, R4SLhave the same meaning as described for formulae (V), (VII), (VI), (VIII).Sophorolipids may be used in accordance with the invention in their acid form or their lactone form.In those embodiments in which cleaning formulation F comprises sophorolipids, it is preferred that these sophorolipids comprised by cleaning formulation F are mixtures of the acid and the lactone form, wherein even more preferably the ratio of the weight of all sophorolipids in the lactone form comprised by cleaning formulation F to the weight of all sophorolipids in the acid form comprised by cleaning formulation F is in the range of from 20 : 80 to 80 : 20, especially preferably in the range of from 30 : 70 to 40 : 60.To determine the content of sophorolipids in the acid or lactone form in a formulation, refer to EP 1 411 1 11 B1 , page 8, paragraph

[0053] , Sophorolipids may be obtained as described in EP 1 411 111 A1 , paragraphs

[0021] ,

[0022] .Cleaning solution F may also comprise derivatives of sophorolipids such as esters of glycerol which are esterified with sophorolipids (mono-, di-, and triesters of sophorolipids with glycerol) and optionally also fatty acids. Cleaning solution F may therefore comprise derivatives of sophorolipids such as those described in EP 3 034 613 A1 or EP 4 317 448 A1 .202400145 Foreign Filings 441.5.1.2In a preferred embodiment, the cleaning formulation F also comprises at least one enzyme E. These may be the same or different from the enzymes that are used by the strains pertaining to component Si and / or the strains pertaining to component S2 during their metabolism of valeric acid VA. Preferably, they are different from the enzymes that are used by the strains pertaining to component Si and the strains pertaining to component S2 during their metabolism of valeric acid VA.In those embodiments where the cleaning formulation F comprises at least one enzyme E, it is further preferred that the enzyme E is selected from the group consisting of protease, amylase, cellulase, mannanase, lipase, cutinase, pectate lyase, peroxidase, oxidase, laccase. It is even more preferred that the at least one enzyme E is selected from the group consisting of protease, amylase, lipase, mannanase. Most preferred, the at least one enzyme E is a lipase.In case the cleaning formulation F comprises at least one enzyme E, it is preferred that the amount of all enzymes E comprised by the cleaning formulation F is in the range of 0.1 to 4 wt.-% per the total weight of cleaning formulation F.The at least one enzyme E may be included in the cleaning formulation F by adding separate additives (“detergent additives”) containing one or more enzymes, or by adding a combined additive comprising all enzymes E comprised by the cleaning formulation F. Such a detergent additive as contemplated herein, i.e., a separate additive or a combined additive, can be formulated, for example, as a granulate, liquid, slurry, etc. Preferred detergent additive formulations are granulates, in particular non-dusting granulates, liquids, in particular stabilized liquids, or slurries.Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 A and US 4,661 ,452 A and may optionally be coated by methods known in the art. Examples of waxy coating materials are polyethylene oxide) products (polyethylene glycol, “PEG”) with mean molar weights of from about 1000 to about 20000 g / mol; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units per molecule; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms per molecule and in which there are 15 to 80 ethylene oxide units per molecule; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1 ,483,591 A. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Protected enzymes may be prepared according to the method disclosed in EP 0238216 A1.1.5.1.2.1 CellulasesIn those embodiments where the cleaning formulation F comprises at least one cellulase, suitable cellulases include those of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Suitable cellulases include cellulases from the genera Bacillus, Pseudomonas, Humicola,202400145 Foreign Filings 45Fusarium, Thielavia, Acremonium, e.g., the fungal cellulases produced from Humicola insolens, Myceliophthora thermophila and Fusarium oxysporum disclosed in US 4,435,307 A, US 5,648,263 A, US 5,691 ,178 A, US 5,776,757 A and WO 89 / 09259 A1 .Especially suitable cellulases are the alkaline or neutral cellulases having color care benefits. Examples of such cellulases are cellulases described in EP 0 495 257 A1 , WO 91 / 17243 A1 , WO 96 / 11262 A1 , WO 96 / 29397 A1 , WO 98 / 08940 A1 . Other examples are cellulase variants such as those described in WO 94 / 07998 A1 , WO 91 / 17244 A1 , US 5,457,046 A, US 5,686,593 A, US 5,763,254 A, WO 95 / 24471 A1 , WO 98 / 12307 A1 , and WO 99 / 01544 A1 .Example of cellulases exhibiting endo-p-1 ,4-glucanase activity (EC 3.2.1.4) are those described in WO 02 / 099091 A2.Commercially available cellulases include Celluzyme™, and Carezyme™ (Novozymes A / S), Clazinase™, and Puradax HA™ (Genencor International Inc.), and KAC-500(B)™ (Kao Corporation).I.5.1.2.2 ProteasesIn those embodiments where the cleaning formulation F comprises at least one protease, suitable proteases include those of bacterial, fungal, plant, viral or animal origin e.g. vegetable or microbial origin. Microbial origin is preferred. Chemically modified or protein engineered mutants are included. It may be an alkaline protease, such as a serine protease or a metalloprotease. A serine protease may for example be of the S1 family such as trypsin, or the S8 family such as subtilisin. A metalloprotease may for example be a thermolysin from e.g. family M4 or other metalloprotease such as those from M5, M7 or M8 families.The term “subtilases” refers to a sub-group of serine protease according to R.J. Siezen, W.M. de Vos,J.A.M. Leunissen, B.W. Dijkstra, Protein Engineering, Design and Selection 1991 , 4, 719-737 and R.J. Siezen & J.A. Leunissen, Protein Science 1997, 6, 501-523. Serine proteases are a subgroup of proteases characterized by having a serine in the active site, which forms a covalent adduct with the substrate. The subtilases may be divided into 6 sub-divisions, i.e. the Subtilisin family, the Thermitase family, the Proteinase K family, the Lantibiotic peptidase family, the Kexin family and the Pyrolysin family. Examples of subtilases are those derived from Bacillus such as Bacillus lentus, Bacillus alkalophilus, Bacillus subtilis, Bacillus amyloliquefaciens, Bacillus pumilus and Bacillus gibsonii described in:US 7,262,042 B2 and WO 2009 / 021867 A2, and subtilisin lentus, subtilisin Novo, subtilisin Carlsberg, Bacillus licheniformis, subtilisin BPN', subtilisin 309, subtilisin 147 and subtilisin 168 described in WO 89 / 06279 A1 and protease PD138 described in WO 93 / 18140 A1. Other useful proteases may be those described in WO 2019 / 105675 A1 , WO 01 / 016285 A2, and WO 02 / 016547 A2. Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the Fusarium protease described in WO 89 / 06270 A1 , WO 94 / 25583 A1 and WO 2005 / 040372 A1 , and the chymotrypsin proteases derived from Cellumonas described in WO 2005 / 052161 A2 and WO 2005 / 052146 A2.202400145 Foreign Filings 46A further preferred protease is the alkaline protease from Bacillus lentus DSM 5483, as described for example in WO 95 / 23221 A1 , and variants thereof which are described in WO 92 / 21760 A2, WO 95 / 23221 A1 , EP 1 921 147 A2, and EP 1 921 148 A2.Examples of metalloproteases are the neutral metalloprotease as described in WO 2007 / 044993 A2 (Genencor I nt.) such as those derived from Bacillus amyloliquefaciens.Examples of useful proteases are the variants described in: WO 92 / 19729 A1 , WO 96 / 34946 A1 , WO 98 / 20115 A1 , WO 98 / 20116 A1 , WO 99 / 11768 A1 , WO 01 / 44452 A1 , WO 03 / 006602 A2, WO 2004 / 03186 A2, WO 2004 / 041979 A2, WO 2007 / 006305 A1 , WO 2011 / 036263 A1 , WO 2011 / 036264 A1 .Suitable commercially available protease enzymes include those sold under the trade names Alcalase®, Duralase™, Durazym™, Relase®, Relase® Ultra, Savinase®, Savinase® Ultra, Primase, Polarzyme®, Kannase®, Liquanase®, Liquanase® Ultra, Liquanase® 2.5 L, Ovozyme®, Coronase, Coronase® Ultra, Neutrase®, Everlase®, and Esperase® (Novozymes A / S), those sold under the tradename Maxatase®, Maxacai®, Maxapem®, Purafect®, Purafect Prime®, Eraser®, Purafect MA®, Purafect Ox®, Purafect OxP®, Puramax®, Properase®, Ultimase®, FN2®, FN3®, FN4®, Excellase®, Opticlean®, and Optimase® (Danisco / DuPont), Axapem™ (Gist-Brocases N.V.), BLAP (sequence shown in Figure 29 of US 5,352,604 A) and variants thereof (Henkel AG), and KAP (Bacillus alkalophilus subtilisin) from Kao. A protease preferably comprised in the composition according to the instant invention is Liquanase® 2.5 L.In a preferred embodiments, the proteases comprised by cleaning formulation F are stabilized by biosurfactants SBIO such as rhamnolipids, as described in US 2018 / 023040 A1 .1.5.1.2.3 Lipases and cutinasesIn those embodiments where cleaning formulation F comprises at least one of lipase, cutinase, suitable lipases and cutinases include those of bacterial or fungal origin. Chemically modified or protein engineered mutant enzymes are included. Examples include lipase from Thermomyces, e.g. from T. lanuginosus (previously named Humicola lanuginosa) as described in EP 0 258 068 A2 and EP 0 305216 A1 , cutinase from Humicola, e.g. Humicola insolens (WO 96 / 13580 A1), lipase from strains of Pseudomonas (some of these now renamed to Burkholderia), e.g. P. alcaligenes or P. pseudoalcaligenes (EP 0218272 A1), P. cepacia (EP 0 331 376 A2), P. sp. strain SD705 (US 5,827,718 A & US 5,942,431 A), P. wisconsinensis QNO 96 / 12012 A1), GDSL-type Streptomyces lipases (WO 2010 / 065455 A2), cutinase from Magnaporthe grisea (WO 2010 / 107560 A2), cutinase from Pseudomonas mendocina (US 5,389,536 A), lipase from Thermobifida fusca (WO 2011 / 084412 A1), Geobacillus stearothermophilus lipase (WO 2011 / 084417 A1), lipase from Bacillus subtilis (WO 2011 / 084599 A1), and lipase from Streptomyces griseus (WO 2011 / 150157 A2) and S. pristinaespiralis QNO 2012 / 137147 A1).Other examples are lipase variants such as those described in EP 0 407 225 A1 , WO 92 / 05249 A1 , WO 94 / 01541 A1 , WO 94 / 25578 A1 , WO 95 / 14783 A1 , WO 95 / 30744 A2, WO 95 / 35381 A1 ,202400145 Foreign Filings 47WO 95 / 22615 A1 , WO 96 / 00292 A1 , WO 97 / 04079 A1 , WO 97 / 07202 A1 , WO 00 / 34450 A1 , WO 00 / 60063 A1 , WO 01 / 92502 A1 , WO 2007 / 87508 A2, ON 104031899 A, and WO 2009 / 109500 A1 . Preferred commercial lipase products include Lipolase™, Lipex™; Lipolex™, Lipex™ 100 L Evity and Lipoclean™ (Novozymes A / S), Lumafast (originally from Genencor) and Lipomax (originally from Gist- Brocades).Still other examples are lipases sometimes referred to as acyltransferases or perhydrolases, e.g. acyltransferases with homology to Candida antarctica lipase A (WO 2010 / 111143 A2), acyltransferase from Mycobacterium smegmatis (WO 2005 / 56782 A2), perhydrolases from the CE 7 family (WO 2009 / 67279 A1), and variants of the Mycobacterium smegmatis perhydrolase in particular the S54V variant used in the commercial product Gentle Power Bleach from Huntsman Textile Effects Pte Ltd.(WO 2010 / 100028 A2).1.5.1.2.4 AmylasesIn those embodiments where cleaning formulation F comprises at least one amylase, suitable amylases which can be used herein may be an a-amylase or a glucoamylase and may be of bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Amylases include, for example, a-amylases obtained from Bacillus, e.g., a special strain of Bacillus licheniformis, described in more detail in GB 1 ,296,839 A.Suitable amylases include amylases having SEQ ID NO: 3 in WO 95 / 10603 A1 or variants having about 90 % sequence identity to SEQ ID NO: 3 thereof. Preferred variants are described in WO 94 / 02597 A1 , WO 94 / 18314 A1 , WO 97 / 43424 A1 , and SEQ ID NO: 4 of WO 99 / 19467 A1.Different suitable amylases include amylases having SEQ ID NO: 6 in WO 02 / 10355 A2 or variants thereof having about 90 % sequence identity thereto.Other amylases which are suitable are hybrid a-amylase comprising residues 1-33 of the a-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 6 of WO 2006 / 066594 A2 and residues 36-483 of the B. licheniformis a-amylase shown in SEQ ID NO: 4 of WO 2006 / 066594 A2 or variants having about 90 % sequence identity thereof.Further amylases which are suitable are amylases having SEQ ID NO: 6 in WO 99 / 019467 A1 or variants thereof having about 90 % sequence identity to SEQ ID NO: 6.Additional amylases which can be used are those having SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 7 of WO 96 / 23873 A1 or variants thereof having 90 % sequence identity to SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 7.Other amylases which can be used are amylases having SEQ ID NO: 2 of WO 2008 / 153815 A1 , SEQ ID NO: 10 in WO 01 / 66712 A2 or variants thereof having about 90 % sequence identity to SEQ ID NO: 2 of WO 2008 / 153815 A1 or about 90 % sequence identity to SEQ ID NO: 10 in WO 01 / 66712 A2.Further suitable amylases are amylases having SEQ ID NO: 2 of WO 2009 / 061380 A2 or variants having about 90 % sequence identity to SEQ ID NO: 2 thereof.Other suitable amylases are the a-amylase having SEQ ID NO: 12 in WO 01 / 66712 A2 or a variant having at least about 90 % sequence identity to SEQ ID NO: 12.202400145 Foreign Filings 48Other examples are amylase variants such as those described in WO 2011 / 098531 A1 , WO 2013 / 001078 A1 and WO 2013 / 001087 A2.Commercially available amylases are Amplify™ Prime 100 L, Duramyl™, Termamyl™, Fungamyl™,Stainzyme™, Stainzyme Plus™, Natalase™, Liquozyme X and BAN™ (from Novozymes A / S), and Rapidase™, Purastar™ / Effectenz™, Powerase and Preferenz S100 (from Genencor International Inc. / DuPont).202400145 Foreign Filings 491.5.1 .2.5 Peroxidases / oxidasesIn those embodiments where cleaning formulation F comprises at least one peroxidase or oxidase, suitable peroxidases / oxidases include those of plant, bacterial or fungal origin. Chemically modified or protein engineered mutants are included. Examples of useful peroxidases include peroxidases from Coprinus, e.g., from C. cinereus, and variants thereof as those described in WO 93 / 24618 A1 , WO 95 / 10602 A1 , and WO 98 / 15257 A1. Commercially available peroxidases include Guardzyme™ (Novozymes A / S).1.5.1 .2.6 MannanasesIn those embodiments where cleaning formulation F comprises at least one mannanase, mannanases which are particularly preferred according to the invention are mannanases which are sold, for example, under the trade names Mannaway® by the company Novozymes or Purabrite® by the company Genencor. A mannanase preferably comprised in the cleaning formulation F is Mannaway® 4.0 L.1.5.1 .3 BuildersCleaning formulation F may also comprise at least one builder Bz. This is especially useful in those cases where cleaning formulation F is applied as laundry composition.In those embodiments where cleaning formulation F comprises at least one builder Bz, the amount of all builders Bz in cleaning formulation F is preferably between 0.1 wt.-% to 10 wt.-%, preferably 1 wt.-% to 7 wt.-%, relative to the total weight of cleaning formulation F.The builder Bz may particularly be a chelating agent that forms water-soluble complexes with calcium and magnesium. Non-limiting examples of builders Bz include zeolites, diphosphates (pyrophosphates), triphosphates such as sodium triphosphate (“STP” or “STPP”), carbonates such as sodium carbonate, soluble silicates such as sodium metasilicate, layered silicates (e.g., SKS-6 from Hoechst), ethanolamines such as 2-aminoethan-1-ol (“MEA”), diethanolamine (“DEA”, also known as iminodiethanol), triethanolamine (“TEA”, also known as 2,2’,2”-nitrilotriethanol), and carboxymethyl inulin (“CMI”), and combinations thereof.Non-limiting examples of builders Bz include homopolymers of polyacrylates or copolymers thereof, such as poly(acrylic acid) (“PAA”) or copoly(acrylic acid / maleic acid) (“PAA / PMA”). Further non-limiting examples of builders Bz include polyaspartic acids and polyglutamic acids and their salts, citrates, ascorbic acid, chelators such as aminocarboxylates, aminopolycarboxylates, like A / ,A / -dicarboxymethyl glutamic acid and methylglycine A / ,A / -diacetic acid, and phosphonates, and alkyl- or alkenylsuccinic acid. Additional specific examples of builders Bz include 2,2’,2”-nitrilotriacetic acid (“NTA”), ethylenediaminetetraacetic acid (“EDTA”), diethylenetriaminepentaacetic acid (“DTPA”), iminodisuccinic acid (“IDS”), ethylenediamine-A / ,A / ’-disuccinic acid (“EDDS”), glutamic acid-A / ,A / -diacetic acid (“GLDA”), 1-hydroxyethane-1 ,1-diphosphonic acid (“HEDP”), ethylenediaminetetra-(methylenephosphonic acid)202400145 Foreign Filings 50(“EDTMPA”), diethylenetriaminepentakis(methylenephosphonic acid) (“DTPMPA” or“DTMPA”), A / -(2-hydroxyethyl)iminodiacetic acid (“EDG”), aspartic acid-AZ-monoacetic acid (“ASMA”), aspartic acid- A / ,A / -diacetic acid (“ASDA”), aspartic acid-AZ-monopropionic acid (“ASMP”), iminodisuccinic acid (“IDA”), A / -(2-sulfomethyl)-aspartic acid (“SMAS”), A / -(2-sulfoethyl)-aspartic acid (“SEAS”), A / -(2-sulfomethyl)- glutamic acid (“SMGL”), A / -(2-sulfoethyl)-glutamic acid (“SEGL”), A / -methyliminodiacetic acid (“MIDA”), a-alanine-A / ,A / -diacetic acid (“a-ALDA”), serine-A / ,A / -diacetic acid (“SEDA”), isoserine-A / ,A / -diacetic acid (“ISDA”), phenylalanine-A / ,A / -diacetic acid (“PHDA”), anthranilic acid-A / ,A / -diacetic acid (“ANDA”), sulfanilic acid-A / ,A / -diacetic acid (“SLDA”), taurine-A / ,A / -diacetic acid (“TUDA”) and sulfomethyl- A / ,A / -diacetic acid (“SMDA”), A / -(2-hydroxyethyl)-ethylidenediamine-A / ,A / ’,A / ’-triacetate (“HEDTA”), diethanolglycine (“DEG”), diethylenetriamine penta(methylenephosphonic acid) (“DTPMP”), aminotris(methylenephosphonic acid) (“ATMP”), and combinations and salts thereof.Preferred builder Bz comprised in the cleaning formulation F according to the instant invention are selected from the group of aminopolycarboxylates, like A / ,A / -dicarboxymethyl glutamic acid and methylglycine A / ,A / -diacetic acid, citrates, polyaspartic acids and polyglutamic acids and their salts.1.5.1 .4 SolventsIn a preferred embodiment, cleaning formulation F may comprise at least one solvent selected from water or non-aqueous solvent. It is preferred that cleaning formulation F comprises water, and that it is an aqueous mixture. Such aqueous mixture optionally contains at least one non-aqueous solvent.In those embodiments where cleaning formulation F is an aqueous mixture, it is preferred that the content of water in cleaning formulation F is from 1 wt.-% to 99 wt.-%, more preferably from 10 wt.-% to 99 wt.-%, more preferably from 30 wt.-% to 98 wt.-%, more preferably from 50 wt.-% to 97 wt.-%, more preferably from 60 wt.-% to 96 wt.-%, more preferably from 70 wt.-% to 95 wt.-%, more preferably from 80 wt.-% to 90 wt.-%, wherein the weight-% give the percentage of water relative to the total weight of the mixture.Where cleaning formulation F comprises at least one non-aqueous solvent (preferably in addition to water), suitable non-aqueous solvents include monohydric or polyhydric alcohols, alkanolamines or glycol ethers, provided they are miscible with water in the specified concentration range. The solvents are preferably selected from ethanol, n-propanol, Zso-propanol, butanols, glycol, propanediol, butanediol, glycerine, diglycol, propyldiglycol, butyldiglycol, hexylene glycol, ethylene glycol methyl ether, ethylene glycol ethyl ether, ethylene glycol propyl ether, n-butyl glycol ether, ethylene glycol mono-glycol ether, diethylene glycol ethyl ether, propylene glycol methyl ether, propylene glycol ethyl ether, propylene glycol propyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monoethyl ether, diisopropylene glycol monomethyl ether, diisopropylene glycol monoethyl ether, methoxy triglycol, ethoxy triglycol, butoxy triglycol, 1-butoxyethoxy-2-propanol, n-butoxyethoxy-2-propanol, di-butoxyethoxy-2-propanol, 3-butyl-3-methoxyether solvents, and mixtures of these solvents, butoxyethoxy-2-propanol, 3-butyl-3-butyl ether, propyl glycol, di-octanol ether, di-butoxy-2-propanol, propylenglycol, di-butoxyethoxy-2- propanol, di-butoxyethoxy-2-propanol, 3-butoxy-3-methoxyether solvents, diisopropylene glycol monomethylether,202400145 Foreign Filings 51 diisopropylene glycol monoethylether, and mixtures of these solvents. Cleaning formulation F preferably contains a polyol as the non-aqueous solvent. The polyol can comprise glycerol, 1 ,2-propanediol, 1 ,3-propanediol, ethylene glycol, diethylene glycol and / or dipropylene glycol.In those embodiments where cleaning formulation F comprises at least one non-aqueous solvent, the amount of all non-aqueous solvents in cleaning formulation F is preferably between 0.5 wt.-% to 15 wt.-%, preferably 1 wt.-% to 10 wt.-%, relative to the total weight of cleaning formulation F.1.5.1 .5 PreservativesIn a preferred embodiment, cleaning formulation F may comprise at least one preservative. Exemplary preservatives include ascorbic acid, phenoxyethanol, sodium levulinate, sodium benzoate, p-anisic acid, potassium sorbate, benzoic acid, glyceryl caprylate, capryl glycol, pentylene glycol, methyl propane diol, bronopol, isothiazolinone (methylisothiazolinone, chloromethylisothiazolinone).In those embodiments where cleaning formulation F comprises at least one preservative, the amount of all preservatives in cleaning formulation F is preferably between 0.001 wt.-% to 2 wt.-%, preferably 0.01 wt.-% to 0.1 wt.-%, relative to the total weight of cleaning formulation F.1.5.1 .6 Benefit agentIn a preferred embodiment, cleaning formulation F comprises at least one benefit agent. A benefit agent is preferably provided in an encapsulate. The cleaning formulation F may also comprise an unconfined (also called non-encapsulated) benefit agent, for example a volatile benefit agent. Where the volatile benefit agent is a perfume, the perfumes are suitable for use as the encapsulated volatile benefit agent and also as the unconfined perfume component.Preferred encapsulates in this context comprise shear / pressu re-sensitive action encapsulates, whereby the sensorial benefit agent is released in response to mechanical force (e.g. friction, pressure, shear stress) on the encapsulate. The encapsulate shell is preferably comprised of materials including but not limited to polyurethane, polyamide, polyolefine, polysaccharide, protein, silicone, lipid, modified cellulose, gums, polyacrylate, polyphosphate, polystyrene, polyesters or combinations of these materials.Preferably, the benefit agent is selected from the group consisting of a sensorial benefit agent, a skin benefit agent, an olfactory benefit agent, more preferably a sensorial benefit agent. The most preferred benefit agent is a perfume. The benefit agent may be a volatile benefit agent.Sensorial benefit agents may also have benefits for hair and / or hard surfaces and / or fabrics. The sensorial benefit may have anti-foam properties, and as such it is advantageous for foaming purposes that it is encapsulated so as not to interfere with the foam until release by rubbing. Suitable volatile benefit agents include but are not limited to perfumes, insect repellents, essential oils, sensates such as menthol and aromatherapy actives, preferably perfumes. Mixtures of volatile benefit agents may be used.202400145 Foreign Filings 52In those embodiments where cleaning formulation F comprises at least one benefit agent, the total amount of benefit agent is preferably from 0.01 wt.-% to 10 wt.-%, more preferably from 0.05 wt.-% to 5 wt.-%, even more preferably from 0.1 wt.-% to 4.0 wt.-%, most preferably from 0.15 wt.-% to 4.0 wt.-%, based on the total weight of the cleaning formulation F.1.5.1 .7 PolymersIn a preferred embodiment, cleaning formulation F comprises at least one polymer for use in detergents that are different from the polymers described before. The polymer may function as a co-builder as mentioned above, or may provide a further anti-redeposition effect or one function selected from fiber protection, soil release, dye transfer inhibition, viscosity modifiers, grease cleaning and / or anti-foaming properties. Exemplary polymers include (carboxymethyl)cellulose (“CMC”), poly(vinyl alcohol) (“PVA”), polyvinylpyrrolidone) (“PVP”), poly(ethyleneglycol) or poly(ethylene oxide) (“PEG”), ethoxylated poly(ethyleneimine), carboxymethyl inulin (“CMI”), and polycarboxylates such as PAA, PAA / PMA, polyaspartic acid, and lauryl methacrylate / acrylic acid copolymers, hydrophobically modified CMC (“HM-CMC”) and silicones, copolymers of terephthalic acid and oligomeric glycols, copolymers of polyethylene terephthalate) and poly(oxyethylene terephthalate) (“PET-POET”), PVP, poly(vinylimidazole) (“PVI”), poly(vinylpyridine-A / -oxide) (“PVPO” or “PVPNO”) and polyvinylpyrrolidone- vinylimidazole (“PVPVI”). Further exemplary polymers include sulfonated polycarboxylates, polyethylene oxide and polypropylene oxide (“PEO-PPO”) and diquaternium ethoxy sulfate. Other exemplary polymers are disclosed in, e.g., WO 2006 / 130575 A2. Salts of the above-mentioned polymers are also contemplated.Preferably a cleaning formulation F according to the instant invention is characterized in that it comprises at least one selected from anti-redeposition polymers and soil release polymers, with soil release polymers being preferred. This has the technical effect, that the cleaning capabilities of the cleaning formulation F according to the instant invention is even more enhanced. It is preferred in the context of the instant invention, that the anti-redeposition polymer or soil release polymer is selected from the group consisting of modified cellulose, preferably carboxymethylcellulose, cellulose acetate and methylcellulose, modified starch, modified inulin, preferably carboxy methyl inulin, polyitaconic acid, polyvinylpyrrolidone, polyvinyl alcohol, and polyethylene glycol, with carboxymethylcellulose and methylcellulose being most preferred.Further preferred soil release polymers are water soluble polyesters as for example from the TexCare® range commercially available under the name TexCare SRN 260, TexCare SRN 170, TexCare SRN 260 Life and combinations thereof, as well as the soil release polymers disclosed in WO 2016 / 075178 A1 , WO 2016 / 075179 A1 , EP 3 489 340 A1 , and EP 3 489 338 A1 . Further preferred soil release polymers are selected from carboxy methyl inulins. A commercial example is CarboxylineOCMI.EP 1 746 109 A2 discloses hybrid polymers of amylose and acrylates, that can also advantageously be used in the cleaning formulation F of the instant invention as soil release polymers. A commercial example for this type of soil release polymers is Alcoguard® H 5941.202400145 Foreign Filings 53Non-limiting examples of biopolymers include: starch, like e.g. corn starch, Zea mays starch and tapioca starch, modified starch, like e.g. starch hydroxypropyltrimonium chloride and hydrolyzed corn starch, cellulose, bacterial cellulose, modified cellulose, like e.g. microcrystalline cellulose, hydroxypropyl methylcellulose and cetyl hydroxyethylcellulose, guar gum, pectin, inulin, carrageenan, alginate, galactoarabinan, polycitronellol, carboxymethyl inulin, carboxymethyl cellulose, polyitaconic acid and combinations and salts thereof.In those embodiments where cleaning formulation F comprises at least one polymer, the amount of all polymers in cleaning formulation F is preferably from 0.05 wt.-% to 8 wt.-%, preferably from 0.1 wt.-% to 5 wt.-%, relative to the total weight of cleaning formulation F.1.5.1 .8 Other AdditivesIn a preferred embodiment, cleaning formulation F comprises at least one further additives selected from the group consisting of bleaching systems, anti-redeposition aids, fibre protection agents, soil release agents, dye transfer inhibitors, fabric hueing agents, blueing dyes, enzyme stabilizing agents like boric acid, pH-regulators, emollients, emulsifiers, thickeners / viscosity regulators / stabilizers, UV photoprotective filters, antioxidants, hydrotropes (or polyols), solids and fillers, film formers, pearlescent additives, deodorant and antiperspirant active ingredients, insect repellents, self-tanning agents, preservatives, conditioners, perfumes, dyes, odour absorbers, cosmetic active ingredients, care additives, superfatting agents, solvents, malodor removers.Substances which can be used as exemplary representatives of the individual groups are known to the person skilled in the art and can be found for example in US 2011 / 0091399 A1 .1.5.2 Form of the cleaning formulation FThe form of the cleaning formulation F depends on the area of use.In particular in those cases, where the cleaning formulation F is used for cleaning an object O, in particular in cases where the object O is a woven or non-woven article A or where object O is crockery (e.g. dishes, cups) or cutlery, the cleaning formulation F may be in any convenient form, e.g., a bar, a homogenous tablet, a tablet having two or more layers, a pouch having one or more compartments, a regular or compact powder, a granule, a paste, a gel, or a regular, compact or concentrated liquid. There are a number of detergent formulation forms such as layers (same or different phases), pouches, as well as forms for machine dosing unit.Pouches can be configured as single or multi-compartments. They can be of any form, shape and material which is suitable for holding the cleaning formulation F, e.g. without allowing the release of the cleaning formulation F from the pouch prior to water contact. The pouch is made from water soluble film which encloses an inner volume. Said inner volume can be divided into compartments of the pouch.Preferred films are polymeric materials, preferably polymers which are formed into a film or sheet. Preferred polymers, copolymers or derivates thereof are selected polyacrylates, and water soluble acrylate copolymers, methyl cellulose, carboxy methyl cellulose, sodium dextrin, ethyl cellulose,202400145 Foreign Filings 54 hydroxyethyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, poly methacrylates, most preferably polyvinyl alcohol copolymers and, hydroxypropyl methyl cellulose (“HPMC”). Preferably the level of polymer in the film, for example PVA, is at least about 60 wt.-%. The preferred average molecular weight of the polymer will typically be from about 20,000 g / mol to about 150,000 g / mol. Films can also be of blend compositions comprising hydrolytically degradable and water soluble polymer blends such as polyactide and polyvinyl alcohol (known under the Trade reference M8630 as sold by Chris Craft In. Prod. Of Gary, Ind., US) plus plasticizers like glycerol, ethylene glycerol, propylene glycol, sorbitol and mixtures thereof. The pouches can comprise a solid laundry detergent composition or part components and / or a liquid cleaning composition or part components separated by the water-soluble film. The compartment for liquid components can be different in composition than compartments containing solids, see for example US 2009 / 0011970 A1.Detergent ingredients can be separated physically from each other by compartments in water dissolvable pouches or in different layers of tablets. Thereby negative storage interaction between components can be avoided. Different dissolution profiles of each of the compartments can also give rise to delayed dissolution of selected components in the wash solution.In those cases where the cleaning formulation F is a deodorant or detergent composition for body, i.e. in which the cleaning formulation F is used to deodorize or clean the human or animal body B, according to the instant invention, the cleaning formulation F can be in form of a laundry soap bar and used for hand washing laundry, fabrics and / or textiles. The term “laundry soap bar” includes laundry bars, soap bars, combo bars, syndet bars and detergent bars. The types of bar usually differ in the type of surfactant they contain, and the term laundry soap bar includes those containing soaps from fatty acids and / or synthetic soaps. The laundry soap bar has a physical form which is solid and not a liquid, gel or a powder at room temperature. The term “solid” is defined as a physical form which does not significantly change over time, i.e. if a solid object (e.g. laundry soap bar) is placed inside a container, the solid object does not change to fill the container it is placed in. The bar is a solid typically in bar form but can be in other solid shapes such as round or oval.Cleaning formulation F, in particular in those embodiments where it is a detergent composition for household care, can be formulated as a granular detergent as described in WO 2009 / 092699 A1 , EP 1 705241 A1 , EP 1 382 668 A1 , WO 2007 / 001262 A1 , US 6,472,364 B1 , WO 2004 / 074419 A2, or WO 2009 / 102854 A1.Nevertheless, in those cases where the cleaning formulation F is a detergent composition for body, i.e. in which the cleaning formulation F is used for cleaning the human or animal body B, according to the instant invention, the cleaning formulation F preferably is in the form of a liquid or gel detergent. This may be aqueous, typically containing at least 20 wt.-% water, with the percentages referring to the total weight of cleaning formulation F. Other types of liquids, including without limitation, alkanols, amines, diols, ethers and polyols may be included in an aqueous liquid or gel. Where cleaning formulation F is an aqueous liquid or gel detergent, it preferably contains from 0 wt-% to 30 wt.-%, more preferably 1 wt.-% to 25 wt.-%, even more preferably 5 wt.-% to 15 wt.-% organic solvent, with the percentages referring to the total weight of cleaning formulation F. While a liquid or gel detergent may be non-aqueous, it is preferred202400145 Foreign Filings 55 that such liquid or gel detergent comprises water.Where the cleaning formulation F is a detergent composition for body, it is characterized in that the pH of such composition at 25 °C is from 3.0 to 9.0, preferably from 4.0 to 7.0 and particularly preferably from 5.0 to 6.6.Where the cleaning formulation F is a deodorant, it may also comprise typical ingredients of deodorants as described in EP 1 051 966 A2 or WO 2013 / 092186 A2.Optionally, the cleaning formulation F applied in step a. of the method according to the invention is diluted. In those embodiments where the cleaning formulation F is diluted, it is preferred that such dilution is carried out with water. The optional dilution may take place before or while F is in contact with O or B. Preferably, the optional dilution takes place while F is in contact with O or B.The optional dilution of the cleaning formulation F with water W may be carried out according to the skilled person’s knowledge and depends on the context in which the method according to the invention is carried out.II. Bacillus velezensis strain DSM 34674 and mutants thereofIn one preferred aspect of component Si in the context of the method according to the first aspect of the invention and component Si in the context of the mixture M according to the second aspect of the invention, component Si is selected from the group consisting of Bacillus velezensis DSM 34674 and mutants of Bacillus velezensis DSM 34674.“Bacillus velezensis DSM 34674” relates to the Bacillus velezensis strain as deposited under DSM 34674 at the DSMZ (abbreviated as “B. velezensis DSM 34674” or “Bacillus velezensis DSM 34674” or simply “DSM 34674”).It was surprisingly found that Bacillus velezensis DSM 34674 and mutants thereof exhibit a high rate of metabolization of valeric acid (1000 ppm), as set forth under point IV. of the Examples.In addition, it was surprisingly found that Bacillus velezensis DSM 34674 and mutants thereof exhibit a high expression of enzymatic activity for protease and cellulase, and also have good enzymatic activity for amylase (confer point I. of the Examples). Therefore, they are particularly well suited to be used in cleaning formulations.The mutants of Bacillus velezensis DSM 34674 are also Bacillus velezensis strains and may be obtained by any kind of method, i.e. by genetic modification methods (“GMO”) or non-GMO methods, but preferably the mutants of Bacillus velezensis DSM 34674 are not genetically modified, i.e. non-GMO. It202400145 Foreign Filings 56 goes without saying that a mutant of Bacillus velezensis DSM 34674 is not identical with Bacillus velezensis DSM 34674. This means that the mutants of the deposited strain of Bacillus velezensis DSM 34674 are preferably either also naturally occurring microorganisms or spontaneous mutants of such naturally occurring microorganisms, i.e. of the deposited strains, or microorganisms which are obtained by another method which is classified as non-GMO.In the context of the present invention, the term “spontaneous mutant’ refers to mutants that arise from naturally occurring microorganisms and / or parent strains without genetically modifying the microorganisms by applying classical gene technological and / or biotechnological methods like site- directed mutagenesis. Such spontaneous mutants may be obtained by classical methods of natural selection, such as growing the microorganisms in the presence of UV light and / or by applying high temperature or protoplast formation and / or in the presence of a certain antibiotic to which the parent strain is susceptible.Spontaneous mutants might further, but less preferably, be obtained by using mutagens, i.e., chemical substances which induce the formation of mutants. As formation of spontaneous mutants by using mutagens is less preferred, in a preferred embodiment of the invention the spontaneous mutants and / or non-GMO mutants are obtained without the use of such mutagens. If the mutants are obtained by applying gene technological and / or biotechnological methods like site-directed mutagenesis, then preferably methods are applied which are classified as non-GMO.A non-GMO method according to the invention is preferably characterized in that the method does not involve introduction of heterologous genetic information into the microorganism. In a particularly preferred embodiment of the invention the microorganisms of the invention are naturally non-occurring mutants, in particular non-GMO and / or spontaneous mutants as defined before. The microorganisms of the invention have preferably the same characteristics like the parent strain from which they are derived.Preferred mutants of Bacillus velezensis DSM 34674 display property (a), even more preferably display properties (a) and (p) as described under point II.2.It is even more preferred that, alternatively or in addition, preferably in addition, the mutants of Bacillus velezensis DSM 34674 have at least characteristic (2) as follows, wherein it is even more preferred that they have at least characteristics (1) and (2) as follows:(1) a DNA sequence identity (in particular of the genomic DNA of the mutant) to the genomic DNA sequence of B. velezensis DSM 34674 as set forth under point 11.1.1);(2) at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six characteristics i., ii., Hi., iv. , v., and vi. as set forth under point 11.1 .2).11.1 Mutants of Bacillus velezensis DSM 34674 defined by DNAII. 1. 1) Sequence identity to genomic DNA202400145 Foreign Filings 57In a preferred embodiment of the present invention, the term “mutant of DSM 34674” refers to Bacillus velezensis strains with a DNA sequence identity (in particular of the genomic DNA of the mutant) of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of B. velezensis DSM 34674.The person skilled in the art is aware that various computer programs are available for the calculation of similarity or identity between two nucleotide sequences or amino acid sequences.Preferred methods for determining the sequence identity initially generate the greatest alignment between the sequences to be compared. Computer programs for determining the identity include, but are not limited to, the GCG program package includingGAP [J. Devereux, P. Haeberli, O. Smithies, Nucleic Acid Res. 1984, 12, 387-395, Genetics Computer Group University of Wisconsin, Medicine (Wl)], andBLASTP, BLASTN and FASTA (S.F. Altschul, W. Gish, W. Miller, E.W. Myers, D.J. Lipman, J Mol Biol. 1990, 215, 403-410; hereinafter “Altschul et al.’"). The BLAST program can be obtained from the National Center for Biotechnology Information (NCBI) and from other sources (BLAST Handbook, Altschul et al., NCBI NLM NIH Bethesda ND 22894).For instance, the percentage identity between two amino acid sequences can be determined by the algorithm developed by S. B. Needleman & C. D. Wunsch, J Mol Biol. 1970, 48, 443-453 (hereinafter “Needleman & Wunsch”), which has been integrated into the GAP program in the GCG software package, using either a BLOSUM62 matrix or a PAM250 matrix, a gap weight of 16, 14, 12, 10, 8, 6 or 4 and a length weight of 1 , 2, 3, 4, 5 or 6. The person skilled in the art will recognize that the use of different parameters will lead to slightly different results, but that the percentage identity between two amino acid sequences overall will not be significantly different. The BLOSUM62 matrix is typically used applying the default settings (gap weight: 12, length weight: 1).In the context of the present invention, a “sequence identity of 95 %" according to the above algorithm means “95 % homology". The same applies to higher identities.Furthermore, in the context of the present invention, “a DNA sequence with a sequence identity of Y % to the polynucleotide sequence according to SEQ ID NO: X”, means those DNA sequences that display the respective sequence identity of Y % when such sequence identity is determined by comparison of the DNA sequence over its whole length to SEQ ID NO: X over the whole length of SEQ ID NO: X.In the context of the present invention SEQ ID NO: X is, for example, selected from SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ202400145 Foreign Filings 58ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29.Most preferably, the degree of identity between two nucleotide sequences is determined in the context of the present invention by the program “Needle” with the gap opening penalty of 10, and the gap extension penalty of 0.5. The Needle program implements the global alignment algorithm described by Needleman & Wunsch. The preferred version used in the context of this invention is the one presented by F. Madeira, M. Pearce, A.R.N Tivey, P. Basutkar, J. Lee, O. Edbali, N. Madhusoodanan, A. Kolesnikov, R. Lopez, Nucleic Acids Res. 2022, 50, \N276-\N279, Web Server issue (preferred version accessible online on JunI , 2024 via https: / / www.ebi.ac.uk / jdispatcher / psa / emboss_needle).The “genomic sequence of B. velezensis DSM 34674” is available / can be determined from the deposited strain B. velezensis DSM 34674 by means according to the state of the art (for example, as summarized in the reviews by T. Hu, N. Chitnis, D. Monos, A. Dinh, Human Immunology 2021 , 82, 801-811 ; S. Levy & E. Boone, Cold Spring Harbor Perspectives in Medicine 2019, 9, a025791).II. 1.2) Sequence identity to conserved DNA sequencesThe following sequences are typical, conserved sequences of B. velezensis DSM 34674:1. SEQ ID NO: 1 : a DNA sequence coding for the 16S rRNA sequence;2. SEQ ID NO: 2: a rpoB sequence;3. SEQ ID NO: 3: a gyrB sequence;4. SEQ ID NO: 4: a groEL sequence;5. SEQ ID NO: 5: a yqfD sequence;6. SEQ ID NO: 6: a uvrC sequence.In a further preferred embodiment, the mutant of DSM 34674 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 1 ; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 3;202400145 Foreign Filings 59 iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 4; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 5; vi. a DNA sequence, which preferably is a uvrC DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 6.In a most preferred embodiment, the mutant of DSM 34674 exhibits all six characteristics i., ii., Hi., iv., v., and vi.“A DNA sequence with a certain sequence identity, in particular with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 1 , 2, 3, 4, 5, or 6” means those DNA sequences that display the respective sequence identity when such sequence identity is determined by comparison of the DNA sequence over its whole length to SEQ ID NO: 1 , 2, 3, 4, 5, or 6, respectively, over the whole length of SEQ ID NO: 1 , 2, 3, 4, 5, or 6, respectively.II .2 Mutants of Bacillus velezensis DSM 34674 defined by functionBacillus velezensis DSM 34674 according to the invention has improved activities in terms of metabolization and thus reduction of valeric acid VA.In addition, Bacillus velezensis DSM 34674 has high protease activity, cellulase activity, and amylase activity, as summarized under point I.4 of the Example section. In particular, the protease activity of Bacillus velezensis DSM 34674 is surprisingly superior to prior art Bacillus velezensis strains. Preferably, protease activity in case of Bacillus velezensis DSM 34674 and mutants thereof means protease activities in the supernatant, i.e. secreted protease activity, as determined by the test according to Assay A-L Preferably, cellulase activity in case of Bacillus velezensis DSM 34674 and mutants thereof means cellulase activities as determined by the test according to Assay C. Preferably, amylase activity in case of Bacillus velezensis DSM 34674 and mutants thereof means amylase activities as determined by the test according to Assay E.In the context of component Si in the context of the method according to the first aspect of the invention and the mixture M according to the second aspect of the invention, those mutants of Bacillus velezensis DSM 34674 are preferred that display property (a), even more preferably display properties (a) and (p) as follows:202400145 Foreign Filings 60(a) the mutant of Bacillus velezensis DSM 34674 is able to metabolize valeric acid (1000 ppm), even more preferably is able to metabolize valeric acid (5000 ppm), wherein, even more preferably, the ability to metabolize valeric acid VA (1000 ppm) as well as the ability to metabolize valeric acid VA (5000 ppm) is determined by the test according to Assay J;(p) the mutant of Bacillus velezensis DSM 34674 has protease activity (wherein, even more preferably, the protease activity is determined by the test according to Assay A-l), where it is more preferred that the mutant of Bacillus velezensis DSM 34674 has protease activity (wherein, even more preferably, the protease activity is determined by the test according to Assay A-l) and cellulase activity (wherein, even more preferably, the cellulase activity is determined by the test according to Assay C), wherein it is even more preferred that the mutant of Bacillus velezensis DSM 34674 has protease activity (wherein, even more preferably, the protease activity is determined by the test according to Assay A-l), cellulase activity (wherein, even more preferably, the cellulase activity is determined by the test according to Assay C), and amylase activity (wherein, even more preferably, the amylase activity is determined by the test according to Assay E).11.2. 1) Mutant of Bacillus velezensis DSM 34674 with ability to metabolize VAWhere a mutant of Bacillus velezensis DSM 34674 (= “Mutant 34674”) is able to metabolize valeric acid VA at a given concentration XVA of VA, wherein in particular XVA = 1000 ppm and preferably XVA = 5000 ppm, it is preferred that, for this concentration XVA, the metabolization rate kxj% (XVA) of valeric acid VA exhibited by the Mutant 34674 relative to the metabolization rate of valeric acid VA of Bacillus velezensis DSM 34674 is at least 50 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.6 %, more preferably at least 99.7 %, more preferably at least 99.8 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 %, wherein kxj% (XVA) is, in particular, determined by the test according to Assay L-ll (point VII.5.3.2).202400145 Foreign Filings 6111.2.2) Mutant of Bacillus velezensis DSM 34674 with protease activityWhere a mutant of Bacillus velezensis DSM 34674 has protease activity, it is further preferred that the mutant of Bacillus velezensis DSM 34674 has a protease activity which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 1 10 %, more preferably at least 120 % the protease activity of Bacillus velezensis DSM 34674, wherein the protease activity of the mutant of Bacillus velezensis DSM 34674 relative to the protease activity of Bacillus velezensis DSM 34674 is, in particular, determined by the test according to Assay B-ll (point VII.1 .2).11.2.3) Mutant of Bacillus velezensis DSM 34674 with cellulase activityWhere a mutant of Bacillus velezensis DSM 34674 has cellulase activity, it is further preferred that the mutant of Bacillus velezensis DSM 34674 has a cellulase activity which is at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.6 %, more preferably at least 99.7 %, more preferably at least 99.8 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % the cellulase activity of Bacillus velezensis DSM 34674, wherein the cellulase activity of the mutant of Bacillus velezensis DSM 34674 relative to the cellulase activity of Bacillus velezensis DSM 34674 is, in particular, determined by the test according to Assay D-ll (point VII.2.2).11.2.4) Mutant of Bacillus velezensis DSM 34674 with amylase activityWhere a mutant of Bacillus velezensis DSM 34674 has amylase activity, it is further preferred that the mutant of Bacillus velezensis DSM 34674 has an amylase activity which is at least 99 %, more preferably at least 99.5 %, more preferably at least 99.6 %, more preferably at least 99.7 %, more preferably at least 99.8 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % the amylase activity of Bacillus velezensis DSM 34674, wherein the amylase activity of the mutant of Bacillus velezensis DSM 34674202400145 Foreign Filings 62 relative to the amylase activity of Bacillus velezensis DSM 34674 is, in particular, determined by the test according to Assay F-ll (point VII.3.2).III. Bacillus velezensis strain DSM 34978 and mutants thereofIn one preferred aspect of component Si in the context of the method according to the first aspect of the invention and component Si in the context of the mixture M according to the second aspect of the invention, component Si is selected from the group consisting of Bacillus velezensis DSM 34978 and mutants of Bacillus velezensis DSM 34978.“Bacillus velezensis DSM 34978” relates to the Bacillus velezensis strain as deposited under DSM 34978 at the DSMZ (abbreviated as “B. velezensis DSM 34978” or “Bacillus velezensis DSM 34978” or simply “DSM 34978”).It was surprisingly found that Bacillus velezensis DSM 34978 and mutants thereof exhibit a high rate of metabolization of valeric acid (1000 ppm), as set forth under point IV. of the Examples.In addition, it was surprisingly found that B. velezensis DSM 34978 and mutants thereof exhibit a high expression of enzymatic activity for protease, amylase, and cellulase, wherein the expression of enzymatic activity for protease is particularly high (confer point I. of the Examples). Therefore, they are particularly well suited to be used in cleaning formulations.The mutants of Bacillus velezensis DSM 34978 are also Bacillus velezensis strains and may be obtained by any kind of method, i.e., by genetic modification methods (“GMO”) or non-GMO methods, but preferably the mutants of Bacillus velezensis DSM 34978 are not genetically modified, i.e. non-GMO. It goes without saying that a mutant of B. velezensis DSM 34978 is not identical with B. velezensis DSM 34978. This means that the mutants of the deposited strain of B. velezensis DSM 34978 are preferably either also naturally occurring microorganisms or spontaneous mutants of such naturally occurring microorganisms, i.e. of the deposited strains, or microorganisms which are obtained by another method which is classified as non-GMO.Preferred mutants of B. velezensis DSM 34978 display property (a), even more preferably display properties (a) and (p) as described under point II 1.2.It is even more preferred that, alternatively or in addition, preferably in addition, the mutants of Bacillus velezensis DSM 34978 have at least characteristic (2) as follows, wherein it is even more preferred that they have at least characteristics (1) and (2) as follows:(1) a DNA sequence identity (in particular of the genomic DNA of the mutant) to the genomic DNA sequence of B. velezensis DSM 34978 as set forth under point 111.1 .1);202400145 Foreign Filings 63(2) at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six characteristics i., ii., Hi., iv., v., and vi. as set forth under point 111.1 .2).111.1 Mutants of B. velezensis DSM 34978 definedIII. 1. 1) Sequence identity to genomic DNAIn a preferred embodiment of the present invention, the term “mutant of DSM 34978” refers to Bacillus velezensis strains with a DNA sequence identity (in particular of the genomic DNA of the mutant) of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of B. velezensis DSM 34978.The “genomic sequence of B. velezensis DSM 34978” is available / can be determined from the deposited strain B. velezensis DSM 34978 by means according to the state of the art (for example, as summarized in the reviews by T. Hu, N. Chitnis, D. Monos, A. Dinh, Human Immunology 2021 , 82, 801-811 ; S. Levy & E. Boone, Cold Spring Harbor Perspectives in Medicine 2019, 9, a025791).III. 1.2) Sequence identity to conserved DNA sequencesThe following sequences are typical, conserved sequences of Bacillus velezensis DSM 34978:SEQ ID NO: 7: a DNA sequence coding for the 16S rRNA sequence;SEQ ID NO: 8: a rpoB DNA sequence;SEQ ID NO: 9: a gyrB DNA sequence;SEQ ID NO: 10: a groEL DNA sequence;SEQ ID NO: 11 : a DNA sequence coding for an ATP synthase C chain;SEQ ID NO: 12: a DNA sequence coding for a chemotaxis protein sequence.In a further preferred embodiment, the mutant of Bacillus velezensis DSM 34978 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for a 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 7;202400145 Foreign Filings 64 ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 8;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 9; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 10; v. a DNA sequence, which preferably is a DNA sequence coding for an ATP synthase C chain, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 1 1 ; vi. a DNA sequence, which preferably is a DNA sequence coding for a chemotaxis protein, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 12.In a most preferred embodiment, the mutant of B. velezensis DSM 34978 exhibits all six characteristics i., ii., Hi., iv., v., and vi.“A DNA sequence with a certain sequence identity, in particular with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 7, 8, 9, 10, 11 , or 12” means those DNA sequences that display the respective sequence identity when such sequence identity is determined by comparison of the DNA sequence over its whole length to SEQ ID NO: 7, 8, 9, 10, 11 , or 12, respectively, over the whole of SEQ ID NO: 7, 8, 9, 10, 11 , or 12, respectively.III.2 Mutants of B. velezensis DSM 34978 defined by functionBacillus velezensis DSM 34978 according to the invention has improved activities in terms of metabolization and thus reduction of valeric acid VA.In addition, Bacillus velezensis DSM 34978 has high protease activity, cellulase activity, and amylase activity, as summarized under point I.4 of the Example section. In particular, the protease activity of Bacillus velezensis DSM 34978 is surprisingly superior to prior art Bacillus velezensis strains. Preferably, protease activity in case of Bacillus velezensis DSM 34978 and mutants thereof means protease activities in the supernatant, i.e. secreted protease activity, as determined by the test according to Assay A-L Preferably, cellulase activity in case of Bacillus velezensis DSM 34978 and mutants thereof means cellulase activities as determined by the test according to Assay C. Preferably, amylase activity in case of202400145 Foreign Filings 65Bacillus velezensis DSM 34978 and mutants thereof means amylase activities as determined by the test according to Assay E.In the context of component Si in the context of the method according to the first aspect of the invention and the mixture M according to the second aspect of the invention, those mutants of Bacillus velezensis DSM 34978 are preferred that display property (a), even more preferably display properties (a) and (p) as follows:(a) the mutant of Bacillus velezensis DSM 34978 is able to metabolize valeric acid (1000 ppm), even more preferably is able to metabolize valeric acid VA (5000 ppm), wherein, even more preferably, the ability to metabolize valeric acid VA (1000 ppm) as well as the ability to metabolize valeric acid VA (5000 ppm) is determined by the test according to Assay J;(p) the mutant of Bacillus velezensis DSM 34978 has protease activity (wherein, even more preferably, the protease activity is determined by the test according to Assay A-l), where it is more preferred that the mutant of Bacillus velezensis DSM 34978 has protease activity (wherein, even more preferably, the protease activity is determined by the test according to Assay A-l) and cellulase activity (wherein, even more preferably, the cellulase activity is determined by the test according to Assay C), where it is even more preferred that the mutant of Bacillus velezensis DSM 34978 has protease activity (wherein, even more preferably, the protease activity is determined by the test according to Assay A-l), cellulase activity (wherein, even more preferably, the cellulase activity is determined by the test according to Assay C), and amylase activity (wherein, even more preferably, the amylase activity is determined by the test according to Assay E).III.2. 1) Mutant of Bacillus velezensis DSM 34978 with ability to metabolize VAWhere a mutant of Bacillus velezensis DSM 34978 (= “Mutant 34978”) is able to metabolize valeric acid VA at a given concentration XVA of VA, wherein in particular XVA = 1000 ppm and preferably XVA = 5000 ppm, it is preferred that, for this concentration XVA, the metabolization rate kxj% (XVA) of valeric acid VA exhibited by the Mutant 34978 relative to the metabolization of valeric acid of Bacillus velezensis DSM 34978 is at least 50 %, at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.6 %, more preferably at least 99.7 %, more preferably at least 99.8 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 %, wherein kxj% (XVA) is, in particular, determined by the test according to Assay L-l (point VII.5.3.1).202400145 Foreign Filings 66III.2.2) Mutant of Bacillus velezensis DSM 34978 with protease activityWhere a mutant of Bacillus velezensis DSM 34978 has protease activity, it is further preferred that such mutant of Bacillus velezensis DSM 34978 has a protease activity which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 1 10 %, more preferably at least 120 % the protease activity of Bacillus velezensis DSM 34978, wherein the protease activity of the mutant of Bacillus velezensis DSM 34978 relative to the protease activity of Bacillus velezensis DSM 34978 is, in particular, determined by the test according to Assay B-l (point VII.1 .2)111.2.3) Mutant of Bacillus velezensis DSM 34978 with cellulase activityWhere a mutant of Bacillus velezensis DSM 34978 has cellulase activity, it is further preferred that such mutant of Bacillus velezensis DSM 34978 has a cellulase activity which is at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.6 %, more preferably at least 99.7 %, more preferably at least 99.8 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % the cellulase activity of Bacillus velezensis DSM 34978, wherein the cellulase activity of the mutant of Bacillus velezensis DSM 34978 relative to the cellulase activity of Bacillus velezensis DSM 34978 is, in particular, determined by the test according to Assay D-l (point VII.2.2).111.2.4) Mutant of Bacillus velezensis DSM 34978 with amylase activityWhere a mutant of B. velezensis DSM 34978 has amylase activity, it is further preferred that such mutant of Bacillus velezensis DSM 34978 has an amylase activity which is at least 99 %, more preferably at least 99.5 %, more preferably at least 99.6 %, more preferably at least 99.7 %, more preferably at least 99.8 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % the amylase activity of Bacillus velezensis DSM 34978, wherein the amylase activity of the mutant of Bacillus velezensis DSM 34978 relative to the amylase activity of Bacillus velezensis DSM 34978 is, in particular, determined by the test according to Assay F-l (point VII.3.2).202400145 Foreign Filings 67IV. Bacillus licheniformis strain DSM 34977 and mutants thereofIn one preferred aspect of component S2 in the context of the method according to the first aspect of the invention and component S2 in the context of the mixture M according to the second aspect of the invention, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977 and mutants of Bacillus licheniformis DSM 34977.“Bacillus licheniformis DSM 34977” relates to the Bacillus licheniformis DSM 34977 strain as deposited under DSM 34977 at the DSMZ (abbreviated as “B. licheniformis DSM 34977” or “Bacillus licheniformis DSM 34977” or simply “DSM 34977”).It was surprisingly found that B. licheniformis DSM 34977 and mutants thereof exhibit a high ability to grow on valeric acid (1000 ppm) and exhibit a high rate of metabolization of valeric acid (1000 ppm), as set forth under point IV. of the Examples.The mutants of Bacillus licheniformis DSM 34977 are also Bacillus licheniformis strains and may be obtained by any kind of method, i.e., by genetic modification methods (“GMO”) or non-GMO methods, but preferably the mutants of Bacillus licheniformis DSM 34977 are not genetically modified, i.e. non-GMO. It goes without saying that a mutant of Bacillus licheniformis DSM 34977 is not identical with Bacillus licheniformis DSM 34977. This means that the mutants of the deposited strain of Bacillus licheniformis DSM 34977 are preferably either also naturally occurring microorganisms or spontaneous mutants of such naturally occurring microorganisms, i.e. of the deposited strains, or microorganisms which are obtained by another method which is classified as non-GMO.Preferred mutants of Bacillus licheniformis DSM 34977 display property (y), even more preferably display properties (y) and (5) as described under point IV.2.It is even more preferred that, alternatively or in addition, preferably in addition, the mutants of Bacillus licheniformis DSM 34977 have at least characteristic (2) as follows, wherein it is even more preferred that they have at least characteristics (1) and (2) as follows:(1) a DNA sequence identity (in particular of the genomic DNA of the mutant) to the genomic DNA sequence of Bacillus licheniformis DSM 34977 as set forth under point IV.1 .1);(2) at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six characteristics i., ii., Hi., iv. , v., and vi. as set forth under point IV.1 .2).IV.1 Mutants of B. licheniformis DSM 34977 defined by DNAIV. 1. 1) Sequence identity to genomic DNA202400145 Foreign Filings 68In a preferred embodiment of the present invention, the term “mutant of DSM 34977” refers to Bacillus licheniformis strains with a DNA sequence identity (in particular of the genomic DNA of the mutant) of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus licheniformis DSM 34977.The “genomic sequence of B. licheniformis DSM 34977” is available / can be determined from the deposited strain B. licheniformis DSM 34977 by means according to the state of the art (for example, as summarized in the reviews by T. Hu, N. Chitnis, D. Monos, A. Dinh, Human Immunology 2021 , 82, 801- 811 ; S. Levy & E. Boone, Cold Spring Harbor Perspectives in Medicine 2019, 9, a025791).IV. 1.2) Sequence identity to conserved DNA sequencesThe following sequences are typical, conserved sequences of B. licheniformis DSM 34977:SEQ ID NO: 19: a DNA sequence coding for the 16S rRNA sequence;SEQ ID NO: 20: a rpoB sequence;SEQ ID NO: 21 : a gyrB sequence;SEQ ID NO: 22: a groEL sequence;SEQ ID NO: 23: a yqfD sequence;SEQ ID NO: 24: an adaA sequence.In a further preferred embodiment, the mutant of DSM 34977 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 19; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 20;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 21 ; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 22;202400145 Foreign Filings 69 v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 23; vi. a DNA sequence, which preferably is an adaA DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 24.In a most preferred embodiment, the mutant of B. licheniformis DSM 34977 exhibits all six characteristics i., ii., Hi., iv., v., and vi.“A DNA sequence with a certain sequence identity, in particular with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 19, 20, 21 , 22, 23, or 24” means those DNA sequences that display the respective sequence identity when such sequence identity is determined by comparison of the DNA sequence over its whole length to SEQ ID NO: 19, 20, 21 , 22, 23, or 24, respectively, over the whole length of SEQ ID NO: 19, 20, 21 , 22, 23, or 24, respectively.IV.2 Mutants of Bacillus licheniformis DSM 34977 defined by functionBacillus licheniformis DSM 34977 according to the invention has improved activities in terms of growth on 1000 ppm valeric acid and metabolization of valeric acid, as shown under point IV. of the Example section. Preferably, the ability to grow on valeric acid (1000 ppm) and the metabolization of valeric acid in case of Bacillus licheniformis DSM 34977 and mutants thereof is determined by the test according to Assay J (point VII.5.1).In the context of component S2 in the context of the method according to the first aspect of the invention and the mixture M according to the second aspect of the invention, those mutants of Bacillus licheniformis DSM 34977 are preferred that display property (y), more preferably display properties (y) and (5) as follows:(y) the mutant of Bacillus licheniformis DSM 34977 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm), wherein, even more preferably, the ability to grow on VA (1000 ppm) as well as the ability to grow on VA (5000 ppm) is determined by the test according to Assay J, wherein “able to grow on valeric acid (1000 ppm)” means in particular that they fulfill the condition XJ;IOOO ppm > 1 ” for XVA = 1000 ppm as determined by the test according to Assay J (point VII.5.1 .4.1) and wherein “able to grow on valeric acid (5000 ppm)” means in particular that they fulfill the condition xj;sooo ppm > 1 ” for XVA = 5000 ppm as determined by the test according to Assay J (point VII.5.1.4.2);202400145 Foreign Filings 70(5) the mutant of Bacillus licheniformis DSM 34977 has an effectiveness EXJ% (XVA) to reduce valeric acid [wherein XVA = 1000 ppm, preferably XVA = 5000 ppm] which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Bacillus licheniformis DSM 34977 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm, preferably XVA = 5000 ppm] is, in particular, determined by the test according to Assay K-l (point VII.5.2.1).V. Priestia megaterium strain DSM 34980 and mutants thereofIn one preferred aspect of component S2 in the context of the method according to the first aspect of the invention and component S2 in the context of the mixture M according to the second aspect of the invention, component S2 is selected from the group consisting of Priestia megaterium DSM 34980 and mutants of Priestia megaterium DSM 34980.“Priestia megaterium DSM 34980” relates to the Priestia megaterium DSM 34980 strain as deposited under DSM 34980 at the DSMZ (abbreviated as “P. megaterium DSM 34980” or “Priestia megaterium DSM 34980” or simply “DSM 34980”).It was surprisingly found that Priestia megaterium DSM 34980 and mutants thereof exhibit a high ability to grow on valeric acid (1000 ppm) and exhibit a high rate of metabolization of valeric acid (1000 ppm), as set forth under point IV. of the Examples.In addition, it was surprisingly found that Priestia megaterium DSM 34980 and mutants thereof exhibit a high expression of enzymatic activity for protease (confer point II. of the Examples). Therefore, they are particularly well suited to be used in cleaning formulations.The mutants of Priestia megaterium DSM 34980 are also Priestia megaterium strains and may be obtained by any kind of method, i.e., by genetic modification methods (“GMO”) or non-GMO methods, but preferably the mutants of Priestia megaterium DSM 34980 are not genetically modified, i.e. non-GMO. It goes without saying that a mutant of Priestia megaterium DSM 34980 is not identical with Priestia megaterium DSM 34980. This means that the mutants of the deposited strain of Priestia megaterium DSM 34980 are preferably either also naturally occurring microorganisms or spontaneous mutants of such naturally occurring microorganisms, i.e. of the deposited strains, or microorganisms which are obtained by another method which is classified as non-GMO.202400145 Foreign Filings 71Preferred mutants of Priestia megaterium DSM 34980 display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (e) as described under point V.2.It is even more preferred that, alternatively or in addition, preferably in addition, the mutants of Priestia megaterium DSM 34980 have at least characteristic (2) as follows, wherein it is even more preferred that they have at least characteristics (1) and (2) as follows:(1) a DNA sequence identity (in particular of the genomic DNA of the mutant) to the genomic DNA sequence of Priestia megaterium DSM 34980 as set forth under point V.1 .1);(2) at least one, preferably at least two, more preferably at least three, even more preferably at least four, most preferably all five characteristics i., ii., Hi., iv. , and v. as set forth under point V.1.2).V.1 Mutants of PriestiaDSM 34980 defined by DNAV. 1. 1) Sequence identity to genomic DNAIn a preferred embodiment of the present invention, the term “mutant of DSM 34980” refers to Priestia megaterium strains with a DNA sequence identity (in particular of the genomic DNA of the mutant) of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Priestia megaterium DSM 34980.The “genomic sequence of P. megaterium DSM 34980” is available / can be determined from the deposited strain P. megaterium DSM 34980 by means according to the state of the art (for example, as summarized in the reviews by T. Hu, N. Chitnis, D. Monos, A. Dinh, Human Immunology 2021 , 82, 801- 811 ; S. Levy & E. Boone, Cold Spring Harbor Perspectives in Medicine 2019, 9, a025791).V. 1.2) Sequence identity to conserved DNA sequencesThe following sequences are typical, conserved sequences of P. megaterium DSM 34980:1 . SEQ ID NO: 25: a DNA sequence coding for the 16S rRNA sequence;2. SEQ ID NO: 26: a rpoB sequence;3. SEQ ID NO: 27: a gyrB sequence;4. SEQ ID NO: 28: a groEL sequence;5. SEQ ID NO: 29: a yqfD sequence.202400145 Foreign Filings 72In a further preferred embodiment, the mutant of DSM 34980 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, most preferably all five of the following characteristics i. to v.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 25; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 26;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 27; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 28; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 29.In a most preferred embodiment, the mutant of DSM 34980 exhibits all five characteristics i., ii., Hi., iv., and v.“A DNA sequence with a certain sequence identity, in particular with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 25, 26, 27, 28, or 29” means those DNA sequences that display the respective sequence identity when such sequence identity is determined by comparison of the DNA sequence over its whole length to SEQ ID NO: 25, 26, 27, 28, or 29, respectively, over the whole of SEQ ID NO: 25, 26, 27, 28, or 29, respectively.V.2 Mutants of Priestia megaterium DSM 34980 defined by functionPriestia megaterium DSM 34980 according to the invention has improved activities in terms of growth on 1000 ppm valeric acid and metabolization of valeric acid, as shown under point IV. of the Example section. Preferably, the ability to grow on valeric acid (1000 ppm) and the metabolization of valeric acid in case of Priestia megaterium DSM 34980 and mutants thereof is determined by the test according to Assay J.202400145 Foreign Filings 73In addition, Priestia megaterium DSM 34980 has improved activities in terms of protease activity, as shown under point II. of the Example section. Preferably, protease activity in case of P. megaterium DSM 34980 and mutants thereof means total protease activities, i.e. secreted protease activity as well as cellbound protease activity, as determined by the test according to Assay A-ll.In the context of component S2 in the context of the method according to the first aspect of the invention and the mixture M according to the second aspect of the invention, those mutants of Priestia megaterium DSM 34980 are preferred that display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (e) as follows:(y) the mutant of Priestia megaterium DSM 34980 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm), wherein, even more preferably, the ability to grow on VA (1000 ppm) as well as the ability to grow on VA (5000 ppm) is determined by the test according to Assay J, wherein “able to grow on valeric acid (1000 ppm)” means in particular that they fulfill the condition XJ;IOOO ppm > 1 ” for XVA = 1000 ppm as determined by the test according to Assay J (point VII.5.1 .4.1) and wherein “able to grow on valeric acid (5000 ppm)” means in particular that they fulfill the condition xj;sooo ppm > 1 ” for XVA = 5000 ppm as determined by the test according to Assay J (point VII.5.1.4.2);(5) the mutant of Priestia megaterium DSM 34980 has an effectiveness EXJ% (XVA) to reduce valeric acid [wherein XVA = 1000 ppm, preferably XVA = 5000 ppm] which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Priestia megaterium DSM 34980 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm, preferably XVA = 5000 ppm] is, in particular, determined by the test according to Assay K-ll (point VII.5.2.2);(e) the mutant of Priestia megaterium DSM 34980 has protease activity, wherein it is further preferred that the mutant of Priestia megaterium DSM 34980 has a protease activity which is at least 45 %, preferably at least 50 %, preferably at least 55 %, preferably at least 60 %, preferably at least 65 %, preferably at least 70 %, preferably at least 75 %, preferably at least 78 %, preferably at least 79 %, more preferably at least 80 %, more preferably at least 81 %, more preferably at least 82 %, more preferably at least 83 %, more preferably at least 84 %, more preferably at least 85 %, more preferably at least 86 %, more preferably at least 87 %, more preferably at least 88 %, more preferably at least 89 %, more preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more202400145 Foreign Filings 74 preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % the protease activity of Priestia megaterium DSM 34980, wherein the protease activity of the mutant of Priestia megaterium DSM 34980 relative to the protease activity of Priestia megaterium DSM 34980 is, in particular, determined by the test according to Assay B-lll (point VI 1.1.4).VI. Bacillus subtilis strain DSM 34981 and mutantsIn one preferred aspect of component S2 in the context of the method according to the first aspect of the invention and component S2 in the context of the mixture M according to the second aspect of the invention, component S2 is selected from the group consisting of Bacillus subtilis DSM 34981 and mutants of Bacillus subtilis DSM 34981 .“Bacillus subtilis DSM 34981 ” relates to the Bacillus subtilis DSM 34981 strain as deposited under DSM 34981 at the DSMZ (abbreviated as “B. subtilis DSM 34981 ” or “Bacillus subtilis DSM 34981 ” or simply “DSM 34981”).It was surprisingly found that Bacillus subtilis DSM 34981 and mutants thereof exhibit a high ability to grow on valeric acid (1000 ppm) and exhibit a high rate of metabolization of valeric acid (1000 ppm), as set forth under point IV. of the Examples.In addition, it was surprisingly found that Bacillus subtilis DSM 34981 and mutants thereof exhibit a high expression of enzymatic activity for lipase (confer point III. of the Examples). Therefore, they are particularly well suited to be used in cleaning formulations.The mutants of Bacillus subtilis DSM 34981 are also Bacillus subtilis strains and may be obtained by any kind of method, i.e., by genetic modification methods (“GMO”) or non-GMO methods, but preferably the mutants of Bacillus subtilis DSM 34981 are not genetically modified, i.e. non-GMO. It goes without saying that a mutant of Bacillus subtilis DSM 34981 is not identical with Bacillus subtilis DSM 34981 . This means that the mutants of the deposited strain of Bacillus subtilis DSM 34981 are preferably either also naturally occurring microorganisms or spontaneous mutants of such naturally occurring microorganisms, i.e. of the deposited strains, or microorganisms which are obtained by another method which is classified as non- GMO.Preferred mutants of Bacillus subtilis DSM 34981 display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (Q as described under point VI.2.202400145 Foreign Filings 75It is even more preferred that, alternatively or in addition, preferably in addition, the mutants of Bacillus subtilis DSM 34981 have at least characteristic (2) as follows, wherein it is even more preferred that they have at least characteristics (1) and (2) as follows:(1) a DNA sequence identity (in particular of the genomic DNA of the mutant) to the genomic DNA sequence of Bacillus subtilis DSM 34981 as set forth under point VI.1 .1);(2) at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six characteristics i., ii., Hi., iv. , v. and vi. as set forth under point VI.1 .2).VI.1 Mutants of Bacillus subtilis DSM 34981 definedVI. 1. 1) Sequence identity to genomic DNAIn a preferred embodiment of the present invention, the term “mutant of DSM 34981” refers to Bacillus subtilis strains with a DNA sequence identity (in particular of the genomic DNA of the mutant) of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus subtilis DSM 34981 .The “genomic sequence of Bacillus subtilis DSM 34981 ” is available / can be determined from the deposited strain B. subtilis DSM 34981 by means according to the state of the art (for example, as summarized in the reviews by T. Hu, N. Chitnis, D. Monos, A. Dinh, Human Immunology 2021 , 82, 801- 811 ; S. Levy & E. Boone, Cold Spring Harbor Perspectives in Medicine 2019, 9, a025791).V. 1.2) Sequence identity to conserved DNA sequencesThe following sequences are typical, conserved sequences of B. subtilis DSM 34981 :1 . SEQ ID NO: 13: a DNA sequence coding for the 16S rRNA sequence;2. SEQ ID NO: 14: a rpoB sequence;3. SEQ ID NO: 15: a gyrB sequence;4. SEQ ID NO: 16: a groEL sequence;5. SEQ ID NO: 17: a lipC sequence;6. SEQ ID NO: 18: a yqcA sequence.In a further preferred embodiment, the mutant of DSM 34981 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.:202400145 Foreign Filings 76 i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 13; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 14;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 15; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 16; v. a DNA sequence, which preferably is a HpC DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 17; vi. a DNA sequence, which preferably is a yqcA DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 18.In a most preferred embodiment, the mutant of Bacillus subtilis DSM 34981 exhibits all six characteristics i., ii., Hi., iv., v., and vi.“A DNA sequence with a certain sequence identity, in particular with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 13, 14, 15, 16, 17, or 18” means those DNA sequences that display the respective sequence identity when such sequence identity is determined by comparison of the DNA sequence over its whole length to SEQ ID NO: 13, 14, 15, 16, 17, or 18, respectively, over the whole length of SEQ ID NO: 13, 14, 15, 16, 17, or 18, respectively.VI .2 Mutants of Bacillus subtilis DSM 34981 defined by functionBacillus subtilis DSM 34981 according to the invention has improved activities in terms of growth on 1000 ppm valeric acid and metabolization of valeric acid, as shown under point IV. of the Example section. Preferably, the ability to grow on valeric acid (1000 ppm) and the metabolization of valeric acid in case of Bacillus subtilis DSM 34981 and mutants thereof is determined by the test according to Assay J.In addition, Bacillus subtilis DSM 34981 has improved activities in terms of lipase activity, as shown under point III. of the Example section. Preferably, lipase activity in case of Bacillus subtilis DSM 34981 and mutants thereof is determined by the test according to Assay G.202400145 Foreign Filings 77In the context of component S2 in the context of the method according to the first aspect of the invention and the mixture M according to the second aspect of the invention, those mutants of Bacillus subtilis DSM 34981 are preferred that display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (q) as follows:(y) the mutant of Bacillus subtilis DSM 34981 is able to grow on valeric acid VA (1000 ppm), even more preferably is able to grow on valeric acid VA (5000 ppm), wherein, even more preferably, the ability to grow on VA (1000 ppm) as well as the ability to grow on VA (5000 ppm) is determined by the test according to Assay J, wherein “able to grow on valeric acid (1000 ppm)” means in particular that they fulfill the condition XJ;IOOO ppm > 1 ” for XVA = 1000 ppm as determined by the test according to Assay J (point VII.5.1 .4.1) and wherein “able to grow on valeric acid (5000 ppm)” means in particular that they fulfill the condition xj;sooo ppm > 1 ” for XVA = 5000 ppm as determined by the test according to Assay J (point VII.5.1 .4.2);(5) the mutant of Bacillus subtilis DSM 34981 has an effectiveness EXJ% (XVA) to reduce valeric acid VA [wherein XVA = 1000 ppm, preferably XVA = 5000 ppm] which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Bacillus subtilis DSM 34981 to reduce valeric acid VA, wherein EXJ% (XVA) [wherein XVA = 1000 ppm, preferably XVA = 5000 ppm] is, in particular, determined by the test according to Assay K-lll (point VII.5.2.3);( ) the mutant of Bacillus subtilis DSM 34981 has lipase activity, wherein it is further preferred that the mutant of Bacillus subtilis DSM 34981 has a lipase activity which is at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % the lipase activity of B. subtilis DSM 34981 , wherein the lipase activity of the mutant of Bacillus subtilis DSM 34981 relative to the lipase activity of Bacillus subtilis DSM 34981 is, in particular, determined by the test according to Assay H (point Vll.4.2).202400145 Foreign Filings 78VII. Assays for qualification and quantification of catalytic activities and valeric acid metabolismVI 1.1 Protease activity“Protease activity” in the sense of the present invention is deemed to be an activity that catalyzes the hydrolytic cleavage of a peptide bond linking two amino acid residues (“proteolytic enzymatic activity”). US 2018 / 023040 A1 discloses cleaning compositions comprising proteases, which provide a biocatalytic composition comprising biosurfactants and a protease.The prior art describes different assays to qualitatively and quantitatively determine protease activity, for example in Zhang et al., ACS Omega 2021 , 6, 3675-3680.In the context of the present invention, two different protease activities may be determined, namely the protease activity that is secreted by a certain strain as well as the total protease activity exerted by a certain strain (i.e. secreted and cell-bound).Assay A-l is the preferred qualitative test for determination of secreted protease activity according to the invention.Assay A-ll is the preferred qualitative test for determination of total protease activity according to the invention.Whether a mutant of Bacillus velezensis DSM 34978 exhibits “protease activity” is preferably determined by the test according to Assay A-l further explained in the following.Whether a mutant of Bacillus velezensis DSM 34674 exhibits “protease activity” is preferably determined by the test according to Assay A-l further explained in the following.Whether a mutant of Priestia megaterium DSM 34980 exhibits “protease activity” is preferably determined by the test according to Assay A-ll further explained in the following.In order to determine the protease activity (in %) of a given mutant of Bacillus velezensis DSM 34978 relative to the protease activity of Bacillus velezensis DSM 34978, the test according to Assay B-l is preferably used.In order to determine the protease activity (in %) of a given mutant of Bacillus velezensis DSM 34674 relative to the protease activity of Bacillus velezensis DSM 34674, the test according to Assay B-ll is preferably used.202400145 Foreign Filings 79In order to determine the protease activity (in %) of a given mutant of Priestia megaterium DSM 34980 relative to the protease activity of Priestia megaterium DSM 34980, the test according to Assay B-lll is preferably used.VI 1. 1.1 Assay A-lAssay A-l may be carried out by the following steps to determine whether a given Strain XAI, for example Bacillus velezensis DSM 34978 or a given mutant of Bacillus velezensis DSM 34978, or Bacillus velezensis DSM 34674 or a given mutant of Bacillus velezensis DSM 34674 exhibit protease activity.Assay A-l may be used to determine secreted protease activity.(A-l-1) Strain XAI is cultivated in 10 ml tryptic-soy-broth (“TSB”; Merck - 105459; peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D(+) glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L) at 37 °C and 200 rpm for 16 h. As inoculum, 20 pl of a cryo-conservation culture was used for each strain XAI.(A-l-2) After the overnight cultivation, the optical density is measured at A = 660 nm using a cuvette photometer. A culture volume CM for OD 1 (in 1 ml) is obtained as follows:The culture medium CM is obtained by centrifugation (5000 x g, 3 min, room temperature). The filter- sterile (filtered by 0.2 pm) supernatant is obtained, adjusted (by dilution with TSB medium) to OD 1 and then used (abbreviated as “SNAI”) for the qualitative protease test on specific selective agar plates [step (A-l-3)].(A-l-3) 10 % Crossley milk agar (“CM0213”, Oxoid; 10 g / L skim milk powder, 1 g / L peptone, 0.01 g / L bromocresol purple, 13 g / L agar-agar) is prepared and 5 pl of the supernatant SNAI [adjusted to OD 1] is dropped on the agar plates.(A-l-4) The agar plates are incubated at 37 °C for 24 h. Through the indicator dye in the agar medium, the elucidation by protease degradation is directly visible. The protease activity is indicated by the extent (area) of the circular / elliptic clearance zone (also referred to as “halo of degradation”). For the determination of the area of the clearance zone, the diameter (in case of a circular clearance zone) or the average value of the largest and smallest diameter (in case of an elliptic circular clearance zone) may be determined. Values are assessed in millimeters (mm) of two independent biological replicates.(A-l-5) As blank control, steps (A-l-1) and (A-l-2) are repeated except that no Strain XAI is cultivated in TSB. In step (A-l-2), the filter-sterile supernatant is diluted in the same ratio as for the tested Strain XAI to give blank culture medium CMAI, Blank- Then, step (A-l-3) is repeated with the difference that 5 pl of CMAI, Blank is dropped on 10 % Crossley milk agar CM0213 prepared as described in step (A-l-3) and incubated for 24 h at 37 °C.202400145 Foreign Filings 80(A-l-6) Optionally, as further control and for quantification of the protease activity, the area of a clearance zone may be compared to the area of a clearance zone of a pure protease from Bacillus licheniformis with protease activity of known quantity (typically in the range of from 7-15 U / mg). For this, pure protease from Bacillus licheniformis (subtilisin, P5380, Sigma-Aldrich) is concentrated to 1 mg / ml, and steps (A-l-3) and (A-l-4) are repeated, except that instead of 5 pl of SNAI, 5 pl of the 1 mg / ml solution is used (typically having a calculated activity of around 35-75 pU). By this, the area size of a clearance zone may be correlated to the quantitative value of protease activity.Qualitative assessment of protease activity according to Assay A-l:Any Strain XAI that shows visible protease degradation in step (A-l-4) of Assay A is, in particular, deemed to exhibit the respective protease activity according to the invention. Preferably, any Strain XA that in step (A-l-4) shows a clearance zone the area of which is larger, preferably at least 10 %, more preferably at least 50 % larger, than the area of the clearance zone observed for CMAI, Blank in step (A-l-5) is deemed to exhibit protease activity.VII. 1.2 Assays B-l, B-llAssays B-l and B-ll are the preferred quantitative tests for determining the protease activity of a given strain, for example a mutant of Bacillus velezensis DSM 34978 (hereinafter “Mutant 34978”) relative to the protease activity of another given strain, for example Bacillus velezensis DSM 34978; or for example for determining the protease activity of a mutant of Bacillus velezensis DSM 34674 (hereinafter “Mutant 34674”) relative to the protease activity of another given strain, for example Bacillus velezensis DSM 34674.Assay B-l is the preferred quantitative test for determining the protease activity of a mutant of Bacillus velezensis DSM 34978 (hereinafter “Mutant 34978”) relative to the protease activity of Bacillus velezensis DSM 34978.In Assay B-l, the following steps are carried out:(B-l-1) Steps (A-l-1) to (A-l-4) of Assay A-l are carried out, wherein Strain XAI = Bacillus velezensis DSM 34978. The area of the clearance zone obtained at the end of step (A-l-4) is measured and abbreviated as “HBII”. Step (B-l-1) is repeated three times and the average value of the three measurements of HBH is calculated and abbreviated as “HBII”.(B-l-2) Steps (A-l-1) to (A-l-4) of Assay A-l are carried out, wherein Strain XAI = Mutant 34978. The area of the clearance zone obtained at the end of step (A-l-4) is measured and abbreviated as “HBI2”. Step (B-l-2) is repeated three times and the average value of the three measurements of HBI2 is calculated and abbreviated as “HBI2”.202400145 Foreign Filings 81The percentage of protease activity Aprot exhibited by the Mutant 34978 relative to Bacillus velezensis DSM 34978 is then calculated by Aprot = (HBI2 / HBM)*100.Assay B-ll is the preferred quantitative test for determining the protease activity of a mutant of Bacillus velezensis DSM 34674 (hereinafter “Mutant 34674”) relative to the protease activity of Bacillus velezensis DSM 34674.In Assay B-ll, the following steps are carried out:(B-ll-1) Steps (A-l-1) to (A-l-4) of Assay A-l are carried out, wherein Strain XAI = Bacillus velezensis DSM 34674. The area of the clearance zone obtained at the end of step (A-l-4) is measured and abbreviated as “HBIH”. Step (B-ll-1) is repeated three times and the average value of the three measurements of HBIH is calculated and abbreviated as “HBIH”.(B-ll-2) Steps (A-l-1) to (A-l-4) of Assay A-l are carried out, wherein Strain XAI = Mutant 34674. The area of the clearance zone obtained at the end of step (A-l-4) is measured and abbreviated as “HBII2”. Step (B-ll-2) is repeated three times and the average value of the three measurements of HBII2 is calculated and abbreviated as “HBH2”.The percentage of protease activity Aprot exhibited by the Mutant 34674 relative to Bacillus velezensis DSM 34674 is then calculated by Aprot = (HBII2 / HBIII)*100.VI 1. 1.3 Assay A-llAssay A-ll may be carried out by the following steps to determine whether a given Strain XAH, for example Priestia megaterium DSM 34980 or a given mutant of Priestia megaterium DSM 34980, exhibits protease activity.Assay A-ll may be used to determine total protease activity of an organism (i.e. protease activity that is secreted and cell-bound).(A-ll-1) Strain XAH is cultivated on TSA agar medium (“TSA”; peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D(+) glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L) at 37 °C for 16 h. Then the strain XAH is collected and washed three times with phosphate-buffered saline (“PBS”; Sigma, P4417-100TAB) at 8000 x g centrifugation, 3 min, room temperature, and adjusted by dilution with PBS to an optical density (OD at A = 600) equal to 0.1 . The thus obtained suspension is then used as culture medium CMAII in step (A-ll-2).202400145 Foreign Filings 82(A-ll-2) Skim milk agar medium (skim milk powder 28 g / L, casein enzymatic hydrolysate 5 g / L, yeast extract 2.5 g / L, glucose 1 g / L, agar 15 g / L) is prepared and 10 pl of the respective culture medium CMAH is dropped on the agar plates.(A-ll-3) The agar plates are incubated at room temperature for 7 d. The protease activity is indicated by the extent (area) of the circular / elliptic clearance zone (also referred to as “halo of degradation”). For the determination of the area of the clearance zone, the diameter (in case of a circular clearance zone) or the average value of the largest and smallest diameter (in case of an elliptic circular clearance zone) may be determined. Values are assessed in millimeters (mm) of two independent biological replicates.(A-ll-4) As blank control, step (A-ll-2) and step (A-ll-3) are repeated except that PBS medium free of any Strain XAII is cultivated on skim milk agar medium.(A-ll-5) Optionally, as further control and for quantification of the protease activity, the area of a clearance zone may be compared to the area of a clearance zone of a pure protease from Bacillus licheniformis with protease activity of known quantity (typically in the range of from 7-15 U / mg). For this, pure protease from Bacillus licheniformis (subtilisin, P5380, Sigma-Aldrich) is concentrated to 1 mg / ml, and steps (A-ll-2) and (A-ll-3) are repeated, except that instead of 10 pl of CMAII, 5 pl of the 1 mg / ml solution is used (typically having a calculated activity of around 35-75 pU). By this, area size of a clearance zone may be correlated to the quantitative value of protease activity.Qualitative assessment of protease activity according to Assay A-ll:Any Strain XAII that shows visible protease degradation in step (A-ll-3) of Assay A-ll is, in particular, deemed to exhibit the respective protease activity according to the invention. Preferably, any Strain XAII that in step (A-ll-3) shows a clearance zone the area of which is larger, preferably at least 10 %, more preferably at least 50 % larger, than the area of the clearance zone observed for the blank control in step (A-ll-4) is deemed to exhibit protease activity.VII.1.4 Assay B-lllAssay B-lll is the preferred quantitative test for determining the protease activity of a mutant of Priestia megaterium DSM 34980 (hereinafter “Mutant 34980”) relative to the protease activity of Priestia megaterium DSM 34980.In Assay B-lll, the following steps are carried out:(B-lll-1) Steps (A-ll-1) to (A-ll-3) of Assay A-ll are carried out, wherein Strain XAII = Priestia megaterium DSM 34980. The area of the clearance zone obtained at the end of step (A-ll-3) is measured and202400145 Foreign Filings 83 abbreviated as “HBIII-I”. Step (B-lll-1) is repeated three times and the average value of the three measurements of HBIIH is calculated and abbreviated as “HBIII-I”.(B-lll-2) Steps (A-ll-1) to (A-ll-3) of Assay A-ll are carried out, wherein Strain XAH = Mutant 34980. The area of the clearance zone obtained at the end of step (A-ll-3) is measured and abbreviated as “HBIII2”. Step (B-lll-2) is repeated three times and the average value of the three measurements of HBIII2 is calculated and abbreviated as “HBIII2”.The percentage of protease activity Aprot exhibited by the Mutant 34980 relative to Priestia megaterium DSM 34980 is then calculated by Aprot = (HBII2 / HBIII)*100.VII.2 Cellulase activity: Assav C and Assays D-I.D-II“Cellulase activity” in the sense of the present invention is deemed to be an activity that catalyzes the hydrolytic cleavage of the p-1 ,4-glykosidic bond of cellulose.The prior art describes different assays to qualitatively and quantitatively determine cellulase activity, for example in Wood & Mahalingeshwara Bhat, Methods in Enzymology 1988, 160, 87-112.Assay C is the preferred qualitative test for cellulase activity according to the invention.Whether a mutant of Bacillus velezensis DSM 34978 or a mutant of Bacillus velezensis DSM 34674 exhibit “cellulase activity” is preferably determined by the following Assay C.In order to determine the cellulase activity (in %) of a given mutant of Bacillus velezensis DSM 34978 relative to the cellulase activity of Bacillus velezensis DSM 34978, Assay D-l is preferably used.In order to determine the cellulase activity (in %) of a given mutant of Bacillus velezensis DSM 34674 relative to the cellulase activity of Bacillus velezensis DSM 34674, Assay D-ll is preferably used.VI 1.2.1 Assay CAssay C may be carried out by the following steps to determine whether a given Strain Xc, for example Bacillus velezensis DSM 34978 or a given mutant of Bacillus velezensis DSM 34978, or Bacillus velezensis DSM 34674 or a given mutant of Bacillus velezensis DSM 34674, exhibit cellulase activity.(C-1) Strain Xc is incubated in a pre-culture in 10 ml VIB medium (Difco Veal Infusion Broth, Ref. 234420) at 37 °C and 200 rpm for 16 h.(C-2) After the incubation, a further culture of 2.5 ml CMC Growth Medium [minimal-salt medium with10 g / L carboxymethyl cellulose (Sigma 419311)] is inoculated with 125 pl of the pre-culture medium using202400145 Foreign Filings 84 a small deep-well incubation plate. After inoculation, the further culture is incubated at 37 °C for 24 h at 300 rpm. After 24 h, the OD of the further culture is measured at A = 660 nm.(C-3) Then, the supernatant SNc of the further culture is harvested by centrifugating of 1 ml aliquot of the further culture in a 1 .5 ml Eppendorf tube for 5 min at 13000 rpm.(C-4) 500 pl of the supernatant SNc are subjected to a cellulase activity test using the EnzChek® Cellulase kit from Molecular Probes / Life technologies according to the manufacturer's instructions (E33953). The principle of this test kit is based on the cellulase-catalyzed conversion of the EnzChek® Cellulase Substrate, blue fluorescent, 339 / 452, whereby the fluorescence is enhanced. The detection limit is 4 mU / ml to 3 U / ml. To prepare a standard curve for quantification, a 2 U / ml cellulase from Aspergillus niger (Sigma-Aldrich, C1184) and dilutions thereof are prepared.The measurement is performed in black 96-well microtiter plates (Greiner FIA-Plate, black 96K, F-form, 655076-225) and in the Tecan plate reader infinite M1000 Pro. Subsequently, the fluorescence is measured at an excitation of A = 339 nm and an emission of A = 452 nm. The cellulase activity is calculated based on the standard curve and the activity is normalized to OD 1 (A = 660 nm) to normalize over cell growth differences after 24 hours incubation at the end of step (C-2).(C-5) As blank control, steps (C-1) to (C-4) are repeated except that the preculture (and logically also the further culture) are cultivated without Strain Xc and at the end of step (C-3), a blank supernatant SNc, Blank is obtained. Step (C-4) is repeated with the difference that 500 pl SNc, Blank is used instead of 500 pl of SNC.Qualitative assessment of cellulase activity according to Assay C:Any Strain Xc, the supernatant SNc of which shows a higher, preferably at least 10 % higher, more preferably at least 50 % higher, cellulase activity than SNc, Blank in step (C-4) of Assay C is, in particular, deemed to exhibit cellulase activity according to the invention.VII.2.2 Assays D-l, D-llAssay D-l is the preferred quantitative test for determining the cellulase activity of a mutant of Bacillus velezensis DSM 34978 (hereinafter “Mutant 34978”) relative to the cellulase activity of Bacillus velezensis DSM 34978.In Assay D-l, the following steps are carried out:(D-l-1) Steps (C-1) to (C-4) of Assay C are carried out, wherein Strain Xc = Bacillus velezensis DSM 34978. The cellulase activity in step (C-4) is measured and abbreviated as “Hcu”. Step (D-l-1) is202400145 Foreign Filings 85 repeated three times, and the average value of the three measurements of Hen is calculated and abbreviated as “Hen”.(D-l-2) Steps (C-1) to (C-4) of Assay C are carried out, wherein Strain Xc = Mutant 34978. The cellulase activity in step (C-4) is measured and abbreviated as “Hci2”. Step (D-l-2) is repeated three times and the average value of the three measurements of Hci2 is calculated and abbreviated as “Hera”.The percentage of cellulase activity Aceii exhibited by the Mutant 34978 relative to Bacillus velezensis DSM 34978 is then calculated by Aceii = (Hci2 / Hcii)*100.Assay D-ll is the preferred quantitative test for determining the cellulase activity of a mutant of Bacillus velezensis DSM 34674 relative to the cellulase activity of Bacillus velezensis DSM 34674.In Assay D-ll, the following steps are carried out:(D-ll-1) Steps (C-1) to (C-4) of Assay C are carried out, wherein Strain Xc = Bacillus velezensis DSM 34674. The cellulase activity in step (C-4) is measured and abbreviated as “Hem”. Step (D-ll-1) is repeated three times and the average value of the three measurements of Hem is calculated and abbreviated as “Hem”.(D-ll-2) Steps (C-1) to (C-4) of Assay C are carried out, wherein Strain Xc = Mutant 34674. The area of the clearance zone obtained at the end of step (C-4) is measured and abbreviated as “Hcira”. Step (D-ll-2) is repeated three times and the average value of the three measurements of Hcii2 is calculated and abbreviated as “Hcii2”.The percentage of cellulase activity Aceii exhibited by the Mutant 34674 relative to Bacillus velezensis DSM 34674 is then calculated by Aceii = (Hcii2 / Hcm)*100.VII.3 Amylase activity: Assay E and Assays F-l, F-ll:“Amylase activity” in the sense of the present invention is deemed to be an activity that catalyzes the hydrolytic cleavage of a glycosidic bond within a polysaccharide such as starch (“glycosidic enzymatic activity”).The prior art describes different assays to qualitatively and quantitatively determine amylase activity, for example in Oliveira et al., MethodsX 2019, 6, 246-258.Assay E is the preferred qualitative test for amylase activity according to the invention.202400145 Foreign Filings 86Whether a mutant of Bacillus velezensis DSM 34978 exhibits “amylase activity” is preferably determined by the following Assay E.Whether a mutant of Bacillus velezensis DSM 34674 exhibits “amylase activity” is preferably determined by the following Assay E.In order to determine the amylase activity (in %) of a given mutant of Bacillus velezensis DSM 34978 relative to the amylase activity of Bacillus velezensis DSM 34978, Assay F-l is preferably used.In order to determine the amylase activity (in %) of a given mutant of Bacillus velezensis DSM 34674 relative to the amylase activity of Bacillus velezensis DSM 34674, Assay F-ll is preferably used.VI 1.3. 1 Assay EAssay E may be carried out by the following steps to determine whether a given Strain XE, for example Bacillus velezensis DSM 34978 or a given mutant of Bacillus velezensis DSM 34978, or Bacillus velezensis DSM 34674 or a given mutant of Bacillus velezensis DSM 34674, exhibit amylase activity.(E-1) Strain XE is cultivated in 10 ml tryptic-soy-broth (“TSB”; Merck - 105459; peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D(+) glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L), wherein the TSB medium further contains 2.5 g / L soluble starch (Merck) at 37 °C and 200 rpm for 16 h. As inoculum, 20 pl of a cryo-conservation culture is used for each strain XE.(E-2) After the overnight cultivation, the optical density is measured at A = 660 nm using a cuvette photometer and a culture volume for OD 1 (in 1 ml) is obtained by centrifugation (5000 x g, 3 min, room temperature). The filter-sterile supernatant (abbreviated as SNE) is obtained, adjusted (by dilution with TSB medium) to OD 1 and sterilized using a 0.2 pm filter and then used for the qualitative amylase test on specific selective agar plates [step (E-3)].(E-3) Starch agar plates are prepared by using 37 g / L Luria-Bertani (“LB”) agar (Merck-110283) with 10 g / L soluble starch (Merck, CAS: 9005-84-9). 5 pl of the supernatant SNE is dropped on the agar plates.(E-4) The plates are incubated at 37 °C for 24 h, and then flooded with 10 % Lugol’s solution (5 g iodine, 10 g potassium iodide in 10 ml distilled water), which is removed directly thereafter. The amylase activity is indicated by the extent (area) of the circular / elliptic clearance zone (also referred to as “halo of degradation”). For the determination of the area of the clearance zone, the diameter (in case of a circular clearance zone) or the average value of the largest and smallest diameter (in case of an elliptic clearance zone) may be determined. Values are assessed in millimeters (mm) of two independent biological replicates.202400145 Foreign Filings 87(E-5) As blank control, step (E-1) is repeated except that no Strain XE is cultivated in TSB. The filter- sterile supernatant is diluted in the same ratio as in the case of the Strain XE in step (E-2) to be tested to give blank supernatant SNE, Blank- Then, step (E-3) is repeated with the difference that 5 pl of SNE, Blank is dropped on the agar plate prepared as described in step (E-3) and incubated for 24 h at 37 °C.(E-6) Optionally, as further control and for quantification of the amylase activity, the area of a clearance zone may be compared to the area of a clearance zone of a pure a-amylase from Bacillus licheniformis (CAS: 9000-85-5) with an amylase activity of known quantity. For this, steps (E-3) and (E-4) are repeated, except that instead of 5 pl of SNE, 5 pl of a prepared solution of the a-amylase (0.1 mg / ml) is used. By this, the area size of a clearance zone may be correlated to a quantitative value of amylase activity.Qualitative assessment of amylase activity according to Assay E:Any Strain XE that shows visible amylase activity in step (E-4) of Assay E is, in particular, deemed to exhibit amylase activity according to the invention. Preferably, any Strain XE that in step (E-4) shows a halo of degradation the area of which is larger, preferably at least 10 %, more preferably at least 50 % larger, than the area of the clearance zone observed for SNE, Blank in step (E-5) is deemed to exhibit amylase activity.VI 1.3.2 Assays F-l, F-llAssay F-l is the preferred quantitative test for determining the amylase activity of a mutant of Bacillus velezensis DSM 34978 (hereinafter “Mutant 34978”) relative to the amylase activity of Bacillus velezensis DSM 34978.In Assay F-l, the following steps are carried out:(F-l-1) Steps (E-1) to (E-4) of Assay E are carried out, wherein Strain XE = Bacillus velezensis DSM 34978. The area of the clearance zone obtained at the end of step (E-4) is measured and abbreviated as “HEM”. Step (F-l-1) is repeated three times and the average value of the three measurements of HEM is calculated and abbreviated as “HEU”.(F-l-2) Steps (E-1) to (E-4) of Assay E are carried out, wherein Strain XE = Mutant 34978. The area of the clearance zone obtained at the end of step (E-4) is measured and abbreviated as “HEI2”. Step (F-l-2) is repeated three times and the average value of the three measurements of HEI2 is calculated and abbreviated as “HEI2”.The percentage of amylase activity AAmy exhibited by the Mutant 34978 relative to Bacillus velezensis DSM 34978 is then calculated by AAmy = (HEI2 / HEII)*100.202400145 Foreign Filings 88Assay F-ll is the preferred quantitative test for determining the amylase activity of a mutant of Bacillus velezensis DSM 34674 relative to the amylase activity of Bacillus velezensis DSM 34674.In Assay F-ll, the following steps are carried out:(F-ll-1) Steps (E-1) to (E-4) of Assay E are carried out, wherein Strain XE = Bacillus velezensis DSM 34674. The area of the clearance zone obtained at the end of step (E-4) is measured and abbreviated as “HEIU”. Step (F-ll-1) is repeated three times and the average value of the three measurements of HEIM is calculated and abbreviated as “HEIM”.(F-ll-2) Steps (E-1) to (E-4) of Assay E are carried out, wherein Strain XE = Mutant 34674. The area of the clearance zone obtained at the end of step (E-4) is measured and abbreviated as “HEII2”. Step (F-ll-2) is repeated three times and the average value of the three measurements of HEII2 is calculated and abbreviated as “HEII2”.The percentage of amylase activity AAmy exhibited by the Mutant 34674 relative to Bacillus velezensis DSM 34674 is then calculated by AAmy = (HEII2 / HEIII)*1 00.VI 1.4 Lipase activity: Assays G, H“Lipase activity” in the sense of the present invention is deemed to be an activity that catalyzes the hydrolytic cleavage of an ester bond within triglycerides, diglycerides, and monoglycerides.P. Chandra et al., Microb Cell Fact. 2020, 19, 169 review the applications of microbial lipases, for example in waste water treatment and as cleaning agents.The prior art describes different assays to qualitatively and quantitatively determine lipase activity, for example in Guo et al., Enzyme and Microbial Technology 2015, 71, 8-12; Javed et al. Prog Biophys Mol Biol. 2018,132, 23-34 (doi: 10.1016 / j.pbiomolbio.2017.07.014.).Assay G is the preferred qualitative test for lipase activity according to the invention.Whether a mutant of Bacillus subtilis DSM 34981 exhibits “lipase activity” is preferably determined by the following Assay G. A variety of para-nitrophenyl (“p-NP”) esters having two to 16 carbon atoms (p-NP acetate to p-NP palmitate) in their fatty acid side chain can be hydrolyzed by bacterial lipases (Javed et al., Progress in Biophysics and Molecular Biology 2018, 132, 23-34). In Assay G the lipase activity is measured by the amount of free p-NP which is the product of the hydrolysis of 4-nitrophenyloctanoate (“4-NP-C8”). In Assay G, free p-NP is directly measured via a photometric assay.In order to determine the lipase activity (in %) of a given mutant of Bacillus subtilis DSM 34981 relative to the lipase activity of Bacillus subtilis DSM 34981 , Assay H is preferably used.202400145 Foreign Filings 89VI 1.4. 1 Assay GAssay G may be carried out by the following steps to determine whether a given Strain XG, for example a given mutant of Bacillus subtilis DSM 34981 , exhibits lipase activity.(G-1) Strain XG is incubated in a pre-culture in 10 ml tryptic-soy-broth (“TSB”; Merck - 105459; peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D(+) glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L), at 37 °C and 200 rpm for 16 h.(G-2) After the incubation, the pre-culture is centrifugated twice and washed with main culture medium MCMo (described in the context of Assay J). The main culture is incubated at 37 °C and 200 rpm agitation for 4 hours. Afterwards, the culture is harvested by centrifugation (5000 x g, 3 min, room temperature) and adjusted to OD 0.25 (A = 660 nm) in 180 pl 0.1 M Tris-buffer. 180 pl of this suspension SB of bacterial cells is then used in step (G-4).(G-3) A stock solution S4NPC8 for the substrate of 4 mmol / L 4-nitrophenyloctanoate (“4-NP-C8”; Sigma- Aldrich, CAS:1956-10-1) is prepared as follows: A solution of 4-NP-C8 in / so-propanol is prepared, and this stock solution is further diluted in 0.1 M Tris-buffer pH 8.5 to give S4NPC8 as follows: 28.8 mg 4-NP-C8 are mixed with 6.25 ml / so-propanol, and 18.75 ml 0.1 M Tris-buffer (pH 8.5) are added.(G-4) 180 pl bacterial cell suspension SB is mixed with 20 pl S4NPC8 in a 96-well microliter plate (Greiner bio one, Ref. 655101) and incubated at 25 °C for 60 min in a Tecan spark plate reader. The determination is carried out in the Tecan plate reader at A = 410 nm. Every 2 min, a measurement is done and after 60 min, the final absorbance at A = 410 nm is used for the evaluation.For the evaluation, a p-nitrophenol (“p-NP”) standard series (0 to 10 mmol / L) is prepared and used to quantify the amount of released p-NP to determine the lipase activity in the Bacillus suspension SB. The activity of expressed lipase is given in mU / ml as mean value from two independent biological experiments.(G-5) For the determination of the baseline, a blank solution SG, blank of 20 pl substrate solution S4NPC8 in 180 pl 0.1 M Tris-buffer is used.As a positive control, different concentrations of a pure lipase from Candida rugosa (Sigma-Aldrich, L174) are used.Qualitative assessment of cellulase activity according to Assay G:Any Strain XG, the suspension SB of which shows a higher, preferably at least 10 % higher, more preferably at least 50 % higher, lipase activity than SNG, Blank in step (G-4) of Assay G is, in particular, deemed to exhibit lipase activity according to the invention.202400145 Foreign Filings 90VI 1.4.2 Assay HAssay H is the preferred quantitative test for determining the lipase activity of a mutant of Bacillus subtilis DSM 34981 (hereinafter “Mutant 34981”) relative to the lipase activity of Bacillus subtilis DSM 34981 .In Assay H, the following steps are carried out:(H-1) Steps (G-1) to (G-4) of Assay G are carried out, wherein Strain XG = Bacillus subtilis DSM 34981 . The lipase activity in step (G-4) is measured and abbreviated as “HHI”. Step (H-1) is repeated three times, and the average value of the three measurements of HHI is calculated and abbreviated as “HHI”.(H-2) Steps (G-1) to (G-4) of Assay G are carried out, wherein Strain XG = Mutant 34981. The lipase activity in step (G-4) is measured and abbreviated as “HH2”. Step (H-2) is repeated three times and the average value of the three measurements of HH2 is calculated and abbreviated as “HH2”.The percentage of lipase activity Aupaexhibited by the Mutant 34981 relative to Bacillus subtilis DSM 34981 is then calculated by Aupa= (HH2 / HHI)*100.VI 1.5 Valeric acid metabolism rate and ability to grow on valeric acid (1000 ppm): Assay JVII.5.1 Assay JAssay J allows to determine two different properties of a given strain, namely1) A strain’s ability to grow in the presence of a certain concentration of VA (exemplified in Assay J on the basis of a concentration of 1000 ppm VA). This ability to grow is expressed as factor TXJ, which is positive for those strains that are deemed to be able to grow on VA with a certain concentration;2) The ability to reduce VA of a certain maximal concentration (exemplified in Assay J on the basis of a concentration of 1000 ppm VA). This ability to reduce VA may then be quantified by a constant kxj, wherein kxj s 1 .VII.5.1 .1 Ability to grow on valeric acid, factor FXJAssay J may be carried out by the following steps to determine whether a given Strain Xj, for example B. velezensis DSM 34978 or a given mutant of B. velezensis DSM 34978, B. velezensis DSM 34674 or a given mutant of B. velezensis DSM 34674, Bacillus licheniformis DSM 34977 or a given mutant of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980 or a given mutant of Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 or a given mutant of Bacillus subtilis DSM 34981 , grows on valeric acid of a certain concentration XVA, in particular of a concentration XVA of 1000 ppm.202400145 Foreign Filings 91The concentration of valeric acid in the medium MCM+vai that is used in Assay J is XVA = 1000 ppm. Thus, Assay J allows to determine whether a given Strain X is able to grow in the presence of 1000 ppm VA. “Able to grow in the presence of 1000 ppm VA” may be abbreviated as “to grow on 1000 ppm valeric acid” or “to grow on valeric acid (1000 ppm)”.In order to determine the ability to grow at lower or higher, in particular higher, concentrations XVA of VA (for example XVA = 5000 ppm), Assay J is easily adapted by substituting MCM+vai by another medium MCM*+vai which is identical to MCM+vai, but has a lower or higher, in particular higher, concentration XVA of VA. For example, for XVA = 5000 ppm, a medium MCM*+vai with 5000 ppm VA may be used which is obtained by the same procedure as stated below for MCM+vai, except that in step 5., 5 g valeric acid are deployed.If such medium MCM*+vai is used in Assay J, Assay J allows to determine whether a given Strain X is able to grow in the presence of 5000 ppm VA. “Able to grow in the presence of 5000 ppm VA” may be abbreviated as “to grow on 5000 ppm valeric acid” or “to grow on valeric acid (5000 ppm)”.The same applies, logically, to any other variation of Assay J where yet another medium MCM**+vai with a yet different concentration XVA of VA is used. The skilled person knows that such medium is simply obtained by the same procedure as described for MCM+vai, by simply adjusting the amount of VA used in step 5.VII.5.1 .2 Rate of metabolization of valeric acid, constant kxjAssay J may furthermore be carried out by the following steps to determine whether a given Strain Xj, for example B. velezensis DSM 34978 or a given mutant of B. velezensis DSM 34978, B. velezensis DSM 34674 or a given mutant of B. velezensis DSM 34674, Bacillus licheniformis DSM 34977 or a given mutant of Bacillus licheniformis DSM 34977, P estia megaterium DSM 34980 or a given mutant of P estia megaterium DSM 34980, Bacillus subtilis DSM 34981 or a given mutant of Bacillus subtilis DSM 34981 is able to metabolize (and thus reduce) valeric acid of a certain concentration XVA, in particular a concentration of XVA = 1000 ppm.The concentration of valeric acid in the medium MCM+vai that is used in Assay J is XVA = 1000 ppm. Thus, Assay J allows to determine the ability to metabolize valeric acid of a given Strain X, wherein the concentration of VA is XVA = 1000 ppm. “Ability to metabolize valeric acid [...], wherein the concentration of VA is 1000 ppm” may be abbreviated as “able to metabolize 1000 ppm valeric acid” or “able to metabolize valeric acid (1000 ppm)”.In order to determine the ability to metabolize VA at lower or higher, in particular higher, concentrations XVA of VA (for example XVA = 5000 ppm), Assay J is easily adapted by substituting MCM+vai by another medium MCM*+vai which is identical to MCM+vai, but has a lower or higher, in particular higher,202400145 Foreign Filings 92 concentration XVA of VA. For example, for XVA = 5000 ppm, a medium MCM*+vai with 5000 ppm VA may be used which is obtained by the same procedure as stated below for MCM+vai, except that in step 5., 5 g valeric acid are deployed.If such medium MCM*+vai is used in Assay J, Assay J allows to determine whether a given Strain X is able to metabolize 5000 ppm VA. “Ability to metabolize valeric acid [...], wherein the concentration of VA is 5000 ppm” may be abbreviated as “able to metabolize 5000 ppm valeric acid” or “able to metabolize valeric acid (5000 ppm)”.The same applies, logically, to any other variation of Assay J where yet another medium MCM**+vai with a yet different concentration XVA is used. The skilled person knows that such medium is simply obtained by the same procedure as described for MCM+vai, by simply adjusting the amount of VA used in step 5.VI 1.5.1 .3 Steps according to Assay JThe following culture media MCM+vai and MCMo are prepared:MCM+vai is a main culture medium containing valeric acid obtained by combining the following solutions / substances:1 . 200 g aqueous salt solution 1 with 20 g / L KH2PO4, 61 g / L K2HPO4, 16 g / L (NH4)2SO4;2. 10 g aqueous salt solution 2 with 0.176 g / L Mn(ll)SO4*H2O and 12.3 g / L MgSO4*H2O;3. 10 g of an aqueous ammonium iron (III) citrate solution with a concentration of 2.2 g / L of ammonium iron (III) citrate;4. 20 g of a 50 % (w / v) aqueous glucose monohydrate solution (50 g glucose monohydrate are dissolved in water to give a final volume of aqueous solution of 100 ml);5. 1 g valeric acid (Sigma-Aldrich, 240370).The stocks 1 . to 5. are combined and filled up to 1 L; the pH is adjusted to 7.MCMo is a main culture medium containing no valeric acid obtained by combining the stocks 1 . to 4. and filling them up to 1 L; the pH is adjusted to 7.In Assay J, the following steps are carried out:(J-1) Strain Xj is incubated in a pre-culture PCj in 10 ml tryptic-soy-broth [“TSB”; Merck - 105459; peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D(+) glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L] . PCj is then divided one half each, PCj+ and PCj..(J-2) PCj+ and PCj. are each centrifugated and the respective pellet is redispersed in aqueous0.9 % w / v) NaCI solution (“aqueous 0.9 % (w / v) NaCI solution” means that 0.9 g NaCI are dissolved in202400145 Foreign Filings 93 water to give a final volume of aqueous solution of 100 ml). Then, each dispersion is centrifugated for 5 min at 5000 x g and the NaCI solution is removed from the obtained pellet (1stwashing).(J-3) Each pellet is redispersed in fresh aqueous 0.9 % (yv / v) NaCI solution. Then, each dispersion is centrifugated for 5 min at 5000 x g and the NaCI solution is removed (2ndwashing). The pellet from PCj+ is used in step (J-4). The pellet from PCj. is used in step (J-5).(J-4) The washed pellet from PCj+ from step (J-3) is diluted with main culture medium MCM+vai until an CD of 0.1 at A = 660 nm (vstart = OD 0.1). MCM+vai contains valeric acid (Sigma-Aldrich, 240370) in a concentration of co = 1 g / L. The incubation is at 30 °C with 225 rpm for 48 h in a small cultivation system (Woulter-Deutz). Then, the OD at A = 660 nm is measured (“v+vai”). Then, the culture is centrifugated at 13000 x g for 3 minutes at room temperature (“RT”) and subsequently the supernatant SN+vai is harvested. The concentration c+vai of valeric acid in SN+vai is quantified using an analytical method.(J-5) The washed pellet from PCj. from step (J-3) is diluted with main culture medium MCMo until an OD of 0.1 at A = 660 nm (vstart = OD 0.1). MCMo comprises no valeric acid. The incubation is at 30 °C with 225 rpm for 48 h in a small cultivation system (Woulter-Deutz). Then, the OD at A = 660 nm is measured (“v.vai”). Then, the culture is centrifugated at 13000 x g for 3 minutes at RT and subsequently the supernatant SN.vai is harvested. The concentration c.vai of valeric acid in SN.vai is quantified using an analytical method (this may be made as a control and / or standardization, since the concentration should be c.vai= 0).(J-6) For a blank control, the same volume of main culture medium MCM+vai as in step (J-4), but without Strain Xj, is incubated at 30 °C with 225 rpm for 48 h in a small cultivation system (Woulter-Deutz). Then, the culture medium is centrifugated at 13000 x g for 3 minutes at RT and subsequently the supernatant SNeiank is harvested. The concentration cvaio of valeric acid in SNeiank is quantified using an analytical method as a control.VI 1.5.1.4 Evaluation of Assav JVll.5.1.4.1 ...at 1000 ppm VAWhere Assay J is carried out with MCM+vai, namely a concentration of valeric acid of XVA = 1000 ppm, the following evaluation may be made:If v+vai is higher than v.vai , then Xj is deemed to grow on 1000 ppm valeric acid according to the invention. The improved growth of Xj on valeric acid medium (1000 ppm) may then be expressed as factor T xj; 1000 ppm = v+vai / v.vai. In particular, according to the invention, in order for a strain Xj to be able to grow on valeric acid medium (1000 ppm), the condition Txj; iooo ppm > 1 is fulfilled.202400145 Foreign Filings 94—>■ If the concentration of valeric acid c+vai in SN+vai is lower than the concentration of valeric acid cvaio in SNeiank, then Xj is able to metabolize valeric acid (1000 ppm). The rate of metabolization of valeric acid (1000 ppm) by Xj may then be expressed as constant kxj; 1000 ppm = 1 - c+vai / cvaio-The effectiveness EXJ;1000 ppm to reduce valeric acid (1000 ppm) of a strain Xj, in particular a strain Xj which fulfills the condition TXJ;ioooppm > 1”, may then be expressed as the ratio EXJ;ioooppm as follows: Exj; 1000 ppm = kxj; 1000 ppm * I" XJ; 1000 ppm-VII.5.1.4.2 ...at 5000 ppm VAWhere Assay J is carried out with another medium MCM*+vai instead of MCM+vai, namely at a concentration of valeric acid of XVA = 5000 ppm, the following evaluation may be made:—> If v+vai is higher than v.vai , then Xj is deemed to grow on 5000 ppm valeric acid according to the invention. The improved growth of Xj on valeric acid medium (5000 ppm) may then be expressed as factor T xj; 5000 ppm = v+vai / v.vai. In particular, according to the invention, in order for a strain Xj to be able to grow on valeric acid medium (5000 ppm), the condition Txj; 5000 ppm > 1 is fulfilled.—> If the concentration of valeric acid c+vai in SN+vai is lower than the concentration of valeric acid cvaio in SNeiank, then Xj is able to metabolize valeric acid (5000 ppm). The rate of metabolization of valeric acid (5000 ppm) by Xj may then be expressed as constant kxj; 5000 ppm = 1 - c+vai / cvaio-The effectiveness EXJ;5000 ppm to reduce valeric acid (5000 ppm) of a strain Xj, in particular a strain Xj which fulfills the condition TXJ;5000 ppm > 1”, may then be expressed as the ratio EXJ;5000 ppm as follows:Exj; 5000 ppm = kxj; 5000 ppm * I" XJ; 5000 ppm-VII.5.1.4.3 ...at a general concentration of VA, i.e. XVAWhere Assay J is carried out with another medium MCM**+vai instead of MCM+vai, namely at a concentration of valeric acid of XVA, the following evaluation may be made:—> If v+vai is higher than v.vai , then Xj is deemed to grow at XVA valeric acid according to the invention. The improved growth of Xj on valeric acid medium (XVA) may then be expressed as factorI"XJ;XVA = v+vai / v.vai. In particular, according to the invention, in order for a strain Xj to be able to grow on valeric acid medium (XVA), the condition TXJ;XVA > 1 is fulfilled.—> If the concentration of valeric acid c+vai in SN+vai is lower than the concentration of valeric acid cvaio in SNeiank, then Xj is able to metabolize valeric acid (XVA). The rate of metabolization of valeric acid (XVA) by Xj may then be expressed as constant kxj; XVA = 1 - c+vai / cvaio-202400145 Foreign Filings 95The effectiveness EXJ;XVA to reduce valeric acid (XVA) of a strain Xj, in particular a strain Xj which fulfills the condition TXJ;XVA > 1 ”, may then be expressed as the ratio EXJ;XVA as follows:Exj;XVA - kxj; xVA * Txj; xVA-VI 1.5.1.5 Analysis of VA concentrations in the context of Assay JIn Assay J, the quantification of valeric acid are done by an analytical method as follows:The respective sample and a series of calibration standards are mixed with an internal standard (2-methylhexanoic acid). An excess of NaCI is added to the sample, and it is then diluted with 1 part 50 wt.-% sulfuric acid to 4 parts sample. The resulting mixture is extracted in a ratio of 1 part diethyl ether to 1.25 parts sample for 10 minutes and then centrifuged for 10 minutes at 3000 g. The organic supernatant is removed and, if necessary, further diluted to a concentration range of 1 g / L. Samples and calibration standards are measured using an Agilent GC 8860 equipped with split / spitless injector and FID detector on a GC column (BP21 30m; ID 0.32 mm; film 0.25 pm) at a flow rate of 1 ml / min He. The separation is carried out by means of a temperature gradient from 130 °C to 180 °C within 8.5 min. The chromatograms are evaluated by means of a multi-point area evaluation linear without zero crossing with 2-methylhexanoic acid as the internal standard. Valeric acid is eluting at 5.4 min within the program.VI 1.5.2 Assays K-l, K-ll, K-lllVII.5.2.1 Assay K-l is the preferred quantitative test for determining the effectiveness EXJ% (XVA) to reduce valeric acid of a mutant of Bacillus licheniformis DSM 34977 (hereinafter “Mutant 34977”) relative to the effectiveness to reduce valeric acid of Bacillus licheniformis DSM 34977, which may be determined for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm.In Assay K-l, the following steps are carried out:(K-l-1) Steps (J-1) to (J-5) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = Bacillus licheniformis DSM 34977. Step (K-l-1) is repeated three times, and the average value of the three measurements of EXJ = TXJ *kxj is calculated and abbreviated as “EKM”.(K-l-2) Steps (J-1) to (J-5) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = mutant of Bacillus licheniformis DSM 34977. Step (K-l-2) is repeated three times, and the average value of the three measurements of EXJ = TXJ *kxj is calculated and abbreviated as “EKI2”.202400145 Foreign Filings 96The effectiveness EXJ% (XVA) exhibited by the Mutant 34977 to reduce valeric acid relative to the effectiveness of Bacillus licheniforms DSM 34977 to reduce valeric acid for a given concentration XVA is then calculatedVI 1.5.2.2 Assayis the preferred quantitative test for determining the effectiveness EXJ% (XVA) to reduce valeric acid of a mutant of Priestia megaterium DSM 34980 (hereinafter “Mutant 34980”) relative to the effectiveness to reduce valeric acid of Priestia megaterium DSM 34980, which may be determined for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm.In Assay K-ll, the following steps are carried out:(K-ll-1) Steps (J-1) to (J-5) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = Priestia megaterium DSM 34980. Step (K-ll-1) is repeated three times, and the average value of the three measurements of EXJ - rxj *kxj is calculated and abbreviated as EKIU ■(K-ll-2) Steps (J-1) to (J-5) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = mutant of Priestia megaterium DSM 34980. Step (K-ll-2) is repeated three times, and the average value of the three measurements of EXJ - rxj *kxj is calculated and abbreviated as EKII2 ■The effectiveness EXJ% exhibited by the Mutant 34980 to reduce valeric acid relative to the effectiveness of Priestia megaterium DSM 34980 to reduce valeric acid for a given concentration XVA is then calculated by EXJ% = (EKII2 / EKIII)*100.VII.5.2.3 Assay K-lll is the preferred quantitative test for determining the effectiveness EXJ% (XVA) to reduce valeric acid of a mutant of Bacillus subtilis DSM 34981 (hereinafter “Mutant 34981 ”) relative to the effectiveness to reduce valeric acid of Bacillus subtilis DSM 34981 , which may be determined for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm.In Assay K-lll, the following steps are carried out:(K-lll-1) Steps (J-1) to (J-5) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = Bacillus subtilis DSM 34981. Step (K-lll-1) is repeated three times, and the average value of the three measurements of EXJ = rXJ*kxj is calculated and abbreviated as “EKIIU”.202400145 Foreign Filings 97(K-lll-2) Steps (J-1) to (J-5) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = mutant of Bacillus subtilis DSM 34981 . Step (K-lll-2) is repeated three times, and the average value of the three measurements of EXJ - TXJ *kxj is calculated and abbreviated as EKIII2 ■The effectiveness EXJ% (XVA) exhibited by the Mutant 34981 to reduce valeric acid relative to the effectiveness of Bacillus subtilis DSM 34981 to reduce valeric acid for a given concentration XVA is then calculated by EXJ% (XVA) = (EKni2 / EKiin)*100.VII.5.3 Assays L-l, L-llVII.5.3.1 Assay L-l is the preferred quantitative test for determining kxj% (XVA) e. the metabolization rate of a valeric acid medium of a mutant of Bacillus velezensis DSM 34978 (hereinafter “Mutant 34978”) relative to the metabolization rate of a valeric acid medium of Bacillus velezensis DSM 34978, which may be determined for a given concentration XVA, in particular for a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm.In Assay L-l, the following steps are carried out:(L-l-1) Steps (J-1) to (J-4) and (J-6) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = Bacillus velezensis DSM 34978. Step (L-l-1) is repeated three times, and the average value of the three measurements of kxj is calculated and abbreviated as “KLU”.(L-l-2) Steps (J-1) to (J-4) and (J-6) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = mutant of Bacillus velezensis DSM 34978. Step (L-l-2) is repeated three times, and the average value of the three measurements of kxj is calculated and abbreviated as “KLI2”.The relative metabolization rate kxj% (XVA) of valeric acid for a given concentration XVA exhibited by the Mutant 34978 relative to the metabolization of valeric acid of Bacillus velezensis DSM 34978 is then calculated by kXj% (XVA) = (KLI2 / KLH)*100.VII.5.3.2 Assay L-ll is the preferred quantitative test for determining kxj% (XVA) e. the metabolization rate of a valeric acid medium of a mutant of Bacillus velezensis DSM 34674 (hereinafter “Mutant 34674”) relative to the metabolization rate of a valeric acid medium of Bacillus velezensis DSM 34674, which may be202400145 Foreign Filings 98 determined for a given concentration XVA, in particular for a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm.In Assay L-ll, the following steps are carried out:(L-ll-1) Steps (J-1) to (J-4) and (J-6) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = Bacillus velezensis DSM 34674. Step (L-ll-1) is repeated three times, and the average value of the three measurements of kxj is calculated and abbreviated as “KLIM”.(L-ll-2) Steps (J-1) to (J-4) and (J-6) of Assay J are carried out for a given concentration XVA, in particular a concentration XVA = 1000 ppm or a concentration XVA = 5000 ppm, wherein Strain Xj = mutant of Bacillus velezensis DSM 34674. Step (L-ll-2) is repeated three times, and the average value of the three measurements of kxj is calculated and abbreviated as “Kura”.The relative metabolization rate of valeric acid kxj% (XVA) exhibited by the Mutant 34674 relative to the metabolization of valeric acid for a given concentration XVA of Bacillus velezensis DSM 34674 is then calculated by kXj% (XVA) = (Kura / KLIH)*100.202400145 Foreign Filings 99VIII. Mixture MIn a second aspect, the present invention relates to a mixture M.Mixture M comprises valeric acid VA, at least one component Si, and at least one component S2.Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978.Si is preferably selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978.Si is more preferably selected from the group consisting of Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674.51 is most preferably Bacillus velezensis DSM 34978.52 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations ofBacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 .S2 is preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981.S2 is more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981.S2 is even more preferably selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980.S2 is most preferably Bacillus licheniformis DSM 34977.Components Si and S2 may be provided as a cleaning formulation F (described above under point 1 .5) and mixed with valeric acid VA to obtain a mixture M.202400145 Foreign Filings 100VIII.1 Component SiIn mixture M according to the second aspect of the invention, component Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978.Preferably, component Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978.Si is more preferably selected from the group consisting of Bacillus velezensis DSM 34978, Bacillus velezensis DSM 34674.Si is most preferably Bacillus velezensis DSM 34978.As shown under point IV.2 of the Examples, it was surprisingly found that Bacillus velezensis DSM 34978 and Bacillus velezensis DSM 34674 exhibit a high VA reduction rate and thus are very efficient in shortterm reduction of malodor which is caused by VA. Although Bacillus velezensis DSM 34978 and Bacillus velezensis DSM 34674 showed smaller tolerances in terms of growth and accumulation of biomass in presence of VA, these strains were still able to metabolize VA over the course of 48 hours, thus being predestined as agent for quick, efficient removal of VA and thus malodor.It is preferred that the Bacillus velezensis strains DSM 34674 and DSM 34978 and their mutants that may be selected as component Si in the mixture M according to the second aspect of the invention are in a living state.It is preferred that the Bacillus velezensis DSM 34978 that may preferably be selected as component Si in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the mutant of Bacillus velezensis DSM 34978 that may preferably be selected as component Si in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the Bacillus velezensis DSM 34674 that may preferably be selected as component Si in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the mutant of Bacillus velezensis DSM 34674 that may preferably be selected as component Si in the mixture M according to the second aspect of the invention is in a living state.202400145 Foreign Filings 101It is preferred that the preparation of Bacillus velezensis DSM 34978 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises Bacillus velezensis DSM 34978, even more preferred comprises Bacillus velezensis DSM 34978 in a living state.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34978 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises the mutant of Bacillus velezensis DSM 34978, even more preferred comprises the mutant of Bacillus velezensis DSM 34978 in a living state.It is preferred that the preparation of Bacillus velezensis DSM 34674 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises Bacillus velezensis DSM 34674, even more preferred comprises Bacillus velezensis DSM 34674 in a living state.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34674 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises the mutant of Bacillus velezensis DSM 34674, even more preferred comprises the mutant of Bacillus velezensis DSM 34674 in a living state.It is preferred that the preparation of Bacillus velezensis DSM 34978 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises the genomic DNA of Bacillus velezensis DSM 34978.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34978 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises the genomic DNA of the mutant of Bacillus velezensis DSM 34978.It is preferred that the preparation of Bacillus velezensis DSM 34674 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises the genomic DNA of Bacillus velezensis DSM 34674.It is preferred that the preparation of a mutant of Bacillus velezensis DSM 34674 that may be selected as component Si in the mixture M according to the second aspect of the invention comprises the genomic DNA of the mutant of Bacillus velezensis DSM 34674.VIII.2 Component S2Component S2 comprised by mixture M according to the second aspect of the invention is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM202400145 Foreign Filings 10234980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981. Preferably, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 . More preferably, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 . Even more preferably, component S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980. Most preferably, component S2 is Bacillus licheniformis DSM 34977.As shown under point IV.2 of the Examples, it was surprisingly found that Priestia megaterium DSM 34980, Bacillus licheniformis DSM 34977, Bacillus subtilis DSM 34981 exhibit a positive, high growth rate in the presence of VA and simultaneously metabolize and thus reduce VA. These species are very efficient in long-term reduction of malodor which is caused by VA, since they are able to metabolize VA over the course of a long incubation period efficiently. Moreover, as they are able to grow on valeric acid medium, the reduction of VA increases over the time.It is preferred that the Priestia megaterium DSM 34980 that may be selected as component S2 in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the mutant of Priestia megaterium DSM 34980 that may be selected as component S2 in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the preparation of Priestia megaterium DSM 34980 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises Priestia megaterium DSM 34980, more preferably comprises Priestia megaterium DSM 34980 in a living state.It is preferred that the preparation of the mutant of Priestia megaterium DSM 34980 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the mutant of Priestia megaterium DSM 34980, more preferably comprises the mutant of Priestia megaterium DSM 34980 in a living state.It is preferred that the Bacillus licheniformis DSM 34977 that may be selected as component S2 in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the mutant of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the mixture M according to the second aspect of the invention is in a living state.202400145 Foreign Filings 103It is preferred that the preparation of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises Bacillus licheniformis DSM 34977, more preferably comprises Bacillus licheniformis DSM 34977 in a living state.It is preferred that the preparation of the mutant of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the mutant of Bacillus licheniformis DSM 34977, more preferably comprises the mutant of Bacillus licheniformis DSM 34977 in a living state.It is preferred that the Bacillus subtilis DSM 34981 that may be selected as component S2 in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the mutant of Bacillus subtilis DSM 34981 that may be selected as component S2 in the mixture M according to the second aspect of the invention is in a living state.It is preferred that the preparation of Bacillus subtilis DSM 34981 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises Bacillus subtilis DSM 34981 , more preferably comprises Bacillus subtilis DSM 34981 in a living state.It is preferred that the preparation of the mutant of Bacillus subtilis DSM 34981 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the mutant of Bacillus subtilis DSM 34981 , more preferably comprises the mutant of Bacillus subtilis DSM 34981 in a living state.It is preferred that the preparation of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the genomic DNA of Bacillus licheniformis DSM 34977.It is preferred that the preparation of a mutant of Bacillus licheniformis DSM 34977 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the genomic DNA of the mutant of Bacillus licheniformis DSM 34977.It is preferred that the preparation of Priestia megaterium DSM 34980 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the genomic DNA of Priestia megaterium DSM 34980.It is preferred that the preparation of a mutant of Priestia megaterium DSM 34980 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the genomic DNA of the mutant of Priestia megaterium DSM 34980.202400145 Foreign Filings 104It is preferred that the preparation of Bacillus subtilis DSM 34981 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the genomic DNA of Bacillus subtilis DSM 34981 .It is preferred that the preparation of a mutant of Bacillus subtilis DSM 34981 that may be selected as component S2 in the mixture M according to the second aspect of the invention comprises the genomic DNA of the mutant of Bacillus subtilis DSM 34981 .In a specific embodiment of the mixture M according to the second aspect of the invention,Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preferably Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34978, more preferably Bacillus velezensis DSM 34978, and S2 is selected from the group consisting Bacillus licheniformis DSM 34977, mutants of Bacillus licheniformis DSM 34977, preferably Bacillus licheniformis DSM 34977.VI II.3 Valeric acid VAMixture M is preferably an aqueous mixture, in particular an aqueous solution, LVA of VA. Even more preferably, the concentration (weight-%) of valeric acid in LVA is preferably < 5000 ppm, in particular in the range of from 1 ppt to 5000 ppm, more preferably in the range of from 1 ppb to 3000 ppm, even more preferably in the range of from 10 ppb to 2000 ppm, even more preferably in the range of from 20 ppb to 1000 ppm, even more preferably in the range of from 30 ppb to 1000 ppm, even more preferably in the range of from 50 ppb to 1000 ppm, even more preferably in the range of from 100 ppb to 1000 ppm, even more preferably in the range of from 1 ppm to 1000 ppm, even more preferably in the range of from 10 ppm to 1000 ppm, even more preferably in the range of from 100 ppm to 1000 ppm, relative to the total weight of LVA.Mixture M according to the second aspect of the invention is typically obtained when component Si and component S2 contact VA according to step a. of the method according to the first aspect of the invention, namely when component Si and component S2 are contacted with VA, for example on the surface of the human or animal body B or an object O.Mixture M is preferably an aqueous mixture, in particular an aqueous solution, LVA of VA, when at least one of the following steps are carried out to obtain mixture M: component Si and / or component S2 are applied as aqueous mixtures;202400145 Foreign Filings 105VA is present as aqueous mixture, in particular on the surface from which it shall be removed (for example, as sweat);Mixture M is obtained and then, water is added to mixture M, to obtain aqueous mixture LVA- Mixture M is thus the mixture in which the metabolization of VA is especially efficient in terms of the discussed combination of short-term and long-term effect of VA removal.It is preferred that the ratio of the weight of all components Si comprised by mixture M according to the second aspect of the present invention to all components S2 comprised by mixture M according to the second aspect of the present invention is in the range of from 99 : 1 to 1 : 99, preferably in the range of from 90 : 10 to 10 : 90, more preferably in the range of from 80 : 20 to 20 : 80, even more preferably in the range of from 70 : 30 to 30 : 70, even more preferably in the range of from 60 : 40 to 40 : 60, most preferably at 50 : 50.202400145 Foreign Filings 106Examples I. to III. show advantageous enzymatic activities of Bacillus and Priestia strains which may advantageously be used in cleaning where metabolization of different substrates underlies the cleaning effect. Example IV. shows the surprising properties of the different bacterial species and strains in terms of positive or negative growth rate in presence of VA and VA reduction rate. The surprising findings described in Example IV. underlie the present invention.I. Determination of protease, amylase, and cellulase activity of Bacillus velezensis DSM 34978 and DSM 34674Six different Bacillus velezensis strains (i.e. DSM 34978, DSM 34674, prior art strain DSM 33857 as well as three commercial Bacillus velezensis strains), one Bacillus licheniformis strain DSM 13, and one Priestia megaterium DSM 33356 were tested for protease, amylase and cellulase activity in a testing procedure according to Assay A-l, Assay E, and Assay C, respectively. The protease activity tested in Assay A-l is protease activities in the supernatant, i.e. secreted protease activity.Bacillus velezensis strains DSM 34978 and DSM 34674 were isolated from the soil.Three further Bacillus velezensis strains (abbreviated as “Bacillus velezensis strain 1”, “Bacillus velezensis strain 2”, and “Bacillus velezensis strain 3”, respectively) were isolated from commercially available cleaning products A, B, and C, respectively, and investigated as comparisons. DSM 33857 is a prior art Bacillus velezensis strain (disclosed in EP 4 130 258 A1). DSM 33356 is a prior art Priestia megaterium strain (disclosed in WO 2021 / 129998 A1). DSM 13 is a prior art Bacillus licheniformis strain (disclosed in B. Veith et al., J Mol Microbiol Biotechnol 2004, 7, 204-211).The protease and amylase activity of each of these strains was assessed in two test series, series A and series B. The cellulase activity of each of these strains was assessed in test series A.The testing for protease activity was carried out as follows:Each of the strains of interest was cultivated in 10 ml tryptic-soy-broth [TSB; Merck - 105459 (peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D (+) glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L)] at 37 °C and 200 rpm overnight (16 h) separately. As inoculum, 20 pl of a cryo-conservation culture was used for each strain. After the overnight cultivation, the optical density was measured at A = 660 nm using a cuvette photometer and a culture volume for OD 1 (in 1 ml) was adjusted by centrifugation (5000 x g, 3 min, room temperature). The filter-sterile supernatant (previously adjusted to OD1) was used for the qualitative protease test on specific selective agar plates.10 % Crossley milk agar (CM0213, Oxoid; 10 g / L skim milk powder, 1 g / L peptone, 0.01 g / L bromocresol purple, 13 g / L agar-agar) was prepared and 5 pl of the supernatant of each strain of interest was dropped on the agar plates. After an incubation at 37 °C for 24 h, the protease activity was indicated by a202400145 Foreign Filings 107 clearance zone (“halo of degradation”), which was measured and compared to a pure protease from Bacillus licheniformis (subtilisin, P5380, Sigma-Aldrich) concentrated to 1 mg / ml. Through the indicator dye in the agar medium, the elucidation by protease degradation is directly visible. The clearance zone is given as an average of the horizontal and vertical diameters. Values are given in millimeters (mm) of two independent biological replicates.Two test series were performed. In the first test series A, the protease activity of Priestia megaterium DSM 33356, Bacillus licheniformis DSM 13, and Bacillus velezensis strains DSM 34978, DSM 34674, as well as Bacillus velezensis strains 1 to 3 was determined. The results are summarized in table 1-A.In the second test series B , the protease activity of Bacillus velezensis strains DSM 34978, DSM 34674, and DSM 33857 was determined. The results are summarized in table 1 -B.Like the protease activity test, the amylase activity was also checked in a qualitative plate test.The strains of interest were cultivated in 10 ml tryptic-soy-broth with soluble starch [TSB; Merck- 105459 (peptone from casein 17.0 g / L; peptone from soymeal 3.0 g / L; D(+)glucose monohydrate 2.5 g / L; sodium chloride 5.0 g / L; di-potassium hydrogen phosphate 2.5 g / L) + 2.5 g / L soluble starch (Merck) at 37 °C and 200 rpm overnight (16 h) separately. As inoculum, 20 pl of a cryo-conservation culture was used for each strain. After the overnight cultivation, the optical density was measured at A = 660 nm using a cuvette photometer and a culture volume for OD 1 (in 1 ml) was adjusted by centrifugation (5000 x g, 3 min, room temperature). The filter-sterile supernatant (previously adjusted to OD 1 and sterilized using a 0.2 pm filter) was used for the qualitative amylase test on specific selective agar plates.Starch agar plates were prepared by using 37 g / L Luria-Bertani (“LB”) agar (Merck-110283) with 10 g / L soluble starch (Merck, CAS: 9005-84-9). 5 pl of the supernatant of each strain were dropped on the agar plate. Plates were incubated at 37 °C for 24 h. The a-amylase from Bacillus licheniformis(CAS: 9000-85-5) was used as control. 5 pl of a prepared 0.1 mg / ml solution was dropped similarly. Specifically, the amylase activity was observed as a clear zone around the bacterial supernatant spots or the a-amylase spot, becoming evident after application of 10 ml of 10 % Lugol’s solution (5 g iodine, 10 g potassium iodide in 10 ml distilled water) to the plate. After removing the Lugol’s solution, the diameter of the clearance zones was measured horizontally and vertically, and the mean thereof used for determining the area of the clearance zone. The test is performed in two independent biological replicates.Two test series were performed. In the first test series A, the amylase activity of Priestia megaterium DSM 33356, Bacillus licheniformis DSM 13, and Bacillus velezensis strains DSM 34978, DSM 34674, as well as Bacillus velezensis strains 1 to 3 was determined. The results obtained in test series A are summarized in table 1-A.202400145 Foreign Filings 108In the second test series B, the amylase activity of Bacillus velezensis strains DSM 34978, DSM 34674, and DSM 33857 was determined. The results obtained in test series B are summarized in table 1 -B.The cell free supernatant of the Bacillus I Priestia strains of interest was tested regarding cellulase activity. Cellulase activity produced by the different Bacillus I Priestia strains of interest and released in the supernatant was quantified with the EnzChek® Cellulase kit from Molecular Probes / life technologies (E33953) following the working protocol. The principle of this test is based on the cellulase-catalyzed conversion of the substrate EnzChek® Cellulase Substrate, blue fluorescent, 339 / 452, whereby the fluorescence is enhanced.The supernatant was prepared beforehand. A pre-culture of each strain of interest was done in 10 ml VIB medium (Difco Veal Infusion Broth, Ref. 234420) at 37 °C and 200 rpm overnight (16 h). After the incubation, a new main culture with 2.5 ml CMC Growth Medium [minimal-salt medium with 10 g / L carboxymethyl cellulose (Sigma 419311)] was inoculated with 125 pl pre-culture using a small deep-well incubation plate and incubated at 37 °C for 24 h at 300 rpm. After 24 hours, the CD at A = 660 nm of each culture was measured and the supernatant harvested by centrifugation. This was done with a 1 ml aliquot of each culture in a 1.5 ml Eppendorf tube for 5 min at 13000 rpm. After that, approx. 500 pl of culture supernatant was used for the enzyme test.The detection limit of the cellulase kit was determined as 4mU-3U / ml activity. Therefore, a 2U / ml cellulase from Aspergillus niger (Sigma-Aldrich, C1184) and dilutions were prepared for a standard curve for quantification. The assay was done according to the kit manual. The measurement was performed in black 96-well microtiter plates (Greiner FIA-Plate, black 96K, F-form, 655076-225) and in the Tecan plate reader infinite M1000 Pro. Subsequently, the fluorescence was measured at an excitation of A = 339 nm and an emission of A = 452 nm. The cellulase activity was calculated based on the standard curve and the activity was normalized to OD 1 (A = 660 nm) to standardize over cell growth differences after 24 hours incubation.One test series A was performed. The cellulase activity of Priestia megaterium DSM 33356, Bacillus velezensis strains DSM 33857, DSM 34978, DSM 34674, and Bacillus velezensis strains 1 to 3 was determined. The results are summarized in table 1 -A.1.4 ResultsThe results obtained in test series A are summarized in the following table 1 -A:Table 1-A: Protease and amylase activities in supernatants (“SN”) measured via a qualitative plate assay by determining the halo of degradation size (0 in mm). Cellulase activity of supernatants is given as quantitative values in mU / OD 1. The experiments were performed in two biological replicates and the means and standard deviations (“a”) are given. Comparative strains 1, 2, 3 from product A, B and C,202400145 Foreign Filings 109 respectively, belong to the Bacillus species velezensis. Strains DSM 34978 and DSM 34674 belong to the Bacillus species velezensis. DSM 33857 is a prior art Bacillus velezensis strain (disclosed in EP 4 130258 A 1). DSM 33356 is a prior art Priestia megaterium strain (disclosed in l / l / O 2021 / 129998 A1). DSM 13 is a prior art Bacillus licheniformis strain (disclosed in B. Veith et al., J Mol Microbiol Biotechnol 2004, 7 , 204-211) (“n.d. ” = not determined; “n.d. *” = not determined in test series A; but determined in test series B).Strain Protease activity SN Amylase activity SN Cellulase activity SN0 halo of degradation [mm] 0 halo of degradation [mm] mU / OD 116.97 7.54 1660.76DSM 34978 (o 0.32) (ct 0.58) (ct 440.15)15.89 7.34 1084.81DSM 34674 (ct 0.32) (ct 1.26) (ct 153.33)12.9 7.50 944.01Strain 1 (ct 0.765) (ct 1 .96) (ct 271 .23)14.30 5.99 764.29Strain 2 (ct 0.53) (ct 0.75) (ct 113.04)13.74 7.50 751.43Strain 3(CT 0.18) (CT 0.45) (CT 77.52)1340.49DSM 33857 n.d.* n.d.*(ct 14.06)DSM 33356DSM 13 - - n.d.The results obtained in test series B are summarized in the following table 1 -B: Table 2-B: Protease and amylase activities in supernatants (“SN”) measured via a qualitative plate assay by determining the halo of degradation size (0 in mm). The experiments were performed in two biological replicates and the means and standard deviations (“a”) are given. Strains DSM 34978 and DSM 34674 belong to the Bacillus species velezensis. DSM 33857 is a prior art Bacillus velezensis strain (disclosed in EP 4 130258 A 1).Strain Protease activity SN Amylase activity SN0 halo of degradation [mm] 0 halo of degradation [mm]DSM 34978 14.30 (ct 0.28) 10.255 (ct 0.035)DSM 34674 14.01 (ct 0.33) 8.875 (ct 0.23)DSM 33857 12.98 (ct 0.01) 10.13 (ct 0.38)1.4. 1 Protease Activities202400145 Foreign Filings 110The results obtained in test series A, summarized in table 1-A, show the following:Bacillus velezensis strains DSM 34978 and DSM 34674 showed remarkably higher activity for protease compared to the other screened Bacillus I Priestia strains. As described under point 1.1 , the supernatants were harvested from a culture of each strain and adjusted to an optical density of OD 1 to standardize over growth effects. The degradation or clearance zones, measured as the diameter (“0”) in mm, have a 0 size of 16.97 mm and 15.89 mm for DSM 34978 and DSM 34674, respectively. Comparative Bacillus velezensis strains 1 , 2, and 3 were tested in the same way and it could be shown that the protease activity of all of these strains was lower (see table 1-A: 0 sizes of 12.9 mm, 14.30 mm, and 13.74 mm, respectively). As a further control, the protease activity of two different species from the prior art was tested: Priestia megaterium DSM 33356 and Bacillus licheniformis DSM 13. Neither strain showed any protease activity.The results obtained in test series B, summarized in table 1-B, show the following:Bacillus velezensis strains DSM 34978 and DSM 34674 also showed remarkably higher activity for protease compared to the prior art Bacillus velezensis strain DSM 33857. As described under point 1.1 , the supernatants were harvested from a culture of each strain and adjusted to an optical density of OD 1 to standardize over growth effects. The degradati...

Claims

202400145 Foreign Filings 123Claims1 . A method for reducing malodor comprising a. contacting valeric acid VA with at least one component Si and at least one component S2 to obtain a mixture M comprising valeric acid VA, at least one component Si, and at least one component S2, wherein Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978, and wherein S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations of Priestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 , b. incubating M so that the at least one component Si and the at least one component S2 metabolize at least a part of the valeric acid VA.

2. The method according to Claim 1 , wherein Si is selected from the group consisting ofBacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, and wherein S2 is selected from the group consisting ofBacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 .

3. The method according to Claim 1 or 2, wherein202400145 Foreign Filings 124 mutants of Bacillus velezensis DSM 34674 display property (a), preferably display properties (a) and (p) as follows:(a) the mutant of Bacillus velezensis DSM 34674 is able to metabolize valeric acid (1000 ppm), more preferably is able to metabolize valeric acid (5000 ppm),(p) the mutant of Bacillus velezensis DSM 34674 has protease activity wherein, preferably, the protease activity is determined by the test according to Assay A-l; mutants of Bacillus velezensis DSM 34978 display property (a), even more preferably display properties (a) and (p) as follows:(a) the mutant of Bacillus velezensis DSM 34978 is able to metabolize valeric acid (1000 ppm), even more preferably is able to metabolize valeric acid (5000 ppm),(p) the mutant of Bacillus velezensis DSM 34978 has protease activity, wherein, preferably, the protease activity is determined by the test according to Assay A-l; mutants of Bacillus licheniformis DSM 34977 display property (y), even more preferably display properties (y) and (5) as follows:(y) the mutant of Bacillus licheniformis DSM 34977 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm),(5) the mutant of Bacillus licheniformis DSM 34977 has an effectiveness EXJ% (XVA) [wherein XVA = 1000 ppm] to reduce valeric acid which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Bacillus licheniformis DSM 34977 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm] is, in particular, determined by the test according to Assay K-l; mutants of Priestia megaterium DSM 34980 display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (e) as follows:(y) the mutant of Priestia megaterium DSM 34980 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm),(5) the mutant of Priestia megaterium DSM 34980 has an effectiveness EXJ% (XVA) [wherein XVA = 1000 ppm] to reduce valeric acid which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more202400145 Foreign Filings 125 preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Priestia megaterium DSM 34980 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm] is, in particular, determined by the test according to Assay K-ll,(e) the mutant of Priestia megaterium DSM 34980 has protease activity, wherein, preferably, the protease activity is determined by the test according to Assay A-ll; mutants of Bacillus subtilis DSM 34981 display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (q) as follows:(y) the mutant of Bacillus subtilis DSM 34981 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm),(5) the mutant of Bacillus subtilis DSM 34981 has an effectiveness EXJ% (XVA) [wherein XVA = 1000 ppm] to reduce valeric acid which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Bacillus subtilis DSM 34981 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm] is, in particular, determined by the test according to Assay K-lll( ) the mutant of Bacillus subtilis DSM 34981 has lipase activity, wherein, preferably, the lipase activity is determined by the test according to Assay G.

4. The method according to one of Claims 1 to 3, wherein the mutant of Bacillus velezensis DSM 34674 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 1 ;202400145 Foreign Filings 126 ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 3; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 4; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 5; vi. a DNA sequence, which preferably is a uvrC DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 6; the mutant of Bacillus velezensis DSM 34978 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for a 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 7; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 8;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 9; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 10; v. a DNA sequence, which preferably is a DNA sequence coding for an ATP synthase C chain, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 1 1 ; vi. a DNA sequence, which preferably is a DNA sequence coding for a chemotaxis protein, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 12;202400145 Foreign Filings 127 the mutant of Bacillus licheniformis DSM 34977 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 19; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 20;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 21 ; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 22; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 23; vi. a DNA sequence, which preferably is an adaA DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 24; the mutant of Priestia megaterium DSM 34980 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, most preferably all five of the following characteristics i. to v.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 25; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 26;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 27; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 28;202400145 Foreign Filings 128 v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 29; the mutant of Bacillus subtilis DSM 34981 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 13; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 14;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 15; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 16; v. a DNA sequence, which preferably is a HpC DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 17; vi. a DNA sequence, which preferably is a yqcA DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 18.

5. The method according to one of Claims 1 to 4, wherein the mutant of Bacillus velezensis DSM 34674 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus velezensis DSM 34674; the mutant of Bacillus velezensis DSM 34978 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of202400145 Foreign Filings 129 at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus velezensis DSM 34978; the mutant of Bacillus licheniformis DSM 34977 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus licheniformis DSM 34977; the mutant of Priestia megaterium DSM 34980 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Priestia megaterium DSM 34980; the mutant of Bacillus subtilis DSM 34981 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus subtilis DSM 34981 .

6. The method according to one of Claims 1 to 5, wherein mixture M is an aqueous solution LVA of VA.

7. The method according to Claim 6, wherein the concentration of VA in LVA is < 5000 ppm, preferably < 1000 ppm, relative to the total weight of LVA.

8. The method according to one of Claims 1 to 7 which is used for reducing malodor of the human or animal body B.

9. The method according to one of Claims 1 to 7 which is used for reducing malodor of an object O.

10. A mixture M comprising a. valeric acid VA, b. at least one component Si, and c. at least one component S2,202400145 Foreign Filings 130 wherein Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, preparations of Bacillus velezensis DSM 34674, preparations of Bacillus velezensis DSM 34978, preparations of mutants of Bacillus velezensis DSM 34674, preparations of mutants of Bacillus velezensis DSM 34978, and wherein S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981 , preparations of Bacillus licheniformis DSM 34977, preparations ofPriestia megaterium DSM 34980, preparations of Bacillus subtilis DSM 34981 , preparations of mutants of Bacillus licheniformis DSM 34977, preparations of mutants of Priestia megaterium DSM 34980, preparations of mutants of Bacillus subtilis DSM 34981 .11 . The mixture M according to Claim 10, wherein Si is selected from the group consisting of Bacillus velezensis DSM 34674, Bacillus velezensis DSM 34978, mutants of Bacillus velezensis DSM 34674, mutants of Bacillus velezensis DSM 34978, and wherein S2 is selected from the group consisting of Bacillus licheniformis DSM 34977, Priestia megaterium DSM 34980, Bacillus subtilis DSM 34981 , mutants of Bacillus licheniformis DSM 34977, mutants of Priestia megaterium DSM 34980, mutants of Bacillus subtilis DSM 34981.

12. The mixture M according to Claim 10 or 1 1 , wherein mutants of Bacillus velezensis DSM 34674 display property (a), preferably display properties (a) and (p) as follows:(a) the mutant of Bacillus velezensis DSM 34674 is able to metabolize valeric acid (1000 ppm), more preferably is able to metabolize valeric acid (5000 ppm),(p) the mutant of Bacillus velezensis DSM 34674 has protease activity wherein, preferably, the protease activity is determined by the test according to Assay A-l; mutants of Bacillus velezensis DSM 34978 display property (a), even more preferably display properties (a) and (p) as follows:(a) the mutant of Bacillus velezensis DSM 34978 is able to metabolize valeric acid (1000 ppm), even more preferably is able to metabolize valeric acid (5000 ppm),202400145 Foreign Filings 131(p) the mutant of Bacillus velezensis DSM 34978 has protease activity, wherein, preferably, the protease activity is determined by the test according to Assay A-l; mutants of Bacillus licheniformis DSM 34977 display property (y), even more preferably display properties (y) and (5) as follows:(y) the mutant of Bacillus licheniformis DSM 34977 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm);(5) the mutant of Bacillus licheniformis DSM 34977 has an effectiveness EXJ% (XVA) [wherein XVA = 1000 ppm] to reduce valeric acid which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Bacillus licheniformis DSM 34977 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm] is, in particular, determined by the test according to Assay K-l; mutants of Priestia megaterium DSM 34980 display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (e) as follows:(y) the mutant of Priestia megaterium DSM 34980 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm),(5) the mutant of Priestia megaterium DSM 34980 has an effectiveness EXJ% (XVA) [wherein XVA = 1000 ppm] to reduce valeric acid which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Priestia megaterium DSM 34980 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm] is, in particular, determined by the test according to Assay K-ll,(e) the mutant of Priestia megaterium DSM 34980 has protease activity, wherein, preferably, the protease activity is determined by the test according to Assay A-ll; mutants of Bacillus subtilis DSM 34981 display property (y), more preferably display properties (y) and (5), even more preferably display properties (y), (5), and (q) as follows:202400145 Foreign Filings 132(y) the mutant of Bacillus subtilis DSM 34981 is able to grow on valeric acid (1000 ppm), even more preferably is able to grow on valeric acid (5000 ppm),(5) the mutant of Bacillus subtilis DSM 34981 has an effectiveness EXJ% (XVA) [wherein XVA = 1000 ppm] to reduce valeric acid which is at least 85 %, preferably at least 86 %, preferably at least 87 %, preferably at least 88 %, preferably at least 89 %, preferably at least 90 %, more preferably at least 91 %, more preferably at least 92 %, more preferably at least 93 %, more preferably at least 94 %, more preferably at least 95 %, more preferably at least 96 %, more preferably at least 97 %, more preferably at least 98 %, more preferably at least 99 %, more preferably at least 99.9 %, more preferably at least 99.99 %, more preferably at least 99.999 %, more preferably at least 100 %, more preferably at least 101 %, more preferably at least 105 %, more preferably at least 110 %, more preferably at least 120 % relative to the effectiveness of Bacillus subtilis DSM 34981 to reduce valeric acid, wherein EXJ% (XVA) [wherein XVA = 1000 ppm] is, in particular, determined by the test according to Assay K-lll,( ) the mutant of Bacillus subtilis DSM 34981 has lipase activity, wherein, preferably, the lipase activity is determined by the test according to Assay G.

13. The mixture M according to one of Claims 10 to 12, wherein the mutant of Bacillus velezensis DSM 34674 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 1 ; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 2;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 3; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 4; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 5;202400145 Foreign Filings 133 vi. a DNA sequence, which preferably is a uvrC DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 6; the mutant of Bacillus velezensis DSM 34978 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for a 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 7; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 8;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 9; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 10; v. a DNA sequence, which preferably is a DNA sequence coding for an ATP synthase C chain, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 1 1 ; vi. a DNA sequence, which preferably is a DNA sequence coding for a chemotaxis protein, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 12; the mutant of Bacillus licheniformis DSM 34977 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 19; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 20;202400145 Foreign Filings 134 iii. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 21 ; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 22; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 23; vi. a DNA sequence, which preferably is an adaA DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 24; the mutant of Priestia megaterium DSM 34980 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, most preferably all five of the following characteristics i. to v.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according toSEQ ID NO: 25; ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 26; iii. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 27; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 28; v. a DNA sequence, which preferably is a yqfD DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 29; the mutant of Bacillus subtilis DSM 34981 exhibits at least one, preferably at least two, more preferably at least three, even more preferably at least four, even more preferably at least five, most preferably all six of the following characteristics i. to vi.: i. a DNA sequence, which preferably is the DNA sequence coding for the 16S rRNA, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 13;202400145 Foreign Filings 135 ii. a DNA sequence, which preferably is a rpoB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 14;Hi. a DNA sequence, which preferably is a gyrB DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 15; iv. a DNA sequence, which preferably is a groEL DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 16; v. a DNA sequence, which preferably is a HpC DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 17; vi. a DNA sequence, which preferably is a yqcA DNA sequence, with a sequence identity of at least 99 %, preferably at least 99.5 %, more preferably at least 99.9 %, even more preferably 100 %, to the polynucleotide sequence according to SEQ ID NO: 18.

14. The mixture M according to one of Claims 10 to 13, wherein the mutant of Bacillus velezensis DSM 34674 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of B. velezensis DSM 34674; the mutant of Bacillus velezensis DSM 34978 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus velezensis DSM 34978; the mutant of Bacillus licheniformis DSM 34977 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus licheniformis DSM 34977; the mutant of Priestia megaterium DSM 34980 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %,202400145 Foreign Filings 136 more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Priestia megaterium DSM 34980; the mutant of Bacillus subtilis DSM 34981 has a DNA sequence identity of at least 95 %, more preferred of at least 97 %, more preferred of at least 98 %, more preferred of at least 99 %, more preferred of at least 99.5 %, more preferred of at least 99.8 %, more preferred of at least 99.9 %, more preferred of at least 99.95 %, more preferred of at least 99.98 %, more preferred of at least 99.99 %, more preferred of at least 99.999 %, more preferred of at least 99.9999 % to the genomic DNA sequence of Bacillus subtilis DSM 34981 .

15. The mixture M according to one of Claims 10 to 14, which is an aqueous mixture LVA of VA.

16. The mixture M according to Claim 15, wherein the concentration of VA in LM is < 5000 ppm, preferably < 1000 ppm, relative to the total weight of LVA-

Images